<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9433542</PMID><DateCompleted><Year>1998</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0741-0395</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>1997</Year></PubDate></JournalIssue><Title>Genetic epidemiology</Title><ISOAbbreviation>Genet Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Genetic analysis of bipolar disorder: summary of GAW10.</ArticleTitle><Pagination><MedlinePgn>549-61</MedlinePgn></Pagination><Abstract><AbstractText>Participants in the Bipolar Disorder component of Genetic Analysis Workshop 10 had access to five distributed data sets containing chromosome 18 marker data and five data sets containing chromosome 5 data. A total of 25 groups participated in analyses and applied a myriad of methodologically innovative approaches to these data. Contributors focused on how to: (1) best define the phenotype from the spectrum of affective diagnoses; (2) test for a parent-of-origin effect in the transmission of bipolar illness and assess whether sharing in affected sib pairs depends on the sex of the transmitting parent; (3) evaluate the effects of misspecification of marker allele frequencies; (4) examine the putative candidate loci provided; (5) investigate the mode of inheritance; and (6) perform a meta-analysis to combine multiple data sets in a single analysis. Taken as a whole, the results would appear suggestive, but not definitive for linkage to a bipolar susceptibility locus on chromosome 18. The evidence for linkage appeared to increase as the diagnostic definition of the phenotype was broadened. Multipoint analyses seem to provide less evidence. It is possible that, because adjacent markers may be present in different data sets, the multipoint methods are combining marker data from different studies in a more comprehensive way than single marker analyses. Evidence on chromosome 5 and evidence for candidate loci were minimal. A discussion of problems inherent in combined analyses is given.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, Washington University, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH31302</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH37685</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH46280</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Genet Epidemiol</MedlineTA><NlmUniqueID>8411723</NlmUniqueID><ISSNLinking>0741-0395</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002887" MajorTopicYN="Y">Chromosomes, Human, Pair 18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002895" MajorTopicYN="Y">Chromosomes, Human, Pair 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9433542</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1098-2272(1997)14:6&lt;549::AID-GEPI1&gt;3.0.CO;2-V</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1098-2272(1997)14:6&lt;549::AID-GEPI1&gt;3.0.CO;2-V</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24135506</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and stigma: a systematic review of the literature.</ArticleTitle><Pagination><MedlinePgn>805-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.08.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00636-8</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The degree to which bipolar disorder is stigmatised by the public and the extent of internalised stigma for people with this disorder, their families, and carers has been a relatively neglected area of research. This review aimed to determine what is currently known about stigma and bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A systematic search of the literature was conducted to identify publications which investigated public attitudes and/or beliefs about bipolar disorder or explored internalised stigma in bipolar disorder. The electronic databases PsychINFO, Medline, Embase, and Web of Science were searched for articles published between 1992 and 2012.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty five articles met the reviews inclusion criteria. There are inconsistent findings regarding public stigma, although there is some evidence that bipolar disorder is viewed more positively than schizophrenia and less positively than depression. There is a moderate to high degree of internalised stigma in bipolar disorder, although the literature raises questions regarding its ubiquity in this population.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Limiting the search by year of publication and excluding studies where stigma was not the main focus could mean stigma has wider implications than were identified.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This review is the first systematic synthesis of research relating to stigma and bipolar disorder. In comparison to research on other mental health problems, there is a dearth of literature exploring stigma in bipolar disorder. The literature is largely inconclusive. Future research is needed to replicate tentative findings and address methodological limitations before the field can move on to the development of anti-stigma interventions.</AbstractText><CopyrightInformation>© 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ellison</LastName><ForeName>Nell</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical, Educational and Health Psychology Research Department, University College London, London WC1E 7HB, United Kingdom. Electronic address: nell.ellison.10@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Scior</LastName><ForeName>Katrina</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="N">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057545" MajorTopicYN="Y">Social Stigma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013240" MajorTopicYN="N">Stereotyping</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Internalised stigma</Keyword><Keyword MajorTopicYN="N">Public stigma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>04</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24135506</ArticleId><ArticleId IdType="pii">S0165-0327(13)00636-8</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.08.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27728870</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>207</Volume><PubDate><Year>2017</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Characterization and structure of hypomania in a British nonclinical adolescent sample.</ArticleTitle><Pagination><MedlinePgn>228-235</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)30524-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.08.033</ELocationID><Abstract><AbstractText Label="BACKGROUND">This study aimed to test the validity of using the Hypomania Checklist-16 [HCL-16] to measure hypomania in a British adolescent community sample. Limited research is available concerning the characterization of hypomania among community adolescent samples, particularly in the UK, despite its potential importance for early intervention policy development.</AbstractText><AbstractText Label="METHOD">To explore the structure and characterization of hypomania in a British adolescent nonclinical cohort, over 1400 17 year olds (Mean=17.05 years; SD=0.88) completed the HCL-16 along with measures of different psychological and psychopathological dimensions.</AbstractText><AbstractText Label="RESULTS">Principal components analysis revealed a 2-component solution for the HCL-16, described as active-elated and irritable/risk-taking. Hypomanic symptoms were significantly correlated with many psychopathological dimensions. There were distinct correlation patterns for the two HCL-16 subscales, with the irritability/risk-taking subscale showing significantly stronger associations with psychotic-like experiences, internalizing and externalizing problems, and reduced life satisfaction relative to the active-elated dimension. Adolescents at 'high-risk' for bipolar disorder reported more psychopathology relative to the comparison group.</AbstractText><AbstractText Label="LIMITATIONS">Absence of the clinical diagnosis of bipolar disorder in the sample means that the classification of the 'high-risk' group cannot be confirmed.</AbstractText><AbstractText Label="CONCLUSIONS">The structure of the HCL-16 in this UK adolescent sample mirrored that observed in adult and clinical cohorts. The observed links between the HCL-16 and psychopathological dimensions that have been previously associated with both hypomania and bipolar disorder lend support to the HCL-16's validity as a hypomania instrument for adolescents. Better understanding of hypomania prior to adulthood has considerable potential for informing early intervention approaches.</AbstractText><CopyrightInformation>Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hosang</LastName><ForeName>Georgina M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Psychology Department, Goldsmiths, University of London, London SE14 6NW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardno</LastName><ForeName>Alastair G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Academic Unit of Psychiatry and Behavioural Sciences, University of Leeds, Leeds Institute of Health Sciences, Charles Thackrah Building, University of Leeds, 101 Clarendon Road, Leeds LS2 9LJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronald</LastName><ForeName>Angelica</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychological Sciences, Birkbeck, University of London, Malet Street, London WC1E 7HX, UK. Electronic address: a.ronald@bbk.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0901245</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100559</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M021475/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RP-2014-05-003</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057189" MajorTopicYN="N">Checklist</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adolescence</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">HCL</Keyword><Keyword MajorTopicYN="Y">Hypomania</Keyword><Keyword MajorTopicYN="Y">Hypomanic Checklist</Keyword><Keyword MajorTopicYN="Y">Youth</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>08</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27728870</ArticleId><ArticleId IdType="pii">S0165-0327(16)30524-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.08.033</ArticleId><ArticleId IdType="pmc">PMC5113133</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Abnorm Child Psychol. 2011 Oct;39(7):925-37</Citation><ArticleIdList><ArticleId IdType="pubmed">21625986</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Aug;41(8):1593-604</Citation><ArticleIdList><ArticleId IdType="pubmed">21134316</ArticleId></ArticleIdList></Reference><Reference><Citation>J Adolesc Health. 2010 Feb;46(2):124-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20113918</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychodyn Psychiatry. 2013 Fall;41(3):419-35</Citation><ArticleIdList><ArticleId IdType="pubmed">24001164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2010 Jan;51(1):31-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19686330</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2009 Apr;18(2):353-90, viii-ix</Citation><ArticleIdList><ArticleId IdType="pubmed">19264268</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 1997 Jul;38(5):581-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9255702</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2007 Jan-Feb;48(1):79-87</Citation><ArticleIdList><ArticleId IdType="pubmed">17145286</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):133-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12507746</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2015 Jul;172(7):638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">25734353</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 May;15(3):240-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23521542</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(2):e30320</Citation><ArticleIdList><ArticleId IdType="pubmed">22312423</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2000 Aug;2(4):286-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11122970</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 May;160:113-21</Citation><ArticleIdList><ArticleId IdType="pubmed">24461633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Oct;88(2):217-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16125784</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 10;141(2-3):143-59</Citation><ArticleIdList><ArticleId IdType="pubmed">22633181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11(4):391-400</Citation><ArticleIdList><ArticleId IdType="pubmed">19500092</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Qual Life Outcomes. 2005 Nov 15;3:72</Citation><ArticleIdList><ArticleId IdType="pubmed">16288650</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment. 2006 Jun;13(2):119-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16672728</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Aug;101(1-3):43-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17189651</ArticleId></ArticleIdList></Reference><Reference><Citation>Twin Res Hum Genet. 2013 Feb;16(1):117-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23110994</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jul;165(7):820-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18519522</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2008 Nov;117(4):812-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19025228</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2011 Nov;199(5):380-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21947654</ArticleId></ArticleIdList></Reference><Reference><Citation>J Adolesc. 2009 Oct;32(5):1075-88</Citation><ArticleIdList><ArticleId IdType="pubmed">19328541</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2014 Dec;55(12):1380-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24865127</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Sep;64(9):1032-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17768268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Jul;40(4):868-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24062593</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Dec;177:534-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11102329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Jun;131(1-3):68-78</Citation><ArticleIdList><ArticleId IdType="pubmed">21227510</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1995 Dec 18;60(6):588-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8825903</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):39-47</Citation><ArticleIdList><ArticleId IdType="pubmed">12507736</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1989 May;28(2):193-213</Citation><ArticleIdList><ArticleId IdType="pubmed">2748771</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Aug;124(3):351-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20129673</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Sep;72 (9):1250-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21672501</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2015 Aug;124(3):674-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25938536</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):48-58</Citation><ArticleIdList><ArticleId IdType="pubmed">14601036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28777982</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><PubDate><Year>2017</Year><Month>12</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Letter to the editor: Longitudinal stability of neurocognitive subtypes in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>46-47</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(17)30524-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2017.07.026</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Diego J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), Argentina; Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro University, Buenos Aires, Argentina. Electronic address: diejmartino@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scápola</LastName><ForeName>María</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina; Institute of Cognitive and Translational Neuroscience (INCyT), INECO Foundation, Favaloro University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>07</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28777982</ArticleId><ArticleId IdType="pii">S0022-3956(17)30524-1</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2017.07.026</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11469669</PMID><DateCompleted><Year>2001</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>62 Suppl 14</Volume><PubDate><Year>2001</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Diagnostic and therapeutic dilemmas in the management of pediatric-onset bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>10-5</MedlinePgn></Pagination><Abstract><AbstractText>Although the diagnosis of pediatric-onset bipolar disorder is controversial, an increasing literature of systematic research has challenged the traditional view that this disorder is a rare condition. This article summarizes research regarding the atypical presentation of pediatric bipolar disorder and its overlap with attention-deficit/hyperactivity disorder and other comorbid conditions, as well as family-genetic and treatment data. When structured interview data were examined, cases of pediatric mania constituted 16% of referrals to our outpatient clinic. Presentation is atypical by adult standards and includes irritability, chronicity, and mixed state. Family-genetic and treatment data help to establish diagnostic validity. Pediatric bipolar disorder is not a rare condition. Treatment requires a combined pharmacotherapy approach to address issues of comorbidity. Atypical antipsychotic medications have provided promising treatment results, but additional controlled clinical trials are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pediatric Psychopharmacology Unit of the Child Psychiatry Service, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA. wozniak@helix.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH50657-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019955" MajorTopicYN="N">Conduct Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>39</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11469669</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18271909</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Effects of trauma on bipolar disorder: the mediational role of interpersonal difficulties and alcohol dependence.</ArticleTitle><Pagination><MedlinePgn>293-302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2007.00504.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study examined: (i) the prevalence of trauma in a bipolar disorder (BD) sample, and (ii) how trauma histories mediated by interpersonal difficulties and alcohol dependence impact on the severity of BD. The prevalence of posttraumatic stress disorder (PTSD) and its relationship to outcomes in BD were also examined.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixty participants were recruited from a geographically well-defined mental health service in Northern Ireland. Self-reported trauma histories, PTSD, interpersonal difficulties and alcohol dependence and were examined in relation to illness severity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A high prevalence of trauma was found. Trauma predicted the frequency of hospital admissions (R(2) = 0.08), quality of life (R(2) = 0.23) and inter-episode depressive symptoms (R(2) = 0.13). Interpersonal difficulties, but not alcohol dependence, appeared to play an important role in mediating these adverse effects. While only 8% of the sample met criteria for active PTSD, this comorbid disorder was associated with BD severity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study indicates that awareness of trauma is important in understanding individual differences in bipolar presentations. The theoretical and clinical implications of evidence that trauma is related to more adverse outcomes in BD are discussed. The finding that interpersonal difficulties mediate the relationship between trauma and BD severity is novel. The need for adjunctive evidence-based treatments targeting interpersonal difficulties is considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>Chrissie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychology, Queens University of Belfast, Belfast, Northern Ireland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCusker</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Meenagh</LastName><ForeName>Ciaran</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mulholland</LastName><ForeName>Ciaran</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Ciaran</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="Y">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18271909</ArticleId><ArticleId IdType="pii">BDI504</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00504.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3766811</PMID><DateCompleted><Year>1986</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>143</Volume><Issue>10</Issue><PubDate><Year>1986</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Rapid switch in a bipolar patient during lithium-tricyclic therapy.</ArticleTitle><Pagination><MedlinePgn>1326-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delisle</LastName><ForeName>J D</ForeName><Initials>JD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>OGG85SX4E4</RegistryNumber><NameOfSubstance UI="D007099">Imipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007099" MajorTopicYN="N">Imipramine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3766811</ArticleId><ArticleId IdType="doi">10.1176/ajp.143.10.1326b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16116946</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2917</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Depressive and bipolar disorders: patients' attitudes and beliefs towards depression and antidepressants.</ArticleTitle><Pagination><MedlinePgn>1205-13</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is increasing evidence that attitudes and beliefs are important in predicting adherence to treatment and medication in depressive and bipolar disorders. However, these attitudes have received little study in patients whose disorders were sufficiently severe to require hospitalization.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The Antidepressant Compliance Questionnaire (ADCQ) was mailed to a large population of patients with depressive or bipolar disorder, representative of patients treated in hospital settings in Denmark.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 1005 recipients, 49.9% responded to the letter. A large proportion of the patients (40-80%) had erroneous views as to the effect of antidepressants. Older patients (over 40 years of age) consistently had a more negative view of the doctor-patient relationship, more erroneous ideas concerning the effect of antidepressants and a more negative view of antidepressants in general. Moreover, their partners agreed on these negative views. Women had a more negative view of the doctor-patient relationship than men, and patients with a depressive disorder had a more negative view of antidepressants than patients with bipolar disorder. The number of psychiatric hospitalizations or the type of treating physician (general practitioner, psychiatrist in private practice, community psychiatrist, hospital psychiatrist, other doctor) did not affect attitudes and beliefs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Lack of knowledge about affective disorder and its treatment and a critical attitude, especially among older patients, may add to an adverse prognosis of depressive and bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>Lars Vedel</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark. lars.kessing@rh.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Hanne Vibe</ForeName><Initials>HV</Initials></Author><Author ValidYN="Y"><LastName>Demyttenaere</LastName><ForeName>Koen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bech</LastName><ForeName>Per</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003469" MajorTopicYN="Y">Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16116946</ArticleId><ArticleId IdType="doi">10.1017/s0033291705004605</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21176026</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Auditory steady state response in bipolar disorder: relation to clinical state, cognitive performance, medication status, and substance disorders.</ArticleTitle><Pagination><MedlinePgn>793-803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2010.00871.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">  Abnormalities in auditory steady state response (ASSR) at gamma range frequencies have been found in bipolar disorder, but the relationship of these neurophysiological disturbances to clinical factors has not been well characterized. We therefore evaluated the ASSR in bipolar disorder and examined its sensitivity to clinical symptoms, cognitive function, and pharmacological treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">  A total of 68 patients with bipolar disorder and 77 control participants were evaluated. Click trains presented at 20, 30, 40, and 50 Hz evoked ASSRs. Mean trial power (MTP) and phase locking factor (PLF) measured response magnitude and phase synchronization of the ASSR at each stimulation frequency. Clinical state, pharmacological treatment, and neuropsychological performance were assessed, and their respective relationships with ASSR measures were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">  Patients with bipolar disorder showed reduced MTP and PLF compared to control participants. Bipolar disorder patients taking psychotropic medications had decreased PLF relative to patients withdrawn from medications. Control participants performed better on neuropsychological tests than bipolar disorder patients; however, test scores did not correlate with ASSR measures.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">  Deficits in the generation and maintenance of ASSR are present in bipolar disorder, implicating disturbances in auditory pathways. ASSR may be sensitive to medication status. Other clinical features, including mood state, psychotic features, cognitive performance, smoking, or history of substance use disorder, were unrelated to MTP or PLF.</AbstractText><CopyrightInformation>© 2010 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rass</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychological and Brain Sciences, Indiana University, 101 East 10th Street, Bloomington, IN 47405, USA. rasso@indiana.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Giri</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Colleen A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Hetrick</LastName><ForeName>William P</ForeName><Initials>WP</Initials></Author><Author ValidYN="Y"><LastName>Merrill</LastName><ForeName>Colleen C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Shekhar</LastName><ForeName>Anantha</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>Brian F</ForeName><Initials>BF</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH07498</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH062150-08</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH071876</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH62150</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH091774</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH091774-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH062150</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000161" MajorTopicYN="N">Acoustic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001306" MajorTopicYN="Y">Auditory Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001309" MajorTopicYN="N">Auditory Threshold</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003344" MajorTopicYN="N">Cortical Synchronization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005072" MajorTopicYN="N">Evoked Potentials, Auditory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21176026</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2010.00871.x</ArticleId><ArticleId IdType="pmc">PMC3060563</ArticleId><ArticleId IdType="mid">NIHMS247620</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schizophr Res. 2009 Sep;113(2-3):158-66</Citation><ArticleIdList><ArticleId IdType="pubmed">19615864</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):939-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17064424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Nov;10(7):776-87</Citation><ArticleIdList><ArticleId IdType="pubmed">19032709</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Nov;56(11):1001-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10565499</ArticleId></ArticleIdList></Reference><Reference><Citation>J Acoust Soc Am. 1989 Sep;86(3):1033-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2794240</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):262-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14754775</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Audiol. 2003 Jun;42(4):177-219</Citation><ArticleIdList><ArticleId IdType="pubmed">12790346</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2004 Jun 3;363(1):65-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15157998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2008 Feb;18(2):371-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17557901</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jul 15;62(2):121-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17123476</ArticleId></ArticleIdList></Reference><Reference><Citation>Electroencephalogr Clin Neurophysiol. 1983 Apr;55(4):468-84</Citation><ArticleIdList><ArticleId IdType="pubmed">6187540</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicotine Tob Res. 2004 Dec;6(6):961-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15801570</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Nov;35(6):1065-77</Citation><ArticleIdList><ArticleId IdType="pubmed">19726534</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychophysiol. 2004 Jun;53(1):45-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15172135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11(4):371-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19500090</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Oct 1;70(2-3):293-302</Citation><ArticleIdList><ArticleId IdType="pubmed">15329305</ArticleId></ArticleIdList></Reference><Reference><Citation>Electroencephalogr Clin Neurophysiol. 1987 Jun;66(6):539-46</Citation><ArticleIdList><ArticleId IdType="pubmed">2438120</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Biochem Behav. 2001 Dec;70(4):561-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11796154</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 May;10(3):377-86</Citation><ArticleIdList><ArticleId IdType="pubmed">18402626</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jan;162(1):43-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15625200</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin EEG Neurosci. 2006 Apr;37(2):81-98</Citation><ArticleIdList><ArticleId IdType="pubmed">16733940</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2007 Sep;32(9):1888-902</Citation><ArticleIdList><ArticleId IdType="pubmed">17299517</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2000 Feb;148(2):132-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10663427</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2008 Feb;117(1):164-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18266494</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Oct 1;42(4):1481-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18634887</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1995 Mar 1;37(5):300-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7748981</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Feb 1;73(1):69-78</Citation><ArticleIdList><ArticleId IdType="pubmed">15567079</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1990 Nov 21;264(19):2511-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2232018</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1981 Apr;78(4):2643-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6941317</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Dec 1;22(23):10501-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12451150</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2004 Jun 7;15(8):1369-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15167568</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2004 Dec;18(4):457-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15582913</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2007 May;37(5):667-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17224092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hear Res. 1996 Nov 1;101(1-2):62-74</Citation><ArticleIdList><ArticleId IdType="pubmed">8951433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1996 Jul 1;16(13):4240-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8753885</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Feb;106(1-2):153-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17655936</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jun;57(6):618-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10839342</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2001 Jul;25(1):1-27</Citation><ArticleIdList><ArticleId IdType="pubmed">11377916</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2006;2:199-235</Citation><ArticleIdList><ArticleId IdType="pubmed">17716069</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2010 May;13(4):487-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19627651</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2005 Sep-Oct;13(5):257-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16251165</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Oct 5;52(1):155-68</Citation><ArticleIdList><ArticleId IdType="pubmed">17015233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Jun;123(1-3):276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19766321</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 2006 Nov;175(4):702-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16826412</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1991 Nov;21(4):867-79</Citation><ArticleIdList><ArticleId IdType="pubmed">1780401</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2238-40</Citation><ArticleIdList><ArticleId IdType="pubmed">14638599</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Sep;195(3):194-201</Citation><ArticleIdList><ArticleId IdType="pubmed">19721106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 Aug;8(8):721-37, 715</Citation><ArticleIdList><ArticleId IdType="pubmed">12888801</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2008 Jul;34(4):760-73</Citation><ArticleIdList><ArticleId IdType="pubmed">18502737</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Sep 1;64(5):369-75</Citation><ArticleIdList><ArticleId IdType="pubmed">18400208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):114-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17391355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 3:26-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9541335</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Dec 1;60(11):1231-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16893524</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1994 Apr;44(4):609-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8164812</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Aug 15;40(4):284-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8871775</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2008 Oct;18(10):717-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18554875</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Nov 17;24(46):10369-78</Citation><ArticleIdList><ArticleId IdType="pubmed">15548651</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1017-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18762588</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2004 Mar;38(3):135-40</Citation><ArticleIdList><ArticleId IdType="pubmed">14961931</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 2004 Mar 15;134(1):9-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15102499</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28263040</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>02</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Influence of cognitive reserve on neuropsychological functioning in bipolar disorder: Findings from a 5-year longitudinal study.</ArticleTitle><Pagination><MedlinePgn>50-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12470</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The present study examined the 5-year longitudinal course of cognitive functioning in a large sample of well-characterized patients with bipolar disorder (BP), compared to healthy controls (HCs), and the influence of cognitive reserve factors (e.g., education and IQ) on cognitive change over time.</AbstractText><AbstractText Label="METHODS">Participants included 159 individuals diagnosed with BP and 54 HCs recruited as part of a longitudinal naturalistic study of BP who had completed neuropsychological testing at the time of their enrollment and again 5 years later.</AbstractText><AbstractText Label="RESULTS">The overall relative rate of change did not differ between the BP and HC groups. In total, 46.5% of the BP group and 37% of the HC group showed evidence of decline on at least one measure over time. T-test analyses did not find differences between BP 'decliners' and 'non-decliners' in cognitive reserve variables. However, we found that higher baseline intellectual ability was associated with more stability in cognitive test scores over time for the BP group. Results of linear regression modeling revealed that lower verbal IQ and education were related to increased cognitive decline in specific domains in the BP group.</AbstractText><AbstractText Label="CONCLUSIONS">This study has explored the influence of cognitive reserve on preservation of specific cognitive abilities over time in BP. The BP group did not demonstrate accelerated cognitive decline over 5 years compared to the HC group. Although the trajectory of cognitive change over time was similar between BP patients and HCs, higher overall intellectual ability may be a protective factor against cognitive decline, particularly for BP patients.</AbstractText><CopyrightInformation>© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hinrichs</LastName><ForeName>Kristin H</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-8345-2277</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Easter</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angers</LastName><ForeName>Kaley</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pester</LastName><ForeName>Bethany</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Zongshan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>David F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamali</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McInnis</LastName><ForeName>Melvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langenecker</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Kelly A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2017 Aug;19(5):405</RefSource><PMID Version="1">28833994</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058245" MajorTopicYN="Y">Cognitive Reserve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="Y">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007807" MajorTopicYN="N">Language Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">clinical neuropsychology</Keyword><Keyword MajorTopicYN="Y">cognitive reserve</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>01</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28263040</ArticleId><ArticleId IdType="doi">10.1111/bdi.12470</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24580856</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2014</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Bipolar II disorder in patients with a current diagnosis of recurrent depression.</ArticleTitle><Pagination><MedlinePgn>389-99</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12192</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The prevalence of bipolar II disorder (BD-II) in Russia has never been studied. Therefore, we sought to identify patients meeting diagnostic criteria for BD-II among patients with a current diagnosis of recurrent depressive disorder (RDD) through the use of the Russian versions of the Hypomania Checklist (HCL-32) and Bipolarity Index scales for differentiating between BD-II and RDD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a non-interventional diagnostic study, we selected 409 patients aged between 18 and 65 years from two medical settings with (i) a current diagnosis of RDD, (ii) an illness duration of at least three years, and (iii) at least two affective episodes. The diagnosis was based on clinical assessment and confirmed by the Russian version of the Mini International Neuropsychiatric Interview. All patients were assessed by the HCL-32, the Bipolarity Index, and the Personal and Social Performance Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among patients with a current diagnosis of RDD, 40.8% had a diagnosis of bipolar disorder (bipolar I disorder: 4.9%; BD-II: 35.9%). The average time lag from onset to a correct diagnosis of BD-II was 15 years and patients were treated only with antidepressants. The sensitivity of the Russian version of the HCL-32 at the optimal cutoff point (≥14.0) was 83.7%, and its specificity was 71.9%. The Bipolarity Index showed significant differences between the total scores of the patients with BD-II and RDD (31.8 versus 20.2; p &lt; 0.0001). The optimal threshold was ≥22.0 (sensitivity 73.5%; specificity 72.3%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In Russia, diagnostic errors are an important cause of the non-detection of bipolar disorder, particularly BD-II. The Russian version of the HCL-32 and the Bipolarity Index, as additional tools, could be useful for bipolarity screening.</AbstractText><CopyrightInformation>© 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosolov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department for Therapy of Mental Disorders, Moscow Research Institute of Psychiatry, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ushkalova</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kostukova</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Shafarenko</LastName><ForeName>Alexey</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Alfimov</LastName><ForeName>Pavel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kostyukova</LastName><ForeName>Anastasiya</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>Jules</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hypomania Checklist (HCL-32)</Keyword><Keyword MajorTopicYN="N">Personal and Social Performance Scale</Keyword><Keyword MajorTopicYN="N">Russia</Keyword><Keyword MajorTopicYN="N">bipolar II disorder</Keyword><Keyword MajorTopicYN="N">bipolarity</Keyword><Keyword MajorTopicYN="N">recurrent depressive disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>07</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24580856</ArticleId><ArticleId IdType="doi">10.1111/bdi.12192</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">23931923</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>382</Volume><Issue>9891</Issue><PubDate><Year>2013</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Somatic treatments for severe bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>505-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(13)61712-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(13)61712-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kellner</LastName><ForeName>Charles H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Briggs</LastName><ForeName>Mimi C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Liebman</LastName><ForeName>Lauren S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Ahle</LastName><ForeName>Gabriella M</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet. 2013 May 11;381(9878):1672-82</RefSource><PMID Version="1">23663953</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23931923</ArticleId><ArticleId IdType="pii">S0140-6736(13)61712-2</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(13)61712-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11925314</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>159</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Ziprasidone induction of hypomania in depression?</ArticleTitle><Pagination><MedlinePgn>673-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Risch</LastName><ForeName>Samuel C</ForeName><Initials>SC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>6UKA5VEJ6X</RegistryNumber><NameOfSubstance UI="C092292">ziprasidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>19</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11925314</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.159.4.673</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30722937</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2019</Year><Month>Jun</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Therapeutic education: A lever to change perceptions of bipolar disorder in family caregivers].</ArticleTitle><Pagination><MedlinePgn>239-244</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0013-7006(19)30023-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2018.11.004</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The patient with bipolar disorder and his family are caught in a reciprocal interaction: on one hand, the pathology leads to family sufferings and on the other hand, family behavior affects the disease of the patient and its development. Therefore, it seems of core importance that the psychologist should work with the family on their perception of bipolar disorder, that is to say, on their knowledge and psychological representations of the pathology. The aim of our study is to assess whether the initial perception of bipolar disorder evolves after a therapeutic education program.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Our research was conducted at the Bipolar Expertise Centre in Bordeaux/Centre Expert Bipolaire in Bordeaux on a sample of 145 participants (78patients and 67 family caregivers). They were all interviewed before and after the therapeutic education program (12 sessions in 6months). The Brief Illness Perception Questionnaire Revised (Moss-Morris, 2002) measures the perception of bipolar disorder and the BP Quizz (Fondation Fondamental) assesses the degree of knowledge of the disorder.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results show that therapeutic education helps families to level up their knowledge about bipolar disorder. Furthermore, representations on bipolar disorder have globally changed so that on average, bipolar disorder is viewed as less threatening by families after 12 sessions of therapeutic education. More precisely, after the program, families have a better understanding and a better insight of the disorder, which is then perceived as being less severe. On the emotional level, anxiety and stress have decreased. So there are an increase of knowledge and a change in perception.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study shows that the therapeutic education program enables families to change their perception of the disease, that is to say, their knowledge but also their representations of the disease, which is a fundamental element according to the models of therapeutic education. Our results point out one of the active processes of therapeutic education at work in the sessions: in the perception of the disease, which is composed of both knowledge and representations of the disease, just a change in representations constitutes a lever for therapeutic education. Therefore, working on representations should be a therapeutic target. As a conclusion, we can say that therapeutic education of families cannot be reduced to an educational dimension which would only consist of gaining knowledge. Then, the right posture of the psychologist is to hold each participant's own development and changing process of representations.</AbstractText><CopyrightInformation>Copyright © 2019 L’Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M'Bailara</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>EA4139, laboratoire de psychologie, université de Bordeaux, 33076 Bordeaux cedex, France; Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Centre expert trouble bipolaire, fondation FondaMental, fondation de Coopération scientifique, 94000 Créteil, France. Electronic address: katia.mbailara@u-bordeaux.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minois</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Centre expert trouble bipolaire, fondation FondaMental, fondation de Coopération scientifique, 94000 Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanouy</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Centre expert trouble bipolaire, fondation FondaMental, fondation de Coopération scientifique, 94000 Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josse</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Centre expert trouble bipolaire, fondation FondaMental, fondation de Coopération scientifique, 94000 Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouan</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cabinet libéral, 33650 Saucat, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maîtrot</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cabinet libéral, 33800 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sportich</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Centre expert trouble bipolaire, fondation FondaMental, fondation de Coopération scientifique, 94000 Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roux</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>EA4139, laboratoire de psychologie, université de Bordeaux, 33076 Bordeaux cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jutant</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deloge</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desage</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gard</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pôle 3-4-7, centre hospitalier Charles-Perrens, 33076 Bordeaux, France; Centre expert trouble bipolaire, fondation FondaMental, fondation de Coopération scientifique, 94000 Créteil, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>L’éducation thérapeutique : un levier pour modifier les perceptions du trouble bipolaire chez les aidants familiaux.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Famille</Keyword><Keyword MajorTopicYN="N">Family</Keyword><Keyword MajorTopicYN="N">Fonctionnement psychosocial</Keyword><Keyword MajorTopicYN="N">Perception</Keyword><Keyword MajorTopicYN="N">Psychosocial functioning</Keyword><Keyword MajorTopicYN="N">Representation</Keyword><Keyword MajorTopicYN="N">Therapeutic education</Keyword><Keyword MajorTopicYN="N">Trouble bipolaire</Keyword><Keyword MajorTopicYN="N">Éducation thérapeutique</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>08</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30722937</ArticleId><ArticleId IdType="pii">S0013-7006(19)30023-5</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2018.11.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16707029</PMID><DateCompleted><Year>2006</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0033-2917</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>9</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>A pilot study of positive mood induction in euthymic bipolar subjects compared with healthy controls.</ArticleTitle><Pagination><MedlinePgn>1213-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Demonstrating differences between euthymic bipolar subjects and healthy controls in response to positive (happy) mood induction may help elucidate how mania evolves. This pilot study evaluates the Go task in a reward paradigm as a method for inducing a happy mood state and compares the response of euthymic bipolar subjects and healthy controls.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The Sense of Hyperpositive Self Scale, the Tellegen positive and negative adjectives, the Global-Local task and a visual analogue scale for measuring positive affect were administered to 15 euthymic bipolar subjects and 19 age-and-sex-matched healthy control subjects before and after they had performed the Go task in a reward paradigm.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significant differences were found between subjects and controls on several measures at each time-point but there were no differences across the groups across time except for the visual analogue scales, where subjects had a more sustained duration in self-reported happiness compared with controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This pilot study has shown that a positive affect can be induced in bipolar subjects and controls which can be demonstrated by changes in scores on several tasks. However, only the visual analogue scales showed a significant difference between cases and controls over time. Such tests may prove valuable in furthering understanding about the evolution of manic mood states.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farmer</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>MRC Social, Genetic and Developmental Psychiatry Research Centre, Institute of Psychiatry, Camberwell, London, UK. a.farmer@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sahakian</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Roiser</LastName><ForeName>Jonathon</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Ailbhe</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Keating</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Georgia Powell</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>McGuffin</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0001354</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701003</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16707029</ArticleId><ArticleId IdType="pii">S0033291706007835</ArticleId><ArticleId IdType="doi">10.1017/S0033291706007835</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">848594</PMID><DateCompleted><Year>1977</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>134</Volume><Issue>5</Issue><PubDate><Year>1977</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Nontoxic hyperlithemia in impending mania.</ArticleTitle><Pagination><MedlinePgn>580-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolpert</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1977</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1977</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1977</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">848594</ArticleId><ArticleId IdType="doi">10.1176/ajp.134.5.580</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31214924</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-8218</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuroscience bulletin</Title><ISOAbbreviation>Neurosci Bull</ISOAbbreviation></Journal><ArticleTitle>The Relationship Between Neuroimmunity and Bipolar Disorder: Mechanism and Translational Application.</ArticleTitle><Pagination><MedlinePgn>595-607</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12264-019-00403-7</ELocationID><Abstract><AbstractText>Neuroimmune system may be involved in the pathological process of bipolar disorder (BD), but the essential association is not fully understood. Accumulating evidence has shown that BD involves the activation of immune cells and the release of inflammatory substances in the central nerve system (CNS). Meanwhile, neuroimmune responses also interact with other hypothesis of the etiology of BD that are widely recognized, such as neurotransmitter systems, neuroendocrine systems, neurotrophic factors, and oxidative stress. Simultaneously, related genes and immune changes in peripheral blood vary with it. Overall, neuroimmunity may play an important role in the pathogenesis of BD, and the inflammatory cytokines, especially interleukin-6 and tumor necrosis factor-alpha, have potential value for the clinical diagnosis and prognosis of BD, as well as predicting the therapeutic effects of drugs. Large-scale studies are needed to extend the evidence on neuroimmunity in BD, and to examine its clinical value for applications such as early prediction and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Zhiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xiaohui</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuncheng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China. doctorcj2010@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yiru</ForeName><Initials>Y</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8748-9085</Identifier><AffiliationInfo><Affiliation>Clinical Research Center, Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China. yirufang@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai, 200031, China. yirufang@aliyun.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 201108, China. yirufang@aliyun.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Neurosci Bull</MedlineTA><NlmUniqueID>101256850</NlmUniqueID><ISSNLinking>1995-8218</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015213" MajorTopicYN="N">Neuroimmunomodulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009490" MajorTopicYN="N">Neurosecretory Systems</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Neuroimmunity</Keyword><Keyword MajorTopicYN="N">Translational application</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>02</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>05</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31214924</ArticleId><ArticleId IdType="doi">10.1007/s12264-019-00403-7</ArticleId><ArticleId IdType="pii">10.1007/s12264-019-00403-7</ArticleId><ArticleId IdType="pmc">PMC6617679</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuroscience. 1999;88(3):823-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10363820</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2001;15(5):361-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11475942</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2001 Nov;36(2):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11596126</ArticleId></ArticleIdList></Reference><Reference><Citation>J Endotoxin Res. 2003;9(1):3-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12691614</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13632-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14581618</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2004 Mar;41(3):219-23</Citation><ArticleIdList><ArticleId IdType="pubmed">14985387</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2006 Mar;40(3):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16476148</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2007 Mar;8(3):247-56</Citation><ArticleIdList><ArticleId IdType="pubmed">17277779</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2007 Jul;87(3):873-904</Citation><ArticleIdList><ArticleId IdType="pubmed">17615391</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2008 Jan;9(1):46-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18073775</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Aug 15;181(4):2683-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18684959</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Feb 15;65(4):296-303</Citation><ArticleIdList><ArticleId IdType="pubmed">18801471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2008 Oct;1139:318-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18991877</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2009 Feb;1153:139-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19236337</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2010 Jan;40(1):1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19335939</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Apr;15(4):384-92</Citation><ArticleIdList><ArticleId IdType="pubmed">19488045</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Aug;70(8):1078-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19497250</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2009 Aug;14(8):419-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19890236</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimmunomodulation. 2010;17(2):126-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19923858</ArticleId></ArticleIdList></Reference><Reference><Citation>Nord J Psychiatry. 2012 Feb;66(1):14-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21728784</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroendocrinology. 2012;95(3):179-86</Citation><ArticleIdList><ArticleId IdType="pubmed">22076031</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2013;67(2):116-21</Citation><ArticleIdList><ArticleId IdType="pubmed">23406623</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jul 1;74(1):15-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23419545</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2013 Apr;30(4):297-306</Citation><ArticleIdList><ArticleId IdType="pubmed">23468190</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:271-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23537502</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Nov;47(11):1694-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23896207</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2014 Jun;29(6):635-44</Citation><ArticleIdList><ArticleId IdType="pubmed">24273017</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2014 Jan;14(1):51-65</Citation><ArticleIdList><ArticleId IdType="pubmed">24308275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 May;16(3):241-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24372850</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2014 May;42:35-54</Citation><ArticleIdList><ArticleId IdType="pubmed">24509064</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2014 May 21;34(21):7113-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24849347</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2015 Apr;232(7):1325-36</Citation><ArticleIdList><ArticleId IdType="pubmed">25345732</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2014 Nov-Dec;22(6):331-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25377604</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Feb 1;172:55-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25451396</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2015 Jan;43:198-204</Citation><ArticleIdList><ArticleId IdType="pubmed">25451615</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Endocrinol. 2015 Jul;173(1):R1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25650405</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2015 Jul;40(4):250-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25768030</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2015 Sep;1351:11-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25943573</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2015 Aug 6;300:141-54</Citation><ArticleIdList><ArticleId IdType="pubmed">25981208</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2015 Aug;131:65-86</Citation><ArticleIdList><ArticleId IdType="pubmed">26067058</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2015 Oct;154:21-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26129625</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Aug;21(8):1090-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26194183</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Sep;17(6):606-14</Citation><ArticleIdList><ArticleId IdType="pubmed">26291962</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2015 Aug 18;6:180</Citation><ArticleIdList><ArticleId IdType="pubmed">26347709</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Dec 1;188:149-59</Citation><ArticleIdList><ArticleId IdType="pubmed">26363613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Apr 9;387(10027):1561-72</Citation><ArticleIdList><ArticleId IdType="pubmed">26388529</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2016 Jan;63:327-42</Citation><ArticleIdList><ArticleId IdType="pubmed">26547798</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Danub. 2015 Dec;27(4):385-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26609651</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Feb;191:29-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26630394</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 Dec;21(12):1696-1709</Citation><ArticleIdList><ArticleId IdType="pubmed">26903267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Mar;18(2):89-101</Citation><ArticleIdList><ArticleId IdType="pubmed">26990051</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Jun;197:167-74</Citation><ArticleIdList><ArticleId IdType="pubmed">26994434</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2016 Jul;50(7):618-30</Citation><ArticleIdList><ArticleId IdType="pubmed">27091850</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Sep 15;202:1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27253210</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Jun 07;6:27431</Citation><ArticleIdList><ArticleId IdType="pubmed">27270858</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Oct;203:364-373</Citation><ArticleIdList><ArticleId IdType="pubmed">27344047</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2016 Oct;176(2-3):191-195</Citation><ArticleIdList><ArticleId IdType="pubmed">27424266</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Immunol. 2016 Sep;37(9):608-620</Citation><ArticleIdList><ArticleId IdType="pubmed">27443914</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Dec;206:210-215</Citation><ArticleIdList><ArticleId IdType="pubmed">27475892</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2017 Jan;47(1):23-33</Citation><ArticleIdList><ArticleId IdType="pubmed">27476619</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2017 Jul;63:108-114</Citation><ArticleIdList><ArticleId IdType="pubmed">27477922</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Cell Dev Biol. 2016 Jun 28;4:71</Citation><ArticleIdList><ArticleId IdType="pubmed">27551677</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2017 Jan;42(1):193-215</Citation><ArticleIdList><ArticleId IdType="pubmed">27629368</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2017 May;232(5):1176-1186</Citation><ArticleIdList><ArticleId IdType="pubmed">27639185</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2017 Jan;84:113-118</Citation><ArticleIdList><ArticleId IdType="pubmed">27718369</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2016 Nov 8;6(11):e946</Citation><ArticleIdList><ArticleId IdType="pubmed">27824355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroimmunol. 2016 Dec 15;301:23-29</Citation><ArticleIdList><ArticleId IdType="pubmed">27836181</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2017 Mar;61:317-325</Citation><ArticleIdList><ArticleId IdType="pubmed">28025071</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Jan 11;7:40530</Citation><ArticleIdList><ArticleId IdType="pubmed">28074937</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2018 Feb;55(2):1430-1439</Citation><ArticleIdList><ArticleId IdType="pubmed">28168425</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2017 Mar;78(3):e286-e293</Citation><ArticleIdList><ArticleId IdType="pubmed">28199074</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2018 Jan 13;44(1):75-83</Citation><ArticleIdList><ArticleId IdType="pubmed">28338954</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2017 Jun 1;20(6):445-454</Citation><ArticleIdList><ArticleId IdType="pubmed">28339618</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2017 Mar 20;8:34</Citation><ArticleIdList><ArticleId IdType="pubmed">28373847</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropsychiatr. 2018 Apr;30(2):70-78</Citation><ArticleIdList><ArticleId IdType="pubmed">28399943</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2017 Aug 1;78:34-50</Citation><ArticleIdList><ArticleId IdType="pubmed">28438472</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2017 Oct;65:195-201</Citation><ArticleIdList><ArticleId IdType="pubmed">28483660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 May;19(3):198-213</Citation><ArticleIdList><ArticleId IdType="pubmed">28599348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 Jun;19(4):246-258</Citation><ArticleIdList><ArticleId IdType="pubmed">28612976</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2017 Oct;84:143-150</Citation><ArticleIdList><ArticleId IdType="pubmed">28711724</ArticleId></ArticleIdList></Reference><Reference><Citation>Mod Trends Pharmacopsychiatry. 2017;31:79-95</Citation><ArticleIdList><ArticleId IdType="pubmed">28738369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2018 Feb;20(1):27-34</Citation><ArticleIdList><ArticleId IdType="pubmed">28833866</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neuropharmacol. 2018;16(5):519-532</Citation><ArticleIdList><ArticleId IdType="pubmed">28847296</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2017 Sep/Oct;78(8):e986-e993</Citation><ArticleIdList><ArticleId IdType="pubmed">28922589</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Immunol. 2017 Dec;86(6):479-485</Citation><ArticleIdList><ArticleId IdType="pubmed">29032575</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Sci. 2017 Oct 30;7(11):null</Citation><ArticleIdList><ArticleId IdType="pubmed">29084144</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2018 Jan 1;75(1):65-74</Citation><ArticleIdList><ArticleId IdType="pubmed">29121268</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Bull. 2018 Apr;34(2):270-282</Citation><ArticleIdList><ArticleId IdType="pubmed">29124672</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neuropharmacol. 2018;16(5):533-558</Citation><ArticleIdList><ArticleId IdType="pubmed">29173175</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Res Int. 2017;2017:4151594</Citation><ArticleIdList><ArticleId IdType="pubmed">29250539</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2018 Mar;261:383-390</Citation><ArticleIdList><ArticleId IdType="pubmed">29353768</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2018 Jan 24;8(1):27</Citation><ArticleIdList><ArticleId IdType="pubmed">29362444</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):103-108</Citation><ArticleIdList><ArticleId IdType="pubmed">29397672</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2018 Jun 1;21(6):582-591</Citation><ArticleIdList><ArticleId IdType="pubmed">29471411</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2018 Sep;92:477-485</Citation><ArticleIdList><ArticleId IdType="pubmed">29940237</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2018 Dec 1;84(11):787-796</Citation><ArticleIdList><ArticleId IdType="pubmed">30177255</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2019 Apr 5;16(1):74</Citation><ArticleIdList><ArticleId IdType="pubmed">30953557</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13290-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9789081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24767016</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>162</Volume><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Screening for bipolar depression in family medicine practices: prevalence and clinical correlates.</ArticleTitle><Pagination><MedlinePgn>120-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2014.03.040</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(14)00151-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To compare individuals in primary care (PC) who screen positive for bipolar depression to those who screened positive for unipolar depression on mental health care ouctomes, PC service utilization, medical comorbidities, suicidal ideation, health-related quality of life (HRQoL) and psychosocial functioning.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this cross-sectional study, participants (N=1197) answered self-reported measures of depressive symptoms (Center for epidemiologic studies depression scale), HRQoL (World Health Organization Quality of Life instrument-Abbreviated version), medical comorbidity (functional comorbidity index) and functioning (Functional Assessment Short test). Participants were partitioned into 'bipolar' and 'unipolar' depression groups based on a predefined cutoff on the Brazilian mood disorder questionnaire.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of bipolar depression was in PC was 4.6% (95% CI: 3.4-5.8). Participants with bipolar depression were more likely to endorse suicidal ideation, present with more medical comorbidities, report a worse physical HRQoL and have a higher rate of PC services utilization as compared to participants who screened positive for unipolar depression. Only six (10.9%) participants were recognized by the general practitioner as having a diagnosis of bipolar depression.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The cross-sectional design prevents firm causal inferences from being drawn. A positive screen for BD does not substantiate the actual diagnosis. Co-morbid mental disorders were not accessed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bipolar depression is common and under-recognized in Brazilian PC services. A positive screen for bipolar depression was associated with worse clinical outcomes and greater PC service utilization.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>André F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil; Department of Clinical Medicine, Faculty of Medicine, Fortaleza, Ceará, Brazil. Electronic address: andrefc7@terra.com.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes-Neto</LastName><ForeName>Paulo R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelo</LastName><ForeName>Milena S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil; Department of Clinical Medicine, Faculty of Medicine, Fortaleza, Ceará, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macêdo</LastName><ForeName>Danielle S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil; Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Ceará, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimellis</LastName><ForeName>Dimos</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soeiro-de-Souza</LastName><ForeName>Márcio G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Mood Disorders Unit (GRUDA), Department and Institute of Psychiatry, School of Medicine, University of Sao Paulo (IPq-HC-FMUSP), Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soczynska</LastName><ForeName>Joanna K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyphantis</LastName><ForeName>Thomas N</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, University of Ioannina, Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fountoulakis</LastName><ForeName>Konstantinos N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005194" MajorTopicYN="N">Family Practice</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar depression</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Functioning</Keyword><Keyword MajorTopicYN="N">Primary care</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Service utilization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>03</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>03</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24767016</ArticleId><ArticleId IdType="pii">S0165-0327(14)00151-7</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2014.03.040</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28503105</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6190</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>04</Month></PubDate></JournalIssue><Title>Current neuropharmacology</Title><ISOAbbreviation>Curr Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Neurobiological Evidence for the Primacy of Mania Hypothesis.</ArticleTitle><Pagination><MedlinePgn>339-352</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1570159X14666160708231216</ELocationID><Abstract><AbstractText Label="BACKGROUND">Athanasios Koukopoulos proposed the primacy of mania hypothesis (PoM) in a 2006 book chapter and later, in two peer-reviewed papers with Nassir Ghaemi and other collaborators. This hypothesis supports that in bipolar disorder, mania leads to depression, while depression does not lead to mania.</AbstractText><AbstractText Label="OBJECTIVE">To identify evidence in literature that supports or falsifies this hypothesis.</AbstractText><AbstractText Label="METHOD">We searched the medical literature (PubMed, Embase, PsycINFO, and the Cochrane Library) for peer-reviewed papers on the primacy of mania, the default mode function of the brain in normal people and in bipolar disorder patients, and on illusion superiority until 6 June, 2016. Papers resulting from searches were considered for appropriateness to our objective. We adopted the PRISMA method for our review. The search for consistency with PoM was filtered through the neurobiological results of superiority illusion studies.</AbstractText><AbstractText Label="RESULTS">Out of a grand total of 139 records, 59 were included in our analysis. Of these, 36 were of uncertain value as to the primacy of mania hypothesis, 22 favoured it, and 1 was contrary, but the latter pooled patients in their manic and depressive phases, so to invalidate possible conclusions about its consistency with regard to PoM. All considered studies were not focused on PoM or superiority illusion, hence most of their results were, as expected, unrelated to the circuitry involved in superiority illusion. A considerable amount of evidence is consistent with the hypothesis, although indirectly so.</AbstractText><AbstractText Label="LIMITATIONS">Only few studies compared manic with depressive phases, with the majority including patients in euthymia.</AbstractText><AbstractText Label="CONCLUSION">It is possible that humans have a natural tendency for elation/optimism and positive self-consideration, that are more akin to mania; the depressive state could be a consequence of frustrated or unsustainable mania. This would be consistent with PoM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kotzalidis</LastName><ForeName>Georgios D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapinesi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savoja</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ASL Roma 3, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuomo</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinica Neuropsichiatrica Villa von Siebenthal, Genzano di Roma (Rome), Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonetti</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambrosi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panaccione</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gubbini</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>USL Umbria 2, Terni, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Rossi</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Chiara</LastName><ForeName>Lavinia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janiri</LastName><ForeName>Delfina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sani</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koukopoulos</LastName><ForeName>Alexia E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napoletano</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Core Trainee in Psychiatry, NELFT (North East London Foundation Trust), London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, Institute of Psychiatry, Psychology and Neuroscience, Department of Psychosis Studies, 16 De Crespigny Park, London SE5 8AF London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caloro</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pancheri</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Italian Psychoanalytical Society (SPI), Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzella</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Studio Multiverso, ATC-SITCC, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callovini</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Federico II University, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angeletti</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro Lucio Bini, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Casale</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NESMOS Department, Sapienza University - Rome, School of Medicine and Psychology, Sant'Andrea Hospital, Via di Grottarossa 1035-1039, 00189 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatric Rehabilitation, Father A. Mileno Onlus Foundation, San Francesco Institute, Vasto (Chieti), Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Neuropharmacol</MedlineTA><NlmUniqueID>101157239</NlmUniqueID><ISSNLinking>1570-159X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="Y">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012146" MajorTopicYN="N">Rest</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar Disorder</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Mania</Keyword><Keyword MajorTopicYN="Y">Primacy of Mania Hypothesis</Keyword><Keyword MajorTopicYN="Y">Superiority Illusion</Keyword><Keyword MajorTopicYN="Y">functional Magnetic Resonance Imaging (fMRI)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>05</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28503105</ArticleId><ArticleId IdType="doi">10.2174/1570159X14666160708231216</ArticleId><ArticleId IdType="pii">CN-15-339</ArticleId><ArticleId IdType="pmc">PMC5405607</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuroimage. 2014 Sep;98:73-81</Citation><ArticleIdList><ArticleId IdType="pubmed">24793833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2016 Aug;41(5):331-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26854755</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Jun;197:116-24</Citation><ArticleIdList><ArticleId IdType="pubmed">26991366</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2012 May 16;516(2):202-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22503728</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Dec 04;8(12):e79999</Citation><ArticleIdList><ArticleId IdType="pubmed">24324588</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2015 Nov 15;122:272-80</Citation><ArticleIdList><ArticleId IdType="pubmed">26216278</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2015 Nov;132(5):400-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25929680</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Jan;40(1):100-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23851068</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Aug;165:182-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24882198</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2016 Apr;63:191-206</Citation><ArticleIdList><ArticleId IdType="pubmed">26877105</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Aug;200:159-64</Citation><ArticleIdList><ArticleId IdType="pubmed">27136413</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychol. 2011 Nov 10;2:330</Citation><ArticleIdList><ArticleId IdType="pubmed">22084637</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):601-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23489402</ArticleId></ArticleIdList></Reference><Reference><Citation>IEEE Trans Auton Ment Dev. 2015 Dec;7(4):320-331</Citation><ArticleIdList><ArticleId IdType="pubmed">26858825</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Nerve. 2014 Jan;66(1):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">24371131</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2013 Mar 5;41:52-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23200830</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2009 Oct;62(10):1006-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19631508</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2014 Feb 17;10:317-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24570585</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Aug 15;182:8-17</Citation><ArticleIdList><ArticleId IdType="pubmed">25942576</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2016 Jan 29;81:265-73</Citation><ArticleIdList><ArticleId IdType="pubmed">26727304</ArticleId></ArticleIdList></Reference><Reference><Citation>Conf Proc IEEE Eng Med Biol Soc. 2013;2013:1057-60</Citation><ArticleIdList><ArticleId IdType="pubmed">24109873</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Nov 1;68(9):839-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20739018</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2016 Apr;34:56-63</Citation><ArticleIdList><ArticleId IdType="pubmed">26945530</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2012 Jul;98(1):38-48</Citation><ArticleIdList><ArticleId IdType="pubmed">22580447</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2014 Aug 06;14:222</Citation><ArticleIdList><ArticleId IdType="pubmed">25095790</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Jan 15;190:483-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26551408</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2016 Feb 17;11(2):e0148045</Citation><ArticleIdList><ArticleId IdType="pubmed">26885824</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 May;12(3):285-97</Citation><ArticleIdList><ArticleId IdType="pubmed">20565435</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Sci. 2013 Sep 12;3(3):1357-73</Citation><ArticleIdList><ArticleId IdType="pubmed">24961532</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2014 Dec;24(12):3116-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23825317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Aug;17(5):486-95</Citation><ArticleIdList><ArticleId IdType="pubmed">26241359</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 Oct 24;9(10 ):e107829</Citation><ArticleIdList><ArticleId IdType="pubmed">25343370</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Feb 28;231(2):141-50</Citation><ArticleIdList><ArticleId IdType="pubmed">25575881</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Mar;40(2):469-77</Citation><ArticleIdList><ArticleId IdType="pubmed">23599250</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Aug-Sep;203(2-3):175-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23017873</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Nov;40(6):1227-43</Citation><ArticleIdList><ArticleId IdType="pubmed">25031221</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2015 Aug;40(9):2258-68</Citation><ArticleIdList><ArticleId IdType="pubmed">25767910</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage Clin. 2014 Aug 23;6:134-44</Citation><ArticleIdList><ArticleId IdType="pubmed">25379425</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Jan;45(1):97-108</Citation><ArticleIdList><ArticleId IdType="pubmed">25066779</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Dec;96(3):165-75</Citation><ArticleIdList><ArticleId IdType="pubmed">16997381</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Mar 31;171(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19230623</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2016 Jan 19;371(1686):20150066</Citation><ArticleIdList><ArticleId IdType="pubmed">26644602</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14069-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22891349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2010 Jun;117(6):781-91</Citation><ArticleIdList><ArticleId IdType="pubmed">20411397</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2066-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24778245</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2016 Jul 1;134:645-57</Citation><ArticleIdList><ArticleId IdType="pubmed">27118088</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(11):e48181</Citation><ArticleIdList><ArticleId IdType="pubmed">23133615</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Mar 15;73(6):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22980587</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2015 Dec 21;6:174</Citation><ArticleIdList><ArticleId IdType="pubmed">26732139</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Connect. 2016 Apr;6(3):255-65</Citation><ArticleIdList><ArticleId IdType="pubmed">26824737</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 1;173:53-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25462396</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Behav Neurosci. 2014 Jun 27;8:232</Citation><ArticleIdList><ArticleId IdType="pubmed">25018710</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jun 30;182(3):207-10</Citation><ArticleIdList><ArticleId IdType="pubmed">20493671</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 May 20;111(20):7438-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24799682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Mar;15(2):156-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23347587</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2015 Jan;41(1):133-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24782562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Nov;16(7):748-55</Citation><ArticleIdList><ArticleId IdType="pubmed">24725219</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2016 Apr 26;113(17 ):4824-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27071087</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology. 2016 Aug;280(2):529-36</Citation><ArticleIdList><ArticleId IdType="pubmed">26909649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Sep;17(6):626-35</Citation><ArticleIdList><ArticleId IdType="pubmed">26291695</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2006;30(6):855-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16904182</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Sep 1;201:79-87</Citation><ArticleIdList><ArticleId IdType="pubmed">27177299</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Hum Neurosci. 2014 Nov 07;8:897</Citation><ArticleIdList><ArticleId IdType="pubmed">25426048</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(3):e57978</Citation><ArticleIdList><ArticleId IdType="pubmed">23526961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Nov;16(7):678-89</Citation><ArticleIdList><ArticleId IdType="pubmed">24938878</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2016 Feb 5;371(1687):20150097</Citation><ArticleIdList><ArticleId IdType="pubmed">26729936</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2016 May;46(7):1509-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26924633</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4363-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23440209</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Feb 28;231(2):120-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25544024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2016 Feb;37(2):808-18</Citation><ArticleIdList><ArticleId IdType="pubmed">26611711</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2009 Mar;24(2):125-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18789854</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 May 15;71(10):881-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22401986</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Pharmacopsychiatry. 1973;8(3):152-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4803866</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2011 Sep;36(10):2009-17</Citation><ArticleIdList><ArticleId IdType="pubmed">21654735</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2015 Feb;36(2):666-82</Citation><ArticleIdList><ArticleId IdType="pubmed">25307723</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Jan;152-154:237-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24120087</ArticleId></ArticleIdList></Reference><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2016 Jan 19;371(1686):20150077</Citation><ArticleIdList><ArticleId IdType="pubmed">26644596</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10192401</PMID><DateCompleted><Year>1999</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>60 Suppl 5</Volume><PubDate><Year>1999</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Introduction: the use of mood stabilizers in the treatment of psychiatric disorders.</ArticleTitle><Pagination><MedlinePgn>3-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>C L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Health Science Center, San Antonio, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>4</Month><Day>7</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>4</Month><Day>7</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10192401</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1101590</PMID><DateCompleted><Year>1976</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0044-4588</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>9</Issue><PubDate><Year>1975</Year></PubDate></JournalIssue><Title>Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)</Title><ISOAbbreviation>Zh Nevropatol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[Lithium prophylaxis].</ArticleTitle><Pagination><MedlinePgn>1409-13</MedlinePgn></Pagination><Abstract><AbstractText>The author considers some difficulties and discrepancies in the diagnosis of schizophrenia, schizo-affective psychoses on the one hand and manic-depressive psychosis on the other in a group of out-patients receiving treatment with lithium for the prophylaxis of affective disorders. Factors common to both groups and being the basis for the selection of lithium prophylaxis are considered. Special attention in these cases is paid to the course of the disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gardner</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Profilaktika litiem</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevropatol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>8710066</NlmUniqueID><ISSNLinking>0044-4588</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N" Type="Geographic">London</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1975</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1975</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1975</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1101590</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17202565</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>164</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Manic episode during treatment with aripiprazole.</ArticleTitle><Pagination><MedlinePgn>172-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Padala</LastName><ForeName>Prasad Rao</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Wengel</LastName><ForeName>Steven P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Petty</LastName><ForeName>Frederick</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17202565</ArticleId><ArticleId IdType="pii">164/1/172-a</ArticleId><ArticleId IdType="doi">10.1176/ajp.2007.164.1.172a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21167689</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2509</ISSN><JournalIssue CitedMedium="Internet"><Volume>125</Volume><Issue>2-3</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Is cognitive enhancement therapy equally effective for patients with schizophrenia and schizoaffective disorder?</ArticleTitle><Pagination><MedlinePgn>291-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.schres.2010.11.017</ELocationID><Abstract><AbstractText>Patients with schizoaffective disorder (SZA) experience significant deficits in cognitive functioning similar to those seen in patients with schizophrenia (SZ), which are associated with poor functional outcomes. Cognitive remediation (CR) has shown promise in improving cognitive and functional outcomes in patients with SZ: however, no studies have compared these effects across diagnoses. We compared patients with SZ and SZA after cognitive enhancement therapy (CET) or enriched supportive therapy (EST). Both patient groups improved in multiple domains after CET, and diagnosis did not significantly moderate this relationship. Extending CR to all patients in which cognitive dysfunction is a core feature may be indicated.</AbstractText><CopyrightInformation>Copyright © 2010. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>Kathryn E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Schizophrenia and Bipolar Disorder Program, McLean Hospital, 115 Mill St., Belmont, MA 02478, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eack</LastName><ForeName>Shaun M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Hogarty</LastName><ForeName>Susan S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Greenwald</LastName><ForeName>Deborah P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Keshavan</LastName><ForeName>Matcheri S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 60902</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 79537</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003194" MajorTopicYN="Y">Computer-Assisted Instruction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012073" MajorTopicYN="N">Remedial Teaching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>06</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>11</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21167689</ArticleId><ArticleId IdType="pii">S0920-9964(10)01646-4</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2010.11.017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16082431</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2017</Year><Month>04</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1699-3993</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>Drugs of today (Barcelona, Spain : 1998)</Title><ISOAbbreviation>Drugs Today (Barc)</ISOAbbreviation></Journal><ArticleTitle>Genetics of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>335-44</MedlinePgn></Pagination><Abstract><AbstractText>Many linkage loci and candidate genes have been reported in molecular genetic studies of bipolar disorder. However, none of these findings have been consistently replicated. Meta-analyses of linkage studies have also reported conflicting results. Among recently reported candidate genes, BDNF, G72, AKT1, GRIN2A, XBP1, GRK3, HTR4, IMPA2 and GABRA1 may have some importance. Study of the possible roles of epigenetics or analysis of genetic diseases, in which bipolar disorder is one of phenotypes, may also be promising. In addition to monoaminergic and intracellular signaling pathways, recent studies have revealed possible roles for mitochondrial dysfunction, for glutamatergic dysfunction and for the endoplasmic reticulum stress pathway.</AbstractText><CopyrightInformation>Copyright 2005 Prous Science. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Tadafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Wako, Saitama, Japan. kato@brain.riken.go.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuratomi</LastName><ForeName>Go</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Nobumasa</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Drugs Today (Barc)</MedlineTA><NlmUniqueID>101160518</NlmUniqueID><ISSNLinking>1699-3993</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002869" MajorTopicYN="N">Chromosome Aberrations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020411" MajorTopicYN="N">Oligonucleotide Array Sequence Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>92</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16082431</ArticleId><ArticleId IdType="pii">893616</ArticleId><ArticleId IdType="doi">10.1358/dot.2005.41.5.893616</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1270764</PMID><DateCompleted><Year>1976</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1422</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>3</Issue><PubDate><Year>1976</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of gerontology</Title><ISOAbbreviation>J Gerontol</ISOAbbreviation></Journal><ArticleTitle>The age factor in depressive illness: some genetic considerations.</ArticleTitle><Pagination><MedlinePgn>300-3</MedlinePgn></Pagination><Abstract><AbstractText>The age of onset of depressive illness may have an association with the genetic character and clinical course of the disorder. There are several genetic models of depressive disorder that are based on differences in age of onset. According to a multifactorial model, for example, a late onset would indicate a smaller genetic and greater environmental component. A correlation has been found between positive family history of affective illness and early age of the first episode. The presence or absence of a family history of affective illness has also been found to be distinguished by pharmacology, physiology, symptomatology, and severity. It is therefore recommended, for purposes of treatment, that a family history be gathered on patients with depressive illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gerontol</MedlineTA><NlmUniqueID>0374762</NlmUniqueID><ISSNLinking>0022-1422</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1976</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1976</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1976</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1270764</ArticleId><ArticleId IdType="doi">10.1093/geronj/31.3.300</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4189687</PMID><DateCompleted><Year>1970</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>7643</Issue><PubDate><Year>1970</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>3',5' cyclic adenosine monophosphate in depression and mania.</ArticleTitle><Pagination><MedlinePgn>378-81</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdulla</LastName><ForeName>Y H</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Hamadah</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000227">Adenine Nucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014149">Tranquilizing Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0399OZS9N</RegistryNumber><NameOfSubstance UI="D000242">Cyclic AMP</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000227" MajorTopicYN="Y">Adenine Nucleotides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000652" MajorTopicYN="Y">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000242" MajorTopicYN="N">Cyclic AMP</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000652" MajorTopicYN="Y">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014149" MajorTopicYN="N">Tranquilizing Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1970</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1970</Year><Month>2</Month><Day>21</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1970</Year><Month>2</Month><Day>21</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4189687</ArticleId><ArticleId IdType="pii">S0140-6736(70)91514-X</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(70)91514-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12716245</PMID><DateCompleted><Year>2003</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>64</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Impact of bipolar disorder on a U.S. community sample.</ArticleTitle><Pagination><MedlinePgn>425-32</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder is a chronic psychiatric illness characterized by depression and at least 1 manic or hypomanic episode during the lifetime of the illness. Bipolar symptoms have been associated with significant functional impairment. We conducted a study to determine the psychosocial impact of bipolar disorder in a U.S. community sample.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">3059 subjects were selected from a large epidemiologic study of bipolar prevalence that used the Mood Disorder Questionnaire (MDQ) to screen for bipolar I and II disorder. Subjects were surveyed from April 24, 2001, to August 6, 2001, using the Sheehan Disability Scale and the Social Adjustment Scale-Self Report. Comorbid disease data were also collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 3059 subjects surveyed, 2450 (80%) returned completed surveys: 1167 (48%) subjects screened positive for bipolar disorder based on MDQ scores; 1283 (52%) screened negative. MDQ-positive subjects reported significantly (p &lt;.0001) more difficulties with work-related performance, social/leisure activities, and social/family interactions compared with MDQ-negative subjects. Younger subjects, aged 18 to 34 years, reported significantly (p =.003) more symptom days than did older MDQ-positive subjects. MDQ-positive women reported more disruption in social and family life, while MDQ-positive men reported being jailed, arrested, and convicted for crimes. Anxiety (30% vs. 6%), panic attacks (18% vs. 4%), migraine (24% vs. 11%), asthma (17% vs. 10%), and allergies (42% vs. 29%) were significantly (p &lt;.05) more common in MDQ-positive versus MDQ-negative subjects.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Bipolar disorder, as identified in a community sample using the Mood Disorder Questionnaire, was significantly associated with negative impact on the performance of work-related, leisure, and interpersonal activities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio 44106, USA. jrc8@po.cwru.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirschfeld</LastName><ForeName>Robert M A</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Marilyn A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Lydia</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>McNulty</LastName><ForeName>James P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Karen D</ForeName><Initials>KD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH079261</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019352" MajorTopicYN="N">Censuses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnic Groups</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005191" MajorTopicYN="N">Family Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007182" MajorTopicYN="N">Income</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011153" MajorTopicYN="N">Population</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>4</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>4</Month><Day>29</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12716245</ArticleId><ArticleId IdType="doi">10.4088/jcp.v64n0412</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11450170</PMID><DateCompleted><Year>2001</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0960-5371</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><PubDate><Year>2001</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The British journal of psychiatry. Supplement</Title><ISOAbbreviation>Br J Psychiatry Suppl</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers.</ArticleTitle><Pagination><MedlinePgn>s107-19</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">New research is dramatically altering our understanding of the molecular mechanisms underlying neuronal communication.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To elucidate the molecular mechanisms underlying the therapeutic effects of mood stabilizers.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Results from integrated clinical and laboratory studies are reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Chronic administration of lithium and valproate produced a striking reduction in protein kinase C (PKC) isozymes in rat frontal cortex and hippocampus. In a small study, tamoxifen (also a PKC inhibitor) had marked antimanic efficacy. Both lithium and valproate regulate the DNA binding activity of the activator protein I family of transcription factors. Using mRNA differential display, it was also shown that chronic administration of lithium and valproate modulates expression of several genes. An exciting finding is that of a robust elevation in the levels of the cytoprotective protein, bcl-2.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results suggest that regulation of signalling pathways may play a major part in the long-term actions of mood stabilizers. Additionally, mood stabilizers may exert underappreciated neuroprotective effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manji</LastName><ForeName>H K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Pathophysiology, Wayne State University School of Medicine, Detroit, Michigan, USA. manjih@intra.nimh.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry Suppl</MedlineTA><NlmUniqueID>9001294</NlmUniqueID><ISSNLinking>0960-5371</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="D017871">Calcium-Calmodulin-Dependent Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017871" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>141</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>7</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>7</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11450170</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30199694</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><PubDate><Year>2018</Year><Month>11</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Psychometric properties and cross-cultural comparison of the cognitive complaints in bipolar disorder rating assessment (COBRA) in Mexican patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>536-541</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(18)30548-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2018.08.098</ELocationID><Abstract><AbstractText>Bipolar Disorder (BD) is a serious and frequent mental health condition that is sometimes fatal. Several longitudinal studies have found an important correlation between cognition and functionality in BD. Despite the known importance of cognitive symptoms in BD, evaluation of cognitive deficits is not routinely done in clinical settings, as assessment is time-consuming and requires neuropsychological testing. The aim was to evaluate the psychometric properties of the subjective cognitive deficits in bipolar disorder (COBRA) rating scale in a Mexican sample of patients with BD and perform a cross-cultural comparison with the results obtained in other cultures. Ninety-two Healthy Subjects and 80 euthymic patients with BD were asked to complete the COBRA rating scale. The psychometric properties found in Mexican population show a good internal consistency and good discriminant validity with control subjects. Adequate congruence coefficients were obtained between the COBRA analyses in Mexican population and Spanish population and acceptable when compared to Japanese population. The COBRA scale is a brief and valid measure of cognitive complaints in BD for use in Mexican population.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoldi-Negrete</LastName><ForeName>María</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Council of Science and Technology, Mexico City, Mexico; Affective Disorders' Clinic, National Institute of Psychiatry "Ramón de la Fuente Muñíz", Mexico City, Mexico. Electronic address: myoldine@conacyt.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fresán-Orellana</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Epidemiology, National Institute of Psychiatry "Ramón de la Fuente Muñíz", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Camarillo</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Affective Disorders' Clinic, National Institute of Psychiatry "Ramón de la Fuente Muñíz", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega-Ortiz</LastName><ForeName>Hiram</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Affective Disorders' Clinic, National Institute of Psychiatry "Ramón de la Fuente Muñíz", Mexico City, Mexico. Electronic address: hiramortega@imp.edu.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juárez García</LastName><ForeName>Francisco Lorenzo</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Epidemiologic and Psychosocial Research Department, National Institute of Psychiatry "Ramón de la Fuente Muñíz", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castañeda-Franco</LastName><ForeName>Marisol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropsychology, National Institute of Psychiatry "Ramón de la Fuente Muñíz", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tirado-Durán</LastName><ForeName>Elsa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neuropsychology, National Institute of Psychiatry "Ramón de la Fuente Muñíz", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becerra-Palars</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Affective Disorders' Clinic, National Institute of Psychiatry "Ramón de la Fuente Muñíz", Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="N">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">COBRA</Keyword><Keyword MajorTopicYN="Y">Cognition</Keyword><Keyword MajorTopicYN="Y">Cognitive assessment</Keyword><Keyword MajorTopicYN="Y">Mexico</Keyword><Keyword MajorTopicYN="Y">Neuropsychological tests</Keyword><Keyword MajorTopicYN="Y">Subjective cognitive impairment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>08</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30199694</ArticleId><ArticleId IdType="pii">S0165-1781(18)30548-1</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2018.08.098</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2054442</PMID><DateCompleted><Year>1991</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>7</Issue><PubDate><Year>1991</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Are there predictors for sleep deprivation response in depressed patients?</ArticleTitle><Pagination><MedlinePgn>707-10</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riemann</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sleep-EEG Laboratory, Central Institute of Mental Health, Mannheim, FRG.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiegand</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010556" MajorTopicYN="N">Personality Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="Y">Sleep Deprivation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012894" MajorTopicYN="N">Sleep Stages</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012895" MajorTopicYN="N">Sleep, REM</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="N">Wakefulness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2054442</ArticleId><ArticleId IdType="pii">0006-3223(91)90145-C</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(91)90145-c</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12804123</PMID><DateCompleted><Year>2003</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: report of a consensus conference.</ArticleTitle><Pagination><MedlinePgn>13-27</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To achieve consensus among researchers, pharmaceutical industry representatives, federal regulatory agency staff, and family advocates on a template for clinical trials of acute mania/bipolar disorder in children and adolescents.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The American Academy of Child and Adolescent Psychiatry, in collaboration with Best Practice, convened a group of experts from the key stakeholder communities (including adult psychiatrists with expertise in bipolar disorder) and assigned them to workgroups to examine core methodological issues surrounding the design of clinical trials and, ultimately, to generate a consensus statement encompassing: (1) inclusion/exclusion criteria, (2) investigator training needs and site selection, (3) assessment and outcome measures, (4) protocol design and ethical issues unique to trials involving children/adolescents, and (5) regulatory agency perspectives on these deliberations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Conference participants reached agreement on 18 broad methodological questions. Key points of consensus were to assign priority to placebo-controlled studies of acute manic episodes in children and adolescents aged 10-17 years, who may or may not be hospitalized, and who may or may not suffer from common comorbid psychiatric disorders; to require that specialist diagnostic "gatekeepers" screen youths' eligibility to participate in trials; to monitor interviewer and rater competency over the course of the trial using agreed upon standards; and to develop new tools for assessment, including scales to measure aggression/rage and cognitive function, while using the best available instruments (e.g., Young Mania Rating Scale) in the interim.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Methodologically rigorous, large-scale clinical trials of treatment of acute mania are urgently needed to provide information regarding the safety and efficacy, in youth, of diverse agents with potential mood-stabilizing properties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Gabrielle A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Stony Brook University-Putnam Hall, Stony Brook, NY 11794-8790, USA. Gabrielle.Carlson@StonyBrook.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Roger E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>DelBello</LastName><ForeName>Melissa P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Emslie</LastName><ForeName>Graham</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Flynn</LastName><ForeName>Laurie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Frederick</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Hellander</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kowatch</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kusumakar</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Laughren</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Leibenluft</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>McCracken</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nottelmann</LastName><ForeName>Editha</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pine</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Shaffer</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Simar</LastName><ForeName>Renee</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Strober</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>Elizabeth B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Youngstrom</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016446">Consensus Development Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><CitationSubset>E</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000296" MajorTopicYN="N">Adolescent Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002665" MajorTopicYN="N">Child Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="N">ethics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>42</NumberOfReferences><OtherID Source="KIE">120908</OtherID><OtherID Source="NRCBL">VF 18.5.2</OtherID><KeywordList Owner="KIE"><Keyword MajorTopicYN="N">American Academy of Child and Adolescent Psychiatry</Keyword><Keyword MajorTopicYN="N">Biomedical and Behavioral Research</Keyword><Keyword MajorTopicYN="N">Mental Health Therapies</Keyword></KeywordList><GeneralNote Owner="KIE">KIE Bib: human experimentation/minors; human experimentation/special populations; human experimentation/research design</GeneralNote></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12804123</ArticleId><ArticleId IdType="doi">10.1089/104454603321666162</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10386179</PMID><DateCompleted><Year>1999</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>8</Issue><PubDate><Year>1999</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>972-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study investigated the effects of catecholamine depletion with alpha-methylparatyrosine (AMPT) on mood indices in patients with bipolar disorder who were in long-term remission with lithium therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eight subjects with DSM-IV bipolar disorder currently in remission for &gt; 3 months on lithium were included in the study. Subjects were given either AMPT or placebo, in a randomized double-blind manner, in two test sessions of 4 days each.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Subjects did not have any significant changes in mood during AMPT or placebo administration; however, 24-48 hours after the last active AMPT dose subjects had a transient relapse of hypomanic symptoms. Relapse of hypomanic symptoms did not correlate with increases in serum levels of homovanillic acid or 3-methoxy-4-hydroxyphenylglycol.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings suggest that the mechanism of prevention of manic relapse by long-term lithium therapy may be dependent on stability of the catecholamine system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darnell</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>H L</ForeName><Initials>HL</Initials></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Cappiello</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Oren</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>S W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Charney</LastName><ForeName>D S</ForeName><Initials>DS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002395">Catecholamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>534-82-7</RegistryNumber><NameOfSubstance UI="D008734">Methoxyhydroxyphenylglycol</NameOfSubstance></Chemical><Chemical><RegistryNumber>658-48-0</RegistryNumber><NameOfSubstance UI="D019805">alpha-Methyltyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>X77S6GMS36</RegistryNumber><NameOfSubstance UI="D006719">Homovanillic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002395" MajorTopicYN="N">Catecholamines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006719" MajorTopicYN="N">Homovanillic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008734" MajorTopicYN="N">Methoxyhydroxyphenylglycol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019805" MajorTopicYN="N">alpha-Methyltyrosine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10386179</ArticleId><ArticleId IdType="pii">S0006-3223(98)00293-5</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(98)00293-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24219657</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2014</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>217-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12148</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Although several studies have reported on predictors of employment in individuals with bipolar disorder (BD), the magnitude of the impact of these variables is unclear as no previous studies have estimated the collective effect sizes (ESs). The present meta-analysis estimated ESs and explored which of these variables are associated with positive employment outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched for articles published between 2000 and 2011 that reported associations between sociodemographic, clinical, psychosocial, and/or cognitive variables with employment outcomes in BD. Of the 781 articles identified, 22 met the inclusion criteria and were included in the final analysis (n = 6,301). Weighted correlation coefficients (r-index) were computed as ESs for each of the predictor variables, which were grouped into six categories: cognitive performance, symptomatology, sociodemographic factors, course of illness, clinical variables, and other personal factors. The overall ES (Rw) was estimated by assuming random-effect models. Sensitivity analyses were also performed to determine the robustness of the findings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significant predictors of favorable employment outcomes included: cognitive performance (e.g., verbal memory, Rw = 0.33; executive function, Rw = 0.26), sociodemographic factors (e.g., years of education, Rw = 0.23), course of illness (e.g., number of lifetime psychiatric hospitalizations, Rw = -0.35), symptomatology (e.g., depression, Rw = -0.25), and other personal factors (e.g., personality disorder, Rw = -0.49).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, the cognitive performance and course of illness had larger average ESs than symptomatology or sociodemographic factors on favorable employment outcomes. These findings may help to guide the design of more effective work interventions for people with BD.</AbstractText><CopyrightInformation>© 2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Samson</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Social Work and Social Administration, Faculty of Social Sciences, The University of Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Sunny</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>King Lam</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>Lakshmi N</ForeName><Initials>LN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004651" MajorTopicYN="N">Employment</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">functional recovery</Keyword><Keyword MajorTopicYN="N">mood disorders</Keyword><Keyword MajorTopicYN="N">paid employment</Keyword><Keyword MajorTopicYN="N">unemployment</Keyword><Keyword MajorTopicYN="N">vocational rehabilitation</Keyword><Keyword MajorTopicYN="N">work impairment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24219657</ArticleId><ArticleId IdType="doi">10.1111/bdi.12148</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24589068</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2014</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Brain regions associated with risk and resistance for bipolar I disorder: a voxel-based MRI study of patients with bipolar disorder and their healthy siblings.</ArticleTitle><Pagination><MedlinePgn>249-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12181</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Bipolar I disorder is a highly heritable disorder but not all siblings manifest with the illness, even though they may share similar genetic and environmental risk factors. Thus, sibling studies may help to identify brain structural endophenotypes associated with risk and resistance for the disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Structural magnetic resonance imaging (MRI) scans were acquired for 28 euthymic patients with bipolar disorder, their healthy siblings, and 30 unrelated healthy controls. Statistical Parametric Mapping 8 (SPM8) was used to identify group differences in regional gray matter volume by voxel-based morphometry (VBM).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using analysis of covariance, gray matter analysis of the groups revealed a group effect indicating that the left orbitofrontal cortex [Brodmann area (BA) 11] was smaller in patients with bipolar disorder than in unrelated healthy controls [F = 14.83, p &lt; 0.05 (family-wise error); 7 mm(3) ]. Paired t-tests indicated that the orbitofrontal cortex of patients with bipolar disorder [t = 5.19, p &lt; 0.05 (family-wise error); 37 mm(3) ] and their healthy siblings [t = 3.89, p &lt; 0.001 (uncorrected); 63 mm(3) ] was smaller than in unrelated healthy controls, and that the left dorsolateral prefrontal cortex was larger in healthy siblings than in patients with bipolar disorder [t = 4.28, p &lt; 0.001 (uncorrected); 323 mm(3) ] and unrelated healthy controls [t = 4.36, p &lt; 0.001 (uncorrected); 245 mm(3) ]. Additional region-of-interest analyses also found volume deficits in the right cerebellum of patients with bipolar disorder [t = 3.92, p &lt; 0.001 (uncorrected); 178 mm(3) ] and their healthy siblings [t = 4.23, p &lt; 0.001 (uncorrected); 489 mm(3) ], and in the left precentral gyrus of patients with bipolar disorder [t = 3.61, p &lt; 0.001 (uncorrected); 115 mm(3) ] compared to unrelated healthy controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of this study suggest that a reduction in the volume of the orbitofrontal cortex, which plays a role in the automatic regulation of emotions and is a part of the medial prefrontal network, is associated with the heritability of bipolar disorder. Conversely, increased dorsolateral prefrontal cortex volume may be a neural marker of a resistance factor as it is part of a network of voluntary emotion regulation and balances the effects of the disrupted automatic emotion regulation system.</AbstractText><CopyrightInformation>© 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eker</LastName><ForeName>Cagdas</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ege University School of Medicine, Bornova, Izmir, Turkey; SoCAT Lab and Affective Disorders Unit, Ege University School of Medicine, Bornova, Izmir, Turkey; Department of Neuroscience, Ege University Institute of Health Sciences, Bornova, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simsek</LastName><ForeName>Fatma</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Yılmazer</LastName><ForeName>Evrim Ebru</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Kitis</LastName><ForeName>Omer</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Cinar</LastName><ForeName>Cem</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Eker</LastName><ForeName>Ozlem Donat</ForeName><Initials>OD</Initials></Author><Author ValidYN="Y"><LastName>Coburn</LastName><ForeName>Kerry</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gonul</LastName><ForeName>Ali Saffet</ForeName><Initials>AS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035781" MajorTopicYN="Y">Siblings</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">dorsolateral prefrontal cortex</Keyword><Keyword MajorTopicYN="N">high risk</Keyword><Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">orbitofrontal cortex</Keyword><Keyword MajorTopicYN="N">relatives</Keyword><Keyword MajorTopicYN="N">resistance</Keyword><Keyword MajorTopicYN="N">voxel based morphometry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24589068</ArticleId><ArticleId IdType="doi">10.1111/bdi.12181</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27693668</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3514</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>Pt A</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Neuropsychologia</Title><ISOAbbreviation>Neuropsychologia</ISOAbbreviation></Journal><ArticleTitle>Altered functional connectivity during self- and close other-reflection in patients with bipolar disorder with past psychosis and patients with schizophrenia.</ArticleTitle><Pagination><MedlinePgn>97-105</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0028-3932(16)30358-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuropsychologia.2016.09.020</ELocationID><Abstract><AbstractText>Disturbances in implicit self-processing have been reported both in psychotic patients with bipolar disorder (BD) and schizophrenia. It remains unclear whether these two psychotic disorders show disturbed functional connectivity during explicit self-reflection, which is associated with social functioning and illness symptoms. Therefore, we investigated functional connectivity during explicit self-reflection in BD with past psychosis and schizophrenia. Twenty-three BD-patients, 17 schizophrenia-patients and 21 health controls (HC) performed a self-reflection task, including the conditions self-reflection, close other-reflection and semantic control. Functional connectivity was investigated with generalized psycho-physiological interaction (gPPI). During self-reflection compared to semantic, BD-patients had decreased connectivity between several cortical-midline structures (CMS) nodes (i.e., anterior cingulate cortex, ventromedial prefrontal cortex), the insula and the head of the caudate while HC showed increased connectivities. Schizophrenia-patients, during close other-reflection compared to semantic, demonstrated reduced ventral-anterior insula-precuneus/posterior cingulate cortex (PCC) functional connectivity, whereas this was increased in HC. There were no differences between BD and schizophrenia during self- and close other-reflection. We propose that decreased functional connectivity between the CMS nodes/insula and head of the caudate in BD-patients may imply a reduced involvement of the motivational system during self-reflection; and the reduced functional connectivity between the ventral-anterior insula and precuneus/PCC during close other-reflection in schizophrenia-patients may subserve difficulties in information integration of autobiographical memory and emotional awareness in relation to close others. These distinctive impaired patterns of functional connectivity in BD and schizophrenia (compared to HC) deserve further investigation to determine their robustness and associations with differences in clinical presentation.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Liwen</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, Department of Neuroscience, NeuroImaging Center, Section Cognitive Neuropsychiatry, Groningen, The Netherlands. Electronic address: wenwenleer@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vander Meer</LastName><ForeName>Lisette</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, Department of Neuroscience, NeuroImaging Center, Section Cognitive Neuropsychiatry, Groningen, The Netherlands; Department of Rehabilitation, Lentis Psychiatric Institute, Zuidlaren, The Netherlands; University of Groningen, Rob Giel Research Center, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opmeer</LastName><ForeName>Esther M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, Department of Neuroscience, NeuroImaging Center, Section Cognitive Neuropsychiatry, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsman</LastName><ForeName>Jan-Bernard C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, Department of Neuroscience, NeuroImaging Center, Section Cognitive Neuropsychiatry, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruhé</LastName><ForeName>Henricus G</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, Program for Mood and Anxiety Disorders, Department of Psychiatry, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aleman</LastName><ForeName>André</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Groningen, University Medical Center Groningen, Department of Neuroscience, NeuroImaging Center, Section Cognitive Neuropsychiatry, Groningen, The Netherlands; University of Groningen, Department of Psychology, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychologia</MedlineTA><NlmUniqueID>0020713</NlmUniqueID><ISSNLinking>0028-3932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007600" MajorTopicYN="N">Judgment</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="Y">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Close other-reflection</Keyword><Keyword MajorTopicYN="Y">Functional connectivity</Keyword><Keyword MajorTopicYN="Y">Generalized psycho-physiological interaction</Keyword><Keyword MajorTopicYN="Y">Schizophrenia</Keyword><Keyword MajorTopicYN="Y">Self-reflection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27693668</ArticleId><ArticleId IdType="pii">S0028-3932(16)30358-X</ArticleId><ArticleId IdType="doi">10.1016/j.neuropsychologia.2016.09.020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10554911</PMID><DateCompleted><Year>1999</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1079-2082</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>19</Issue><PubDate><Year>1999</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</Title><ISOAbbreviation>Am J Health Syst Pharm</ISOAbbreviation></Journal><ArticleTitle>Gabapentin and lamotrigine in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1939-44</MedlinePgn></Pagination><Abstract><AbstractText>The utility of gabapentin and lamotrigine for the treatment of bipolar disorder is reviewed. Bipolar disorder is characterized by extreme mood fluctuations, including mania, hypomania, depression, and mixed episodes. Extrapolation of postulated mechanisms of anticonvulsant activity in bipolar disorder has led to the use of the newer anticonvulsants gabapentin and lamotrigine for therapy. Both agents appear promising on the basis of limited (often anecdotal) evidence. They may prove effective in patients with difficult cases of bipolar disorder, such as patients with rapid cycling, mixed episodes, and illness refractory to other treatments. Lamotrigine may offer a much-needed treatment alternative for bipolar depression and could be found effective for acute mania, but the need for slow dosage adjustment and the risk of rash may limit overall clinical utility. Gabapentin may offer significant advantages for acute mania: The dosage can be adjusted rapidly, adverse effects are generally minimal, the therapeutic index is high, there is no required laboratory monitoring, and there is minimal potential for interactions with other psychotropics. Until the results of randomized controlled trials are known, however, these two agents should be reserved for patients with bipolar disorder unresponsive to traditional therapies and for patients who cannot tolerate traditional agents. Preliminary evidence indicates that gabapentin and lamotrigine may be useful for the treatment of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Botts</LastName><ForeName>S R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>College of Pharmacy and Allied Health Professions, St. John's University, Jamaica, NY 11439, USA. Botts@lij.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Health Syst Pharm</MedlineTA><NlmUniqueID>9503023</NlmUniqueID><ISSNLinking>1079-2082</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000085">Acetates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6CW7F3G59X</RegistryNumber><NameOfSubstance UI="D000077206">Gabapentin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="Y">Amines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003509" MajorTopicYN="Y">Cyclohexanecarboxylic Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077206" MajorTopicYN="N">Gabapentin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="Y">gamma-Aminobutyric Acid</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>36</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>11</Month><Day>11</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>11</Month><Day>11</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10554911</ArticleId><ArticleId IdType="doi">10.1093/ajhp/56.19.1939</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32521383</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3360</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><PubDate><Year>2020</Year><Month>09</Month></PubDate></JournalIssue><Title>Psychoneuroendocrinology</Title><ISOAbbreviation>Psychoneuroendocrinology</ISOAbbreviation></Journal><ArticleTitle>Higher cortisol levels may proceed a manic episode and are related to disease severity in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>104658</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0306-4530(20)30077-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psyneuen.2020.104658</ELocationID><Abstract><AbstractText Label="BACKGROUND">Regulation of the hypothalamic-pituitary-adrenal (HPA) axis is implicated in the pathogenesis of bipolar disorder (BD). However, the relationship between HPA-activity and disease severity is not fully elucidated. In this pilot study we aimed to explore the temporal relationship between HPA-activity and the risk of a manic episode in BD patients type I, by assessing long-term hair cortisol concentrations (HCC). Second, we explored the relation between HCC and the number of previous episodes.</AbstractText><AbstractText Label="METHODS">Hair samples were collected from 45 BD I patients in euthymic or manic state and compared to 17 controls. From each participant, two hair samples of 3 cm length were used to measure long-term cortisol, reflecting retrospect time frames of 1-3 months and 4-6 months respectively prior to sampling.</AbstractText><AbstractText Label="RESULTS">HCC in the BD group was slightly higher than in the control group in both hair segments (p = 0.049 and 0.03; after adjustment for age, sex, BMI and hair washing frequency p = 0.222 and 0.139). A significant peak in hair cortisol was observed prior to a manic episode (p = 0.036). Furthermore, we found a positive correlation between the number of mood episodes HCC (p = 0.03).</AbstractText><AbstractText Label="CONCLUSIONS">Our results indicate that long-term cortisol levels are slightly higher in BD, and in particular elevated in the months prior to a manic relapse. In addition HCC are positively associated with the number of previous mood episodes in the course of BD type I.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Monique T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Mood Disorders, Parnassia NAH, Rotterdam, The Netherlands. Electronic address: monique.vandenberg@parnassiagroep.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wester</LastName><ForeName>Vincent L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vreeker</LastName><ForeName>Annabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Brain Center Rudolf Magnus, Department of Psychiatry, Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koenders</LastName><ForeName>Manja A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Mood Disorders, Parnassia NAH, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boks</LastName><ForeName>Marco P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Brain Center Rudolf Magnus, Department of Psychiatry, Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rossum</LastName><ForeName>Elisabeth F C</ForeName><Initials>EFC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spijker</LastName><ForeName>Anne T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Mood Disorders, Parnassia NAH, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH090553</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychoneuroendocrinology</MedlineTA><NlmUniqueID>7612148</NlmUniqueID><ISSNLinking>0306-4530</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006197" MajorTopicYN="N">Hair</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087122" MajorTopicYN="N">Mania</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Hair cortisol concentrations</Keyword><Keyword MajorTopicYN="Y">Manic episodes</Keyword><Keyword MajorTopicYN="Y">Mood</Keyword><Keyword MajorTopicYN="Y">Severity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32521383</ArticleId><ArticleId IdType="pii">S0306-4530(20)30077-9</ArticleId><ArticleId IdType="doi">10.1016/j.psyneuen.2020.104658</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17284142</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The evolving paradigm for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>139-50</MedlinePgn></Pagination><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17284142</ArticleId><ArticleId IdType="doi">10.4088/jcp.v68n0119</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21320253</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Pain and rejection sensitivity in bipolar depression.</ArticleTitle><Pagination><MedlinePgn>59-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2011.00892.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Little is known regarding the correlates of pain in bipolar disorder. Recent neuroimaging studies support the contention that depression, as well as pain distress and rejection distress, share the same neurobiological circuits. In a recently published study, we confirmed the hypothesis that perception of increased pain during treatment-refractory depression, predominantly unipolar, was related to increased rejection sensitivity. In the present study, we aimed to test this same hypothesis for bipolar depression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The present study analysed data from 67 patients presenting to the Black Dog Institute Bipolar Disorders Clinic in Sydney, Australia. The patients all met DSM-IV criteria for bipolar disorder and had completed a self-report questionnaire regarding perceived pain and rejection sensitivity during depression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A significant increase in the experience of headaches (p=0.003) as well as chest pain (p=0.004) during bipolar depression was predicted by a major increase in rejection sensitivity when depressed, i.e., state rejection sensitivity. Being rejection sensitive in general, i.e., trait rejection sensitivity, did not predict pain during depression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The experience of increased headaches and chest pain during bipolar depression is related to increased rejection sensitivity during depression. Research to further elucidate this relationship is required.</AbstractText><CopyrightInformation>© 2011 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ehnvall</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neuroscience, Gothenburg University, and Psychiatric Outpatient Clinic, Oskarsdalgatan 7, Varberg, Sweden. anna.ehnvall@lthalland.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Philip B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Hadzi-Pavlovic</LastName><ForeName>Dusan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Loo</LastName><ForeName>Colleen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Breakspear</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Gloria</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Frankland</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Corry</LastName><ForeName>Justine</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002637" MajorTopicYN="N">Chest Pain</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012059" MajorTopicYN="Y">Rejection, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21320253</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2011.00892.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28577590</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1888</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>07</Month></PubDate></JournalIssue><Title>Behavior therapy</Title><ISOAbbreviation>Behav Ther</ISOAbbreviation></Journal><ArticleTitle>Dialectical Behavior Therapy Group Skills Training for Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>557-566</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0005-7894(17)30001-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.beth.2016.12.006</ELocationID><Abstract><AbstractText>There is growing evidence that the capacity for emotion regulation is compromised in individuals with bipolar disorder. Dialectical behavior therapy (DBT), an empirically supported treatment that specifically targets emotion dysregulation, may be an effective adjunct treatment for improving emotion regulation and residual mood symptoms in patients with bipolar disorder. In this open, proof-of-concept pilot study, 37 participants engaged in a 12-week DBT group skills training program, learning mindfulness, emotion regulation, and distress tolerance skills. Repeated measures mixed models revealed skill acquisition in the areas of mindfulness, emotion regulation and distress tolerance, as well as improved psychological well-being and decreased emotion reactivity. The results of this study support a burgeoning literature that DBT is a feasible adjunct intervention for patients with bipolar disorder.</AbstractText><CopyrightInformation>Copyright © 2017. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eisner</LastName><ForeName>Lori</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital. Electronic address: leisnerphd@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eddie</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harley</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobo</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deckersbach</LastName><ForeName>Thilo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 AA025251</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AA026135</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Behav Ther</MedlineTA><NlmUniqueID>1251640</NlmUniqueID><ISSNLinking>0005-7894</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="N">Behavior Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064866" MajorTopicYN="N">Mindfulness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="N">Proof of Concept Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">dialectical behavior therapy</Keyword><Keyword MajorTopicYN="Y">emotion regulation</Keyword><Keyword MajorTopicYN="Y">group skills training</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28577590</ArticleId><ArticleId IdType="pii">S0005-7894(17)30001-1</ArticleId><ArticleId IdType="doi">10.1016/j.beth.2016.12.006</ArticleId><ArticleId IdType="pmc">PMC6145450</ArticleId><ArticleId IdType="mid">NIHMS985587</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Int J Methods Psychiatr Res. 2013 Mar;22(1):46-58</Citation><ArticleIdList><ArticleId IdType="pubmed">23526724</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jan 1;59(1):31-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16112653</ArticleId></ArticleIdList></Reference><Reference><Citation>Monogr Soc Res Child Dev. 1994;59(2-3):25-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7984164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):29-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17328959</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurosci Ther. 2012 Feb;18(2):133-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22070469</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Apr;107(1-3):275-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17884176</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2016 Jan;125(1):40-52</Citation><ArticleIdList><ArticleId IdType="pubmed">26480234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Jun;7(3):281-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15898966</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1992 Jun;42(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">1496056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2015 Mar;25(2):140-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25010702</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 May;155(5):646-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9585716</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment. 2006 Mar;13(1):27-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16443717</ArticleId></ArticleIdList></Reference><Reference><Citation>Eval Program Plann. 1983;6(3-4):299-313</Citation><ArticleIdList><ArticleId IdType="pubmed">10267258</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Med. 2008 Feb;31(1):23-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17899351</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2005 Sep;43(9):1231-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16005708</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 1997 Fall;11(3):279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">9348491</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Anxiety Disord. 2009 Jun;23(5):591-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19233609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2001 Feb;57(2):183-96</Citation><ArticleIdList><ArticleId IdType="pubmed">11180146</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 1995 Oct;69(4):719-27</Citation><ArticleIdList><ArticleId IdType="pubmed">7473027</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Aug 30;189(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21276619</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2014 Aug;59:40-51</Citation><ArticleIdList><ArticleId IdType="pubmed">24974307</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Ther. 2007 Sep;38(3):303-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17697854</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1996 Jul;57(7):292-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8666570</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychophysiology. 2002 May;39(3):281-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12212647</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jun;160(6):1172-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12777278</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2008 Nov;196(11):847-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19008737</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):820-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17581446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2015 Jan;71(1):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">25042066</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Ther. 2008 Jun;39(2):107-16</Citation><ArticleIdList><ArticleId IdType="pubmed">18502244</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Mar 5;145(3):386-93</Citation><ArticleIdList><ArticleId IdType="pubmed">22858264</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Sep;13(9):829, 833-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18574483</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1999 Nov;29(6):1307-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10616937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14569473</PMID><DateCompleted><Year>2004</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Season>Fall</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>[Structural magnetic resonance imaging (MRI) studies in bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>225-32</MedlinePgn></Pagination><Abstract><AbstractText>To review structural MRI studies in bipolar disorder. A computer-assisted literature search of the Medline Ovid files for the period 1966 to November 2002 was performed, augmented by the use of articles meeting the criteria of this study from recent reviews. The studies included in this review show that there are abnormalities in the regions playing a role in the prefrontal-subcortical circuits that have been implicated in the pathophysiology of bipolar disorder, rather than generalized abnormalities like cerebral volume reduction or ventricular enlargement. The most widely studied and frequently reported finding of T2 signal hyperintensities is not considered to be specific to bipolar disorder. The findings of dorsolateral and subgenual prefrontal cortical volumetric reductions are in agreement with the findings of few neuropathological studies of bipolar disorder and suggest that prefrontal cortex plays an important role in the pathophysiology of the disorder. Among the medial temporal structures, the increase in amygdala volume seems to be specific to bipolar disorder. The findings in structures like the striatum and thalamus are conflicting, due to difficulties in the detailed measuring of the volumes of these structures with current techniques. Bipolar disorder is associated with brain abnormalities detected with structural MRI. Studies integrating structural neuroimaging methods with functional neuroimaging are needed to specifically determine how these abnormalities affect the function of these brain regions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monkul</LastName><ForeName>E Serap</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Ozerdem</LastName><ForeName>Ayşegül</ForeName><Initials>A</Initials></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Bipolar bozuklukta yapisal manyetik rezonans görüntüleme (MRG) calişmalari.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>84</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>2</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14569473</ArticleId><ArticleId IdType="pii">440</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31985560</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-736X</ISSN><JournalIssue CitedMedium="Internet"><Volume>208</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Toxoplasmosis in a Cohort of Italian Patients With Bipolar and Psychotic Disorders: How Infection May Affect Clinical Features?</ArticleTitle><Pagination><MedlinePgn>118-126</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NMD.0000000000001102</ELocationID><Abstract><AbstractText>This study investigated the seroprevalence of Toxoplasma gondii in a cohort of 101 Italian inpatients affected by mood or schizophrenia-spectrum disorders and compared clinical features between seronegative and seropositive subjects. Patients diagnosed according to DSM-5 criteria underwent clinical assessments and blood collection to test parasite-specific IgG/IgM serum levels. Twenty-eight patients (27.7%) had IgG anti-T. gondii, and none had IgM antibodies. We found higher prevalence rate in patients aged 40 years or older, as compared with younger. No significant association was detected between T. gondii and a specific diagnostic category; however, bipolar disorder (BD)-II showed the highest positivity rate (40.9%). The seropositive status was significantly associated with a lower presence of psychotic symptoms, higher number of total episodes of predominant excitatory polarity, longer illness duration, and lower severity of current episode, particularly anxiety, depressive, and withdrawal/retardation symptoms. These preliminary results seem to point out an association between chronic toxoplasmosis and a specific subtype of BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Del Grande</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiavi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masci</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbuti</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maccariello</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massimetti</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruschi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Translational Research, N.T.M.S., School of Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dell'Osso</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Section of Psychiatry, Department of Clinical and Experimental Medicine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078331" MajorTopicYN="N">Correlation of Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014123" MajorTopicYN="N">Toxoplasmosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31985560</ArticleId><ArticleId IdType="doi">10.1097/NMD.0000000000001102</ArticleId><ArticleId IdType="pii">00005053-202002000-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdollahian E, Shafiei R, Mokhber N, Kalantar K, Fata A (2017) Seroepidemiological study of Toxoplasma gondii infection among psychiatric patients in Mashhad, Northeast of Iran. Iran J Parasitol. 12:117–122.</Citation></Reference><Reference><Citation>Alvarado-Esquivel C, Sánchez-Anguiano LF, Arnaud-Gil CA, López-Longoria JC, Molina-Espinoza LF, Estrada-Martínez S, Liesenfeld O, Hernández-Tinoco J, Sifuentes-Álvarez A, Salas-Martínez C (2013) Toxoplasma gondii infection and suicide attempts: A case-control study in psychiatric outpatients. J Nerv Ment Dis. 201:948–952.</Citation></Reference><Reference><Citation>Alvarado-Esquivel C, Sanchez-Anguiano LF, Hernandez-Tinoco J, Berumen-Segovia LO, Torres-Prieto YE, Estrada-Martinez S, Perez-Alamos AR, Ortiz-Jurado MN, Molotla-de-Leon G, Beristain Garcia I, Rabago-Sanchez E, Liesenfeld O (2016) Toxoplasma gondii infection and mixed anxiety and depressive disorder: A case-control seroprevalence study in Durango, Mexico. J Clin Med Res. 8:519–523.</Citation></Reference><Reference><Citation>Alvarado-Esquivel C, Urbina-Alvarez JD, Estrada-Martinez S, Torres-Castorena A, Molotla-de-León G, Liesenfeld O, Dubey JP (2011) Toxoplasma gondii infection and schizophrenia: A case control study in a low Toxoplasma seroprevalence Mexican population. Parasitol Int. 60:151–155.</Citation></Reference><Reference><Citation>American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed). Arlington, VA: American Psychiatric Publishing.</Citation></Reference><Reference><Citation>Amminger GP, McGorry PD, Berger GE, Wade D, Yung AR, Phillips LJ, Harrigan SM, Francey SM, Yolken RH (2007) Antibodies to infectious agents in individuals at ultra-high risk for psychosis. Biol Psychiatry. 61:1215–1217.</Citation></Reference><Reference><Citation>Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, Zimmerman SA, Balis T, Cabassa JA, Scrandis DA, Tonelli LH, Postolache TT (2009) Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. J Nerv Ment Dis. 197:905–908.</Citation></Reference><Reference><Citation>Bahia-Oliveira LM, Jones JL, Azevedo-Silva J, Alves CC, Oréfice F, Addiss DG (2003) Highly endemic, waterborne toxoplasmosis in north Rio de Janeiro state, Brazil. Emerg Infect Dis. 9:55–62.</Citation></Reference><Reference><Citation>Bak J, Shim SH, Kwon YJ, Lee HY, Kim JS, Yoon H, Lee YJ (2018) The association between suicide attempts and Toxoplasma gondii infection. Clin Psychopharmacol Neurosci. 16:95–102.</Citation></Reference><Reference><Citation>Barichello T, Badawy M, Pitcher MR, Saigal P, Generoso JS, Goularte JA, Simões LR, Quevedo J, Carvalho AF (2016) Exposure to perinatal infections and bipolar disorder: A systematic review. Curr Mol Med. 16:106–118.</Citation></Reference><Reference><Citation>Berenreiterova M, Flegr J, Kuběna AA, Němec P (2011) The distribution of Toxoplasma gondii cysts in the brain of a mouse with latent toxoplasmosis: Implications for the behavioral manipulation hypothesis. PLoS One. 6:e28925.</Citation></Reference><Reference><Citation>Bortolato B, Köhler CA, Evangelou E, León-Caballero J, Solmi M, Stubbs B, Belbasis L, Pacchiarotti I, Kessing LV, Berk M, Vieta E, Carvalho AF (2017) Systematic assessment of environmental risk factors for bipolar disorder: An umbrella review of systematic reviews and meta-analyses. Bipolar Disord. 19:84–96.</Citation></Reference><Reference><Citation>Burgdorf KS, Trabjerg BB, Pedersen MG, Nissen J, Banasik K, Pedersen OB, Sørensen E, Nielsen KR, Larsen MH, Erikstrup C, Bruun-Rasmussen P, Westergaard D, Thørner LW, Hjalgrim H, Paarup HM, Brunak S, Pedersen CB, Torrey EF, Werge T, Mortensen PB, Yolken RH, Ullum H (2019) Large-scale study of Toxoplasma and cytomegalovirus shows an association between infection and serious psychiatric disorders. Brain Behav Immun. 79:152–158.</Citation></Reference><Reference><Citation>Carruthers VB, Suzuki Y (2007) Effects of Toxoplasma gondii infection on the brain. Schizophr Bull. 33:745–751.</Citation></Reference><Reference><Citation>Cetinkaya Z, Yazar S, Gecici O, Namli MN (2007) Anti–Toxoplasma gondii antibodies in patients with schizophrenia—Preliminary findings in a Turkish sample. Schizophr Bull. 33:789–791.</Citation></Reference><Reference><Citation>Coccaro EF, Lee R, Kavoussi RJ (2010) Aggression, suicidality, and intermittent explosive disorder: Serotonergic correlates in personality disorder and healthy control subjects. Neuropsychopharmacology. 35:435–444.</Citation></Reference><Reference><Citation>Coccaro EF, Lee R, Vezina P (2013) Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects. J Psychiatr Res. 47:1247–1253.</Citation></Reference><Reference><Citation>Cook TB, Brenner LA, Cloninger CR, Langenberg P, Igbide A, Giegling I, Hartmann AM, Konte B, Friedl M, Brundin L, Groer MW, Can A, Rujescu D, Postolache TT (2015) "Latent" infection with Toxoplasma gondii: Association with trait aggression and impulsivity in healthy adults. J Psychiatr Res. 60:87–94.</Citation></Reference><Reference><Citation>Del Grande C, Contini C, Schiavi E, Rutigliano G, Maritati M, Seraceni S, Pinto B, Dell'Osso L, Bruschi F (2017a) Bipolar disorder with psychotic features and ocular toxoplasmosis: A possible pathogenetic role of the parasite? J Nerv Ment Dis. 205:192–195.</Citation></Reference><Reference><Citation>Del Grande C, Galli L, Schiavi E, Dell'Osso L, Bruschi F (2017b) Is Toxoplasma gondii a trigger of bipolar disorder? Pathogens. 6:pii: E3.</Citation></Reference><Reference><Citation>Dickerson F, Stallings C, Origoni A, Katsafanas E, Schweinfurth L, Savage C, Khushalani S, Yolken R (2014) Antibodies to Toxoplasma gondii and cognitive functioning in schizophrenia, bipolar disorder, and nonpsychiatric controls. J Nerv Ment Dis. 202:589–593.</Citation></Reference><Reference><Citation>Dubey JP, Jones JL (2008) Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol. 38:1257–1278.</Citation></Reference><Reference><Citation>Dunn AJ (2006) Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res. 6:52–68.</Citation></Reference><Reference><Citation>Esshili A, Thabet S, Jemli A, Trifa F, Mechri A, Zaafrane F, Gaha L, Juckel G, Babba H, Bel Hadj Jrad B (2016) Toxoplasma gondii infection in schizophrenia and associated clinical features. Psychiatry Res. 245:327–332.</Citation></Reference><Reference><Citation>Fabiani S, Pinto B, Bonuccelli U, Bruschi F (2015) Neurobiological studies on the relationship between toxoplasmosis and neuropsychiatric diseases. J Neurol Sci. 351:3–8.</Citation></Reference><Reference><Citation>First MB, Williams JBW, Karg RS, Spitzer RL (2015) Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV, Version 1.0.0). Arlington, VA: American Psychiatric Association.</Citation></Reference><Reference><Citation>Flegr J (2007) Effects of Toxoplasma on human behaviour. Schizophr Bull. 33:757–760.</Citation></Reference><Reference><Citation>Flegr J (2013a) Influence of latent Toxoplasma infection on human personality, physiology and morphology: Pros and cons of the Toxoplasma-human model in studying the manipulation hypothesis. J Exp Biol. 216(pt 1):127–133.</Citation></Reference><Reference><Citation>Flegr J (2013b) How and why Toxoplasma makes us crazy. Trends Parasitol. 29:156–163.</Citation></Reference><Reference><Citation>Flegr J, Prandota J, Sovičková M, Israili ZH (2014) Toxoplasmosis—A global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 9:e90203.</Citation></Reference><Reference><Citation>Freedman D, Bao Y, Shen L, Schaefer CA, Brown AS (2016) Maternal T. gondii, offspring bipolar disorder and neurocognition. Psychiatry Res. 243:382–389.</Citation></Reference><Reference><Citation>Galli L, Del Grande C, Rindi L, Mangia C, Mangano V, Schiavi E, Masci I, Pinto B, Kramer L, Dell'Osso L, Bruschi F (2019) Lack of circulating Toxoplasma gondii DNA in seropositive patients with bipolar or schizophrenia spectrum disorders. Psychiatry Res. 273:706–711.</Citation></Reference><Reference><Citation>Gatkowska J, Wieczorek M, Dziadek B, Dzitko K, Dlugonska H (2012) Behavioral changes in mice caused by Toxoplasma gondii invasion of brain. Parasitol Res. 111:53–58.</Citation></Reference><Reference><Citation>Gelaye W, Kebede T, Hailu A (2015) High prevalence of anti-Toxoplasma antibodies and absence of Toxoplasma gondii infection risk factors among pregnant women attending routine antenatal care in two Hospitals of Addis Ababa, Ethiopia. Int J Infect Dis. 34:41–45.</Citation></Reference><Reference><Citation>Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS (2008) Evaluation of the mood-stabilizing agent valproic acid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. J Parasitol. 94:555–557.</Citation></Reference><Reference><Citation>Guy W (Ed) (1976) ECDEU Assessment Manual for Psychopharmacology (pp 218–222). US Department of Health, Education, and Welfare publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health.</Citation></Reference><Reference><Citation>Hamdani N, Daban-Huard C, Lajnef M, Gadel R, Le Corvoisier P, Delavest M, Carde S, Lépine JP, Jamain S, Houenou J, Galeh B, Richard JR, Aoki M, Charron D, Krishnamoorthy R, Yolken R, Dickerson F, Tamouza R, Leboyer M (2015) Cognitive deterioration among bipolar disorder patients infected by Toxoplasma gondii is correlated to interleukin 6 levels. J Affect Disord. 179:161–166.</Citation></Reference><Reference><Citation>Hamdani N, Daban-Huard C, Lajnef M, Richard JR, Delavest M, Godin O, Le Guen E, Vederine FE, Lépine JP, Jamain S, Houenou J, Le Corvoisier P, Aoki M, Moins-Teisserenc H, Charron D, Krishnamoorthy R, Yolken R, Dickerson F, Tamouza R, Leboyer M (2013) Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord. 148:444–448.</Citation></Reference><Reference><Citation>Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:56–62.</Citation></Reference><Reference><Citation>Hinze-Selch D, Däubener W, Eggert L, Erdag S, Stoltenberg R, Wilms S (2007) A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: Beyond seroprevalence. Schizophr Bull. 33:782–788.</Citation></Reference><Reference><Citation>Hofhuis A, van Pelt W, van Duynhoven YT, Nijhuis CD, Mollema L, van der Klis FR, Havelaar AH, Kortbeek LM (2011) Decreased prevalence and age-specific risk factors for Toxoplasma gondii IgG antibodies in The Netherlands between 1995/1996 and 2006/2007. Epidemiol Infect. 139:530–538.</Citation></Reference><Reference><Citation>Jones JL, Dargelas V, Roberts J, Press C, Remington JS, Montoya JG (2009) Risk factors for Toxoplasma gondii infection in the United States. Clin Infect Dis. 49:878–884.</Citation></Reference><Reference><Citation>Jones JL, Kruszon-Moran D, Elder S, Rivera HN, Press C, Montoya JG, McQuillan GM (2018) Toxoplasma gondii infection in the United States, 2011–2014. Am J Trop Med Hyg. 98:551–557.</Citation></Reference><Reference><Citation>Jones-Brando L, Torrey EF, Yolken R (2003) Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 62:237–244.</Citation></Reference><Reference><Citation>Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:261–276.</Citation></Reference><Reference><Citation>Leweke FM, Gerth CW, Koethe D, Klosterkötter J, Ruslanova I, Krivogorsky B, Torrey EF, Yolken RH (2004) Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 254:4–8.</Citation></Reference><Reference><Citation>Ling VJ, Lester D, Mortensen PB, Langenberg PW, Postolache TT (2011) Toxoplasma gondii seropositivity and suicide rates in women. J Nerv Ment Dis. 199:440–444.</Citation></Reference><Reference><Citation>Markovitz AA, Simanek AM, Yolken RH, Galea S, Koenen KC, Chen S, Aiello AE (2015) Toxoplasma gondii and anxiety disorders in a community-based sample. Brain Behav Immun. 43:192–197.</Citation></Reference><Reference><Citation>McConkey GA, Martin HL, Bristow GC, Webster JP (2013) Toxoplasma gondii infection and behaviour - location, location, location? J Exp Biol. 216(pt 1):113–119.</Citation></Reference><Reference><Citation>Montoya JG, Liesenfeld O (2004) Toxoplasmosis. Lancet. 363:1965–1976.</Citation></Reference><Reference><Citation>Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000) Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 101:323–329.</Citation></Reference><Reference><Citation>Mosti M, Pinto B, Giromella A, Fabiani S, Cristofani R, Panichi M, Bruschi F (2013) A 4-year evaluation of toxoplasmosis seroprevalence in the general population and in women of reproductive age in central Italy. Epidemiol Infect. 141:2192–2195.</Citation></Reference><Reference><Citation>Oliveira J, Kazma R, Le Floch E, Bennabi M, Hamdani N, Bengoufa D, Dahoun M, Manier C, Bellivier F, Krishnamoorthy R, Deleuze JF, Yolken R, Leboyer M, Tamouza R (2016) Toxoplasma gondii exposure may modulate the influence of TLR2 genetic variation on bipolar disorder: A gene-environment interaction study. Int J Bipolar Disord. 4:11.</Citation></Reference><Reference><Citation>Omar A, Bakar OC, Adam NF, Osman H, Osman A, Suleiman AH, Manaf MR, Selamat MI (2015) Seropositivity and serointensity of Toxoplasma gondii antibodies and DNA among patients with schizophrenia. Korean J Parasitol. 53:29–34.</Citation></Reference><Reference><Citation>Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep. 10:799–812.</Citation></Reference><Reference><Citation>Parlog A, Schluter D, Dunay IR (2015) Toxoplasma gondii-induced neuronal alterations. Parasite Immunol. 37:159–170.</Citation></Reference><Reference><Citation>Pearce BD, Kruszon-Moran D, Jones JL (2012) The relationship between Toxoplasma gondii infection and mood disorders in the third National Health and Nutrition Survey. Biol Psychiatry. 72:290–295.</Citation></Reference><Reference><Citation>Pedersen MG, Mortensen PB, Nørgaard-Pedersen B, Postolache TT (2012) Toxoplasma gondii infection and self-directed violence in mothers. Arch Gen Psychiatry. 69:1123–1130.</Citation></Reference><Reference><Citation>Pedersen MG, Stevens H, Pedersen CB, Nørgaard-Pedersen B, Mortensen PB (2011) Toxoplasma infection and later development of schizophrenia in mothers. Am J Psychiatry. 168:814–821.</Citation></Reference><Reference><Citation>Pinto B, Castagna B, Mattei R, Bruzzi R, Chiumiento L, Cristofani R, Buffolano W, Bruschi F (2012) Seroprevalence for toxoplasmosis in individuals living in North West Tuscany: Access to Toxo-test in central Italy. Eur J Clin Microbiol Infect Dis. 31:1151–1156.</Citation></Reference><Reference><Citation>Pinto B, Mattei R, Moscato GA, Cristofano M, Giraldi M, Scarpato R, Buffolano W, Bruschi F (2017) Toxoplasma infection in individuals in central Italy: Does a gender-linked risk exist? Eur J Clin Microbiol Infect Dis. 36:739–746.</Citation></Reference><Reference><Citation>Prandovszky E, Gaskell E, Martin H, Dubey JP, Webster JP, McConkey GA (2011) The neurotropic parasite Toxoplasma gondii increases dopamine metabolism. PLoS One. 6:e23866.</Citation></Reference><Reference><Citation>Remington JS, McLeod R, Thulliez P, Desmonts G (2001) Toxoplasmosis. In Remington JS, Klein J (Eds), Infectious diseases of the fetus and newborn infant (5th ed, pp 205–346). Philadelphia, PA: WB Saunders.</Citation></Reference><Reference><Citation>Robert-Gangneux F, Dardé ML (2012) Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 25:264–296.</Citation></Reference><Reference><Citation>Sanches M, Keshavan MS, Brambilla P, Soares JC (2008) Neurodevelopmental basis of bipolar disorder: A critical appraisal. Prog Neuropsychopharmacol Biol Psychiatry. 32:1617–1627.</Citation></Reference><Reference><Citation>Sinai AP, Watts EA, Dhara A, Murphy RD, Gentry MS, Patwardhan A (2016) Re-examining chronic Toxoplasma gondii infection: Surprising activity for a "dormant" parasite. Curr Clin Microbiol Rep. 3:175–185.</Citation></Reference><Reference><Citation>Song J, Bergen SE, Kuja-Halkola R, Larsson H, Landen M, Lichtenstein P (2015) Bipolar disorder and its relation to major psychiatric disorders: A family-based study in the Swedish population. Bipolar Disord. 17:184–193.</Citation></Reference><Reference><Citation>Sugden K, Moffitt TE, Pinto L, Poulton R, Williams BS, Caspi A (2016) Is Toxoplasma gondii infection related to brain and behavior impairments in humans? Evidence from a population-representative birth cohort. PLoS One. 11:e0148435.</Citation></Reference><Reference><Citation>Sutterland AL, Fond G, Kuin A, Koeter MW, Lutter R, van Gool T, Yolken R, Szoke A, Leboyer M, de Haan L (2015) Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: Systematic review and meta-analysis. Acta Psychiatr Scand. 132:161–179.</Citation></Reference><Reference><Citation>Suvisaari J, Torniainen-Holm M, Lindgren M, Härkänen T, Yolken RG (2017) Toxoplasma gondii infection and common mental disorders in the Finnish general population. J Affect Disord. 223:20–25.</Citation></Reference><Reference><Citation>Tedla Y, Shibre T, Ali O, Tadele G, Woldeamanuel Y, Asrat D, Aseffa A, Mihret W, Abebe M, Alem A, Medhin G, Habte A (2011) Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: A case-control study. Ethiop Med J. 49:211–220.</Citation></Reference><Reference><Citation>Torrey EF, Bartko JJ, Lun ZR, Yolken RH (2007) Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-analysis. Schizophr Bull. 33:729–736.</Citation></Reference><Reference><Citation>Torrey EF, Bartko JJ, Yolken RH (2012) Toxoplasma gondii and other risk factors for schizophrenia: An update. Schizophr Bull. 38:642–647.</Citation></Reference><Reference><Citation>Wang HL, Wang GH, Li QY, Shu C, Jiang MS, Guo Y (2006) Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand. 114:40–48.</Citation></Reference><Reference><Citation>Webster JP, Lamberton PH, Donnelly CA, Torrey EF (2006) Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc Biol Sci. 273:1023–1030.</Citation></Reference><Reference><Citation>Weiss LM, Dubey JP (2009) Toxoplasmosis: A history of clinical observations. Int J Parasitol. 39:895–901.</Citation></Reference><Reference><Citation>Xiao J, Jones-Brando L, Talbot CC Jr., Yolken RH (2011) Differential effects of three canonical Toxoplasma strains on gene expression in human neuroepithelial cells. Infect Immun. 79:1363–1373.</Citation></Reference><Reference><Citation>Yolken RH, Dickerson FB, Fuller Torrey E (2009) Toxoplasma and schizophrenia. Parasite Immunol. 31:706–715.</Citation></Reference><Reference><Citation>Yolken R, Torrey EF, Dickerson F (2017) Evidence of increased exposure to Toxoplasma gondii in individuals with recent onset psychosis but not with established schizophrenia. PLoS Negl Trop Dis. 11:e0006040.</Citation></Reference><Reference><Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry. 133:429–435.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28345388</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1814-1412</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>12</Month></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cortisol levels in fingernails, neurocognitive performance and clinical variables in euthymic bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>633-644</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15622975.2017.1298838</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Neurocognitive impairment has been found in bipolar patients. Hypercortisolemia is one possible cause but there has been no agreement on this. Previous sampling methods assessed only acute cortisol levels, whereas the association between cortisol and psychopathology might be better understood by investigating chronic levels. Fingernails are a novel method for measuring chronic cortisol concentration (CCC). Here, we measured CCC in euthymic bipolar disorder I (BD-I) patients and healthy controls using fingernails to investigate whether differences in CCC influenced neurocognitive performance. We also investigated whether differences in clinical illness variables influenced CCC in euthymic BD-I patients.</AbstractText><AbstractText Label="METHODS">A previous study demonstrated neurocognitive impairment in euthymic BD-I patients. The current study included a portion of this sample: 40 BD-I versus 42 matched controls who provided fingernail samples.</AbstractText><AbstractText Label="RESULTS">There was no statistically significant difference in CCC between controls and BD-I (P = .09). Logistic regression analyses revealed that euthymic bipolar I subjects with more than five years of current euthymia had decreased odds of having higher fingernail cortisol concentration (&gt;71.2 pg/mg) compared to those with less than 1.5 years (P = .04). There was no association between CCC and cognitive impairment in all domains before and after adjustment for age and sex.</AbstractText><AbstractText Label="CONCLUSIONS">The current evidence suggests CCC is not a trait biomarker in euthymic BD-I (BD-I). Longer periods of stability in affective disorders are associated with lower CCC. Fingernail cortisol does not seem to be implicated in neurocognitive impairment and BD-I. Future studies may investigate CCC in different illness phases of BD-I.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herane-Vives</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience , King's College London , London , UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Departamento de Clínicas, Facultad de Medicina , Universidad Católica del Norte , Coquimbo , Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cleare</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>a Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience , King's College London , London , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chin-Kuo</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>a Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience , King's College London , London , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Angel</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>c Facultad de Medicina , Universidad de Chile , Santiago , Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience , King's College London , London , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience , King's College London , London , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halari</LastName><ForeName>Rozmin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>a Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience , King's College London , London , UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Eric Y W</ForeName><Initials>EYW</Initials><AffiliationInfo><Affiliation>d Tuen Mun Mental Health Centre, TMMHC , Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Allan H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>a Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience , King's College London , London , UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009262" MajorTopicYN="N">Nails</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Fingernails</Keyword><Keyword MajorTopicYN="Y">bipolar I disorder</Keyword><Keyword MajorTopicYN="Y">cognition</Keyword><Keyword MajorTopicYN="Y">cortisol</Keyword><Keyword MajorTopicYN="Y">euthymia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28345388</ArticleId><ArticleId IdType="doi">10.1080/15622975.2017.1298838</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28176421</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>02</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Incidence and predictors of suicide attempts in bipolar I and II disorders: A 5-year follow-up study.</ArticleTitle><Pagination><MedlinePgn>13-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12464</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Few long-term studies on bipolar disorder (BD) have investigated the incidence and risk factors of suicide attempts (SAs) specifically related to illness phases. We examined the incidence of SAs during different phases of BD in a long-term prospective cohort of bipolar I (BD-I) and bipolar II (BD-II) patients, and risk factors specifically for SAs during major depressive episodes (MDEs).</AbstractText><AbstractText Label="METHODS">In the Jorvi Bipolar Study (JoBS), 191 BD-I and BD-II patients were followed using life-chart methodology. Prospective information on SAs of 177 patients (92.7%) during different illness phases was available up to 5 years. The incidence of SAs and their predictors were investigated using logistic and Poisson regression models. Analyses of risk factors for SAs occurring during MDEs were conducted using two-level random-intercept logistic regression models.</AbstractText><AbstractText Label="RESULTS">During the 5 years of follow-up, 90 SAs per 718 patient-years occurred. The incidence was highest, over 120-fold higher than in euthymia, during mixed states (765/1000 person-years; 95% confidence interval [CI] 461-1269 person-years), and also very high in MDEs, almost 60-fold higher than in euthymia (354/1000 person-years; 95% CI 277-451 person-years). For risk of SAs during MDEs, the duration of MDEs, severity of depression, and cluster C personality disorders were significant predictors.</AbstractText><AbstractText Label="CONCLUSIONS">We confirmed in this long-term study that the highest incidences of SAs occur in mixed and major depressive illness phases. The variations in incidence rates between euthymia and illness phases were remarkably large, suggesting that the question "when" rather than "who" may be more relevant for suicide risk in BD. However, risk during MDEs is likely also influenced by personality factors.</AbstractText><CopyrightInformation>© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pallaskorpi</LastName><ForeName>Sanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mental Health Unit, National Institute of Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric and Substance Abuse Services, Helsinki City Department of Social Services and Healthcare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suominen</LastName><ForeName>Kirsi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Psychiatric and Substance Abuse Services, Helsinki City Department of Social Services and Healthcare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ketokivi</LastName><ForeName>Mikko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Operations and Technology Department, IE Business School - IE University, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valtonen</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Psychiatric and Substance Abuse Services, Helsinki City Department of Social Services and Healthcare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arvilommi</LastName><ForeName>Petri</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Mental Health Unit, National Institute of Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatric and Substance Abuse Services, Helsinki City Department of Social Services and Healthcare, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mantere</LastName><ForeName>Outi</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McGill University, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leppämäki</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isometsä</LastName><ForeName>Erkki</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Mental Health Unit, National Institute of Health and Welfare, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2017 Jun;19(4):314-315</RefSource><PMID Version="1">28493632</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="Y">Suicide, Attempted</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">incidence</Keyword><Keyword MajorTopicYN="Y">risk factors</Keyword><Keyword MajorTopicYN="Y">suicide</Keyword><Keyword MajorTopicYN="Y">suicide attempt</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28176421</ArticleId><ArticleId IdType="doi">10.1111/bdi.12464</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17280569</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-1591</ISSN><JournalIssue CitedMedium="Print"><Issue>433</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica. Supplementum</Title><ISOAbbreviation>Acta Psychiatr Scand Suppl</ISOAbbreviation></Journal><ArticleTitle>The incidence and prevalence of manic-melancholic syndromes in North West Wales: 1875-2005.</ArticleTitle><Pagination><MedlinePgn>37-43</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Against a background of recent interest in the concept of melancholia, we report data on the incidence and prevalence of manic, melancholic and postpartum syndromes from North West Wales.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We have utilized a database of the complete records of all admission to the North Wales Asylum from 1875 to 1924, and compared the findings for mania, melancholia, and postpartum psychoses from this sample, with admissions for these disorders to the North West Wales mental health services between 1995 and 2005.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of bipolar disorder, as well as melancholia with and without psychotic features appears stable from 1875 to 2005 but there has been a dramatic decline in the incidence of de novo onset psychoses in the postpartum period. The prevalence of admissions for bipolar disorder, and for severe depressive disorders has increased dramatically during this period.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There are some grounds for revisiting the concept of manic-melancholic disorder put forward by Rafaelsen. The changes in the incidence of postpartum psychoses may have a wider significance for the affective disorders in general.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farquhar</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>North Wales Department of Psychological Medicine, Cardiff University, Hergest Unit, Bangor, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Noury</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tschinkel</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kurien</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Psychiatr Scand Suppl</MedlineTA><NlmUniqueID>0370365</NlmUniqueID><ISSNLinking>0065-1591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002391" MajorTopicYN="N">Catchment Area, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019052" MajorTopicYN="N">Depression, Postpartum</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049672" MajorTopicYN="N">History, 19th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014852" MajorTopicYN="N" Type="Geographic">Wales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17280569</ArticleId><ArticleId IdType="pii">ACP961</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2007.00961.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7264059</PMID><DateCompleted><Year>1981</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-843X</ISSN><JournalIssue CitedMedium="Print"><Volume>90</Volume><Issue>4</Issue><PubDate><Year>1981</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of abnormal psychology</Title><ISOAbbreviation>J Abnorm Psychol</ISOAbbreviation></Journal><ArticleTitle>Distractibility in children vulnerable to psychopathology.</ArticleTitle><Pagination><MedlinePgn>298-304</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Winters</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Neale</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 21145</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Abnorm Psychol</MedlineTA><NlmUniqueID>0034461</NlmUniqueID><ISSNLinking>0021-843X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="Y">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7264059</ArticleId><ArticleId IdType="doi">10.1037//0021-843x.90.4.298</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20699193</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2011</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><Issue>1-3</Issue><PubDate><Year>2011</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Cyclothymic and hyperthymic temperaments may predict bipolarity in major depressive disorder: a supportive evidence for bipolar II1/2 and IV.</ArticleTitle><Pagination><MedlinePgn>34-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2010.07.016</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The concept of soft bipolar spectrum has not been fully confirmed. The aim of the present study is to investigate the validity of bipolar II1/2 and IV concept.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The subjects were 46 consecutive outpatients. The individual temperament of each patient was recorded using the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego-Autoquestionnaire (TEMPS-A). The operational definition of bipolar II1/2 was those who had depression with cyclothymic temperament and that of bipolar IV was those who had depression with hyperthymic temperament. Finally, drug responses were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DSM-IV-TR diagnoses were bipolar I (N=1), bipolar II (N=9), major depressive disorder (N=34) and depressive disorder not otherwise specified (N=2). Excluding one bipolar I patient, who had both cyclothymic and hyperthymic temperaments, patients with bipolar II1/2 (N=32) and IV (N=13) as well as bipolar II (N=9) were classified into the soft bipolar spectrum, although there was considerable overlap. The categorization of soft bipolar spectrum and unipolar depression significantly predicted depressive, cyclothymic, irritable, and anxious temperaments. Moreover, soft bipolar spectrum patients with lithium treatment were significantly more in remission than those without lithium treatment. In addition, more of those with selective serotonin reuptake inhibitors (SSRIs) had a significant tendency to lower remission than those without SSRIs.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This is a cross-sectional study with a relatively small number of subjects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The present findings suggest that cyclothymic and hyperthymic temperaments may predict bipolarity, and the validity of bipolar II1/2 and IV concept is supported.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goto</LastName><ForeName>Shinjiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Oita University Faculty of Medicine, Idaigaoka 1-1, Hasama machi, Yufu city, Oita, 879-5593, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terao</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hoaki</LastName><ForeName>Nobuhiko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yumei</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>06</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20699193</ArticleId><ArticleId IdType="pii">S0165-0327(10)00497-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2010.07.016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1853981</PMID><DateCompleted><Year>1991</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>148</Volume><Issue>8</Issue><PubDate><Year>1991</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cyclothymic mood swings in major and minor psychiatric disorders.</ArticleTitle><Pagination><MedlinePgn>1104-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rihmer</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 1989 Sep;146(9):1149-54</RefSource><PMID Version="1">2764171</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1853981</ArticleId><ArticleId IdType="doi">10.1176/ajp.148.8.aj14881104</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21865958</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2011</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4112</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of ECT</Title><ISOAbbreviation>J ECT</ISOAbbreviation></Journal><ArticleTitle>Continuous transthoracic echocardiography in a 93-year-old patient with hypertrophic cardiomyopathy during electroconvulsive therapy.</ArticleTitle><Pagination><MedlinePgn>224-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCT.0b013e318223821b</ELocationID><Abstract><AbstractText>Electroconvulsive therapy (ECT) is the treatment of choice for patients with a major depression disorder who have failed antidepressant therapy. Patients with hypertrophic cardiomyopathy (HCM) may have dynamic obstruction to left ventricular (LV) outflow. The effects on myocardial function during ECT and pretreatment with antihypertensive agents in patients with HCM and LV outflow tract obstruction gradients are unknown. We report the first use of continuous transthoracic echocardiography during ECT in a patient with HCM. We confirmed an outflow tract obstruction and showed a decrease in LV outflow tract gradients. Continuous transthoracic echocardiography monitoring using Doppler echocardiography during ECT is feasible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Albert R</ForeName><Initials>AR</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>University of Florida College of Medicine, Gainesville, FL 32610-0254, USA. arobinson@anest.ufl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holbert</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Modell</LastName><ForeName>Jerome H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Gravenstein</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J ECT</MedlineTA><NlmUniqueID>9808943</NlmUniqueID><ISSNLinking>1095-0680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002312" MajorTopicYN="N">Cardiomyopathy, Hypertrophic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="Y">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="Y">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018487" MajorTopicYN="N">Ventricular Dysfunction, Left</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21865958</ArticleId><ArticleId IdType="doi">10.1097/YCT.0b013e318223821b</ArticleId><ArticleId IdType="pii">00124509-201109000-00009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29627698</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>264</Volume><PubDate><Year>2018</Year><Month>06</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Differentiating positive schizotypy and mania risk scales and their associations with spontaneous eye blink rate.</ArticleTitle><Pagination><MedlinePgn>58-66</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(17)31203-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2018.03.068</ELocationID><Abstract><AbstractText>Positive schizotypy and mania risk scales are strongly correlated, and both are linked to alterations in striatal dopamine. Previous research has not examined whether these risk scales form distinct factors or whether they are differentially related to other measures of psychopathology risk or striatal dopamine. In the current study (N = 596), undergraduate students completed both positive schizotypy and mania risk scales as well as scales assessing related psychopathology (i.e., negative and disorganized schizotypy; self-reported manic-like episodes). Additionally, we measured spontaneous eye blink rate, which has been consistently associated with striatal dopamine levels. Positive schizotypy and mania risk factors were strongly correlated (factor correlation = 0.73). However, a two-factor model with positive schizotypy and mania risk as separate factors fit significantly better than a one-factor risk model. After removing shared variance, only positive schizotypy was positively associated with both negative and disorganized schizotypy, and only mania risk was related to self-reported manic-like episodes. Furthermore, positive schizotypy was associated with decreased spontaneous eye blink rate, and mania risk was associated with increased spontaneous eye blink rate. Overall, these results suggest that positive schizotypy and mania risk can be distinguished as separate factors and that they might be differentially associated with striatal dopamine measures.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Jessica P Y</ForeName><Initials>JPY</Initials><AffiliationInfo><Affiliation>Department of Psychological Sciences, University of Missouri, Columbia, MO, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerns</LastName><ForeName>John G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Psychological Sciences, University of Missouri, Columbia, MO, United States. Electronic address: kernsj@missouri.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001767" MajorTopicYN="N">Blinking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010775" MajorTopicYN="N">Photic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29627698</ArticleId><ArticleId IdType="pii">S0165-1781(17)31203-9</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2018.03.068</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2244802</PMID><DateCompleted><Year>1991</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>12</Issue><PubDate><Year>1990</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>White matter abnormalities on magnetic resonance imaging in bipolar patients.</ArticleTitle><Pagination><MedlinePgn>1172-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ron</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>du Boulay</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Arch Gen Psychiatry. 1990 Jan;47(1):55-9</RefSource><PMID Version="1">2294856</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2244802</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1990.01810240092016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20712759</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2010</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Bipolar affective disorder in the postnatal period: investigating the role of sleep.</ArticleTitle><Pagination><MedlinePgn>568-78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2010.00845.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Psychotic disorders have a high rate of relapse in the postpartum period for reasons that are unclear, but may be related to changes in sleep patterns that occur during pregnancy and after birth. Understanding of the influence of sleep on postpartum psychosis presentation is limited. The aim of the current study was to investigate changes in sleep/wake activity during pregnancy and the postpartum period in women with a history of psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Women with a history of bipolar disorder and/or postpartum psychosis (HxW) were recruited (n = 23) together with a control population (CtW) (n = 15). Data on demographic and psychosocial factors, mental health status, and sleep/wake activity were collected at seven timepoints-the last week of each trimester of pregnancy and four times during the postpartum (weeks 1, 4, and 8, and at month 6). Longitudinal data were analysed using an HLM version 6 repeated-measures multilevel model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences were noted in sleep/wake activity between HxW and CtW. None of the HxW who were taking a mood stabilizer during their pregnancy, including at delivery, relapsed during the study. Of those taking an antidepressant or antipsychotic, or no medication, 3 relapsed within the first six months and 2 within the first two months. HxW were more likely to report a poor partner relationship than CtW.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Results suggest that during the perinatal period, there is no difference in sleep/wake activity in women with a history of a psychotic disorder. Use of mood stabilizer during pregnancy and at delivery appears important in preventing psychotic relapse in the postpartum.</AbstractText><CopyrightInformation>(c) 2010 John Wiley &amp; Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bilszta</LastName><ForeName>Justin L C</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Melbourne, Melbourne, Australia. jbilszta@unimelb.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Denny</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Buist</LastName><ForeName>Anne E</ForeName><Initials>AE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017533" MajorTopicYN="N">Marital Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="N">Postpartum Period</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011584" MajorTopicYN="N">Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="Y">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20712759</ArticleId><ArticleId IdType="pii">BDI845</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2010.00845.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2750983</PMID><DateCompleted><Year>1989</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>146</Volume><Issue>8</Issue><PubDate><Year>1989</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania triggered by a steroid nasal spray in a patient with stable bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1076-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>E T</ForeName><Initials>ET</Initials></Author><Author ValidYN="Y"><LastName>Preskorn</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>KGZ1SLC28Z</RegistryNumber><NameOfSubstance UI="D001507">Beclomethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001507" MajorTopicYN="N">Beclomethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009330" MajorTopicYN="N">Nebulizers and Vaporizers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2750983</ArticleId><ArticleId IdType="doi">10.1176/ajp.146.8.1076</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19440881</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Evaluation of treatment in 35 cases of bipolar suicide.</ArticleTitle><Pagination><MedlinePgn>503-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/00048670902873680</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the present study was to evaluate clinical factors relevant to suicide prevention (including treatment) in cases of bipolar suicide with available therapeutic histories.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Victorian Coroner's Office data enabled identification of suicides that occurred between March 1993 and December 2001. Cases involving sufficient clinical notes to enable diagnosis of DSM-IV bipolar disorder and review of treatment were de-identified and assessed by an expert clinical panel.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From 3752 suicides, 35 eligible bipolar subjects (22 men, 13 women) aged 40.3 +/- 1.8 years were identified. Duration of illness was 11.9 +/- 1.1 years. A total of 86% had made at least one previous suicide attempt, and 83% were in the depressed phase of illness. A total of 63% manifested psychosis at some time during lifetime illness. Fourteen per cent were inpatients, and 26% suicided within 6 weeks of hospital discharge. The panel's retrospective risk assessment concluded that only 48% of cases could have been assessed as high risk. In the 4 weeks prior to suicide, treatment was rated as not reaching benchmark standards in 60% of cases. Electroconvulsive therapy had been given to 11%, lithium to 43% (but definitely therapeutic in only 11%), 31% had never been treated with lithium, and psychosocial interventions did not reach adequate standards in 57% during the previous year.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the majority of bipolar suicide cases in the present case series the subjects did not receive treatment at or above a benchmark standard, often due to illness and situational factors, but also possibly due to inadequate clinical interventions. Strategies to improve treatment may reduce suicide in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Keks</LastName><ForeName>Nicholas A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Mental Health Research Institute of Victoria, Melbourne, Victoria, Australia. nicholas.keks@med.monash.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sundram</LastName><ForeName>Suresh</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bellingham</LastName><ForeName>Kylee</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Opeskin</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Dorissa</LastName><ForeName>Arrigo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Copolov</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19440881</ArticleId><ArticleId IdType="pii">911161419</ArticleId><ArticleId IdType="doi">10.1080/00048670902873680</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33368908</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>08</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Aripiprazole in the treatment of bipolar disorder due to traumatic brain injury: A case description.</ArticleTitle><Pagination><MedlinePgn>521-523</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.13038</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernández Leonor</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4128-3265</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Santiago Apóstol Hospital, Vitoria-Gasteiz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez de Mendiola Etxezarraga</LastName><ForeName>Xabier</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-7617-9786</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Santiago Apóstol Hospital, Vitoria-Gasteiz, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="Y">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>28</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33368908</ArticleId><ArticleId IdType="doi">10.1111/bdi.13038</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Chang HK, Hsu JW, Wu JC, et al. Risk of attempted suicide among adolescents and young adults with traumatic brain injury: a nationwide longitudinal study. J Affect Disord. 2019;250:21-25.</Citation></Reference><Reference><Citation>Drange OK, Vaaler AE, Morken G, Andreassen OA, Malt UF, Finseth PI. Clinical characteristics of patients with bipolar disorder and premorbid traumatic brain injury: a cross-sectional study. Int J Bipolar Disord. 2018;6:19.</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.</Citation></Reference><Reference><Citation>Satzer D, Bond DJ. Mania secondary to focal brain lesions: implications for understanding the functional neuroanatomy of bipolar disorder. Bipolar Disord. 2016;18:205-220.</Citation></Reference><Reference><Citation>Moreira T, Khemiri L, Runeson L. Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions. Case Rep. 2011;2011:bcr0920114756.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6711698</PMID><DateCompleted><Year>1984</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>141</Volume><Issue>5</Issue><PubDate><Year>1984</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Replication of "Prediction of antidepressant response to lithium": problems in generalizing to a clinical setting.</ArticleTitle><Pagination><MedlinePgn>706-7</MedlinePgn></Pagination><Abstract><AbstractText>In another study, a simple procedure accurately predicting antidepressant response to lithium was developed in an experimental research setting. The present study failed to replicate these predictors in a clinical setting. The authors suggest using caution in applying these predictors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Kimball</LastName><ForeName>R R</ForeName><Initials>RR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008950" MajorTopicYN="Y">MMPI</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6711698</ArticleId><ArticleId IdType="doi">10.1176/ajp.141.5.706</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3691078</PMID><DateCompleted><Year>1988</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>6</Issue><PubDate><MedlineDate>1987 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Age of onset in bipolar and unipolar illness with and without delusions or hallucinations.</ArticleTitle><Pagination><MedlinePgn>547-54</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blumenthal</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Egeland</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Sharpe</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Nee</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Endicott</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>28287</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>30906</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3691078</ArticleId><ArticleId IdType="pii">0010-440X(87)90021-6</ArticleId><ArticleId IdType="doi">10.1016/0010-440x(87)90021-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23551834</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>C9ORF72 expansion in a family with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>326-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12063</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the role in bipolar disorder of the C9ORF72 hexanucleotide repeat expansion responsible for frontotemporal lobe dementia and amyotrophic lateral sclerosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Eighty-nine subjects from a previously described panel of individuals with bipolar disorder ascertained for genetic studies were screened to detect expansion of the C9ORF72 repeat. One two-generation family with bipolar disorder and an expanded repeat was characterized in depth using molecular diagnostics, imaging, histopathology, and neurological and neuropsychological evaluation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One proband, with the typical clinical presentation of bipolar disorder, carried an expanded C9ORF72 allele of heterogeneous length between 14 and 20 kilobases (kb) as assessed by Southern blot. The expanded allele was inherited from a parent with atypical, late onset clinical features of bipolar disorder, who subsequently progressed to frontotemporal lobe dementia. The expansion in peripheral blood of the parent ranged from 8.5 to 20 kb. Cultured lymphoblastoid cells from this parent exhibited a homogeneous expansion of only 8.5 kb.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The disease course in the two generations described here demonstrates that expansion of the C9ORF72 may be associated with a form of bipolar disorder that presents clinically with classic phenomenology and progression to neurodegenerative disease. The frequency in our bipolar disorder cohort was only 1%, indicating that C9ORF72 is not a major contributor to bipolar disorder. DNA from cultured cells may be biased towards shorter repeats and nonrepresentative of the endogenous C9ORF72 expansion.</AbstractText><CopyrightInformation>© 2013 John Wiley and Sons A/S. Published by Blackwell Publishing Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meisler</LastName><ForeName>Miriam H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, University of Michigan School of Medicine, Ann Arbor, MI 48109-5618, USA. meislerm@umich.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Adrienne E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Julie M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Lenk</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Fang</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Todd</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Kamali</LastName><ForeName>Masoud</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Andrew P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Langenecker</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>McInnis</LastName><ForeName>Melvin G</ForeName><Initials>MG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG008671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS15655</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08671</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS015655</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS034509</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013283</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS34509</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS069809</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH074459</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH74459</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2014 Jun;16(4):448-9</RefSource><PMID Version="1">24329881</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="Y">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23551834</ArticleId><ArticleId IdType="doi">10.1111/bdi.12063</ArticleId><ArticleId IdType="pmc">PMC3660726</ArticleId><ArticleId IdType="mid">NIHMS449587</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuron. 2011 Oct 20;72(2):257-68</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Jun;134(Pt 6):1647-57</Citation><ArticleIdList><ArticleId IdType="pubmed">21555336</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2012 Apr;11(4):323-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Genet. 2013 Mar;83(3):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">22650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):245-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2012 Mar;135(Pt 3):693-708</Citation><ArticleIdList><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2006;29:259-77</Citation><ArticleIdList><ArticleId IdType="pubmed">16776586</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Sep;69(9):1164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22637471</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2012 Jun 20;23(9):556-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22564974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2012 Aug 15;21(16):3558-67</Citation><ArticleIdList><ArticleId IdType="pubmed">22595968</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2012 Sep;69(9):1149-53</Citation><ArticleIdList><ArticleId IdType="pubmed">22964910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2012 Jan;11(1):54-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22154785</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Diagn. 2005 Nov;7(5):605-12</Citation><ArticleIdList><ArticleId IdType="pubmed">16258159</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2007 Dec;27(6):722-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18004150</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2011 Jan;134(Pt 1):137-42</Citation><ArticleIdList><ArticleId IdType="pubmed">20923788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 May;122(3):285-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19800130</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics. 1996 Aug 15;36(1):47-53</Citation><ArticleIdList><ArticleId IdType="pubmed">8812415</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2012;31(2):447-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22571983</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2013 Jan;21(1):102-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22692064</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1993 Aug;53(2):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8328456</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2012 Jan;8(1):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">22265587</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Case Rep. 2011 Feb 02;2011:</Citation><ArticleIdList><ArticleId IdType="pubmed">22714610</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19476688</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials.</ArticleTitle><Pagination><MedlinePgn>9-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S003329170900590X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although cognitive behavioural therapy (CBT) is claimed to be effective in schizophrenia, major depression and bipolar disorder, there have been negative findings in well-conducted studies and meta-analyses have not fully considered the potential influence of blindness or the use of control interventions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We pooled data from published trials of CBT in schizophrenia, major depression and bipolar disorder that used controls for non-specific effects of intervention. Trials of effectiveness against relapse were also pooled, including those that compared CBT to treatment as usual (TAU). Blinding was examined as a moderating factor.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CBT was not effective in reducing symptoms in schizophrenia or in preventing relapse. CBT was effective in reducing symptoms in major depression, although the effect size was small, and in reducing relapse. CBT was ineffective in reducing relapse in bipolar disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CBT is no better than non-specific control interventions in the treatment of schizophrenia and does not reduce relapse rates. It is effective in major depression but the size of the effect is small in treatment studies. On present evidence CBT is not an effective treatment strategy for prevention of relapse in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Stobhill Hospital, Glasgow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laws</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Psychol Med. 2010 Jan;40(1):25-7</RefSource><PMID Version="1">19570315</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Psychol Med. 2010 May;40(5):877-80</RefSource><PMID Version="1">19917145</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Psychol Med. 2010 Jun;40(6):1055-6</RefSource><PMID Version="1">20158935</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19476688</ArticleId><ArticleId IdType="pii">S003329170900590X</ArticleId><ArticleId IdType="doi">10.1017/S003329170900590X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1982184</PMID><DateCompleted><Year>1991</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>4-6</Issue><PubDate><Year>1990</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Clinical pharmacology and Leonhard's classification of endogenous psychoses.</ArticleTitle><Pagination><MedlinePgn>331-8</MedlinePgn></Pagination><Abstract><AbstractText>Introduction of therapeutically effective psychotropic drugs focused attention on the heterogeneity of psychiatric populations within the traditional diagnostic categories of psychiatric disorders. Recognition that valid diagnostic concepts are essential for progress in the biology and pharmacotherapy of psychiatric disorders resulted in a revival of interest in psychiatric nosology with a special emphasis on Leonhard's classification of 'endogenous psychoses'. Of particular importance for psychopharmacology in Leonhard's system is the recognition of two distinctive populations within the schizophrenic disorders, i.e., 'unsystematic schizophrenias' and 'systematic schizophrenias'; three distinctive populations within the bipolar disorders, i.e., 'manic-depressive illness,' 'cycloid psychoses' and 'unsystematic schizophrenias'; and two distinctive populations within depressive disorders, i.e., 'unipolar depression' and 'bipolar depression'. In this paper supporting data for Leonhard's classification of 'endogenous psychoses' are presented.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ban</LastName><ForeName>T A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Vanderbilt University, Nashville, Tenn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>36</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1982184</ArticleId><ArticleId IdType="doi">10.1159/000284677</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19658123</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2011</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-0879</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><MedlineDate>2009 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Clinical psychology &amp; psychotherapy</Title><ISOAbbreviation>Clin Psychol Psychother</ISOAbbreviation></Journal><ArticleTitle>A novel scale for measuring mixed states in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>497-509</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpp.633</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Conventional descriptions of bipolar disorder tend to treat the mixed state as something of an afterthought. There is no scale that specifically measures the phenomena of the mixed state. This study aimed to test a novel scale for mixed state in a clinical and community population of bipolar patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The scale included clinically relevant symptoms of both mania and depression in a bivariate scale. Recovered respondents were asked to recall their last manic episode. The scale allowed endorsement of one or more of the manic and depressive symptoms. Internal consistency analyses were carried out using Cronbach alpha. Factor analysis was carried out using a standard Principal Components Analysis followed by Varimax Rotation. A confirmatory factor analytic method was used to validate the scale structure in a representative clinical sample.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The reliability analysis gave a Cronbach alpha value of 0.950, with a range of corrected-item-total-scale correlations from 0.546 (weight change) to 0.830 (mood). The factor analysis revealed a two-factor solution for the manic and depressed items which accounted for 61.2% of the variance in the data. Factor 1 represented physical activity, verbal activity, thought processes and mood. Factor 2 represented eating habits, weight change, passage of time and pain sensitivity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This novel scale appears to capture the key features of mixed states. The two-factor solution fits well with previous models of bipolar disorder and concurs with the view that mixed states may be more than the sum of their parts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cavanagh</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Glasgow Section of Psychological Medicine, Sackler Institute of Psychobiological Research, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK. jc199d@clinmed.gla.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwannauer</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Power</LastName><ForeName>Mick</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Psychol Psychother</MedlineTA><NlmUniqueID>9416196</NlmUniqueID><ISSNLinking>1063-3995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19658123</ArticleId><ArticleId IdType="doi">10.1002/cpp.633</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8366481</PMID><DateCompleted><Year>1993</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0279-3695</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>6</Issue><PubDate><Year>1993</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of psychosocial nursing and mental health services</Title><ISOAbbreviation>J Psychosoc Nurs Ment Health Serv</ISOAbbreviation></Journal><ArticleTitle>Depression in primary care: detection, diagnosis, and treatment. US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research.</ArticleTitle><Pagination><MedlinePgn>19-28</MedlinePgn></Pagination><Abstract><AbstractText>1. About 15% of the general public will suffer from major depressive disorder sometime in their life, but fewer than one in three will be accurately diagnosed and treated. 2. About 10% to 15% or more of major depressive conditions are caused by general medical illnesses or other conditions. Generally, treat the associated condition first. If the depression persists after treatment, major depressive disorder should be diagnosed and treated. 3. In over 50% of depressed outpatients, antidepressant medication caused marked improvement or complete remission of their depressive symptoms. Several forms of short-term psychotherapy are effective for mild or moderate depression; combined treatment should be considered in certain situations.</AbstractText></Abstract><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychosoc Nurs Ment Health Serv</MedlineTA><NlmUniqueID>8200911</NlmUniqueID><ISSNLinking>0279-3695</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011602" MajorTopicYN="N">Psychophysiologic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013001" MajorTopicYN="N">Somatoform Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8366481</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11434641</PMID><DateCompleted><Year>2001</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>189</Volume><Issue>6</Issue><PubDate><Year>2001</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Insight is greater in mixed than in pure manic episodes of bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>398-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cassidy</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>John Umstead Hospital, Butner, North Carolina 27509, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Y K</ForeName><Initials>YK</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>W H</ForeName><Initials>WH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="Y">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>7</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>7</Month><Day>20</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>7</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11434641</ArticleId><ArticleId IdType="doi">10.1097/00005053-200106000-00008</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25562540</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1943-2763</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of personality disorders</Title><ISOAbbreviation>J Pers Disord</ISOAbbreviation></Journal><ArticleTitle>The Relationship Between Psychopathology and a Hierarchical Model of Normal Personality Traits: Evidence From a Psychiatric Patient Sample.</ArticleTitle><Pagination><MedlinePgn>719-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1521/pedi_2014_28_170</ELocationID><Abstract><AbstractText>Shifts in the conceptualization of psychopathology have favored a dimensional approach, with the five-factor model (FFM) playing a prominent role in this research. However, reservations about the utility of the FFM in differentiating disorders have risen. In the current investigation, a "bottom-up" analytical method was used to ascertain the hierarchical structure of personality, with investigation of the specificity of the traits in categorizing diagnostic categories across an expanded array of psychiatric disorders. Following earlier investigations, which used a hierarchical structural approach, this study presents new results relating to the differentiation of several forms of psychopathology not included in these earlier analyses--bipolar disorder, psychotic disorders, problem gambling, posttraumatic stress disorder, and somatoform disorders--across distinct levels of a personality hierarchy based on the FFM. These results bolster the argument for the use of FFM personality traits in characterizing and differentiating psychiatric diagnostic groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uliaszek</LastName><ForeName>Amanda A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Al-Dajani</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Bagby</LastName><ForeName>R Michael</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>University of Toronto Scarborough.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pers Disord</MedlineTA><NlmUniqueID>8710838</NlmUniqueID><ISSNLinking>0885-579X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005715" MajorTopicYN="N">Gambling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="Y">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="Y">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25562540</ArticleId><ArticleId IdType="doi">10.1521/pedi_2014_28_170</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18794513</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7206</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>5</Issue><PubDate><MedlineDate>2008 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Psychosomatics</Title><ISOAbbreviation>Psychosomatics</ISOAbbreviation></Journal><ArticleTitle>Mania: psychiatric manifestations of the antiphospholipid syndrome.</ArticleTitle><Pagination><MedlinePgn>438-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.psy.49.5.438</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Antiphospholipid syndrome (APS) is a prothrombotic condition characterized by recurrent vascular thrombosis and/or pregnancy morbidity in the presence of circulating antiphospholipid antibodies. Central nervous system (CNS) involvement is a prominent feature of APS, and many neurological manifestations have been described in published reports. There are limited data on psychiatric syndromes occurring in association with APS, and there have been no previous reports of mania associated with APS.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors present the case of a 31-year-old man who experienced an acute manic episode in association with APS. They review the literature on psychiatric manifestations of APS, discuss potential mechanisms of CNS pathogenesis, and consider diagnostic and treatment implications of the co-occurrence of APS and psychiatric symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raza</LastName><ForeName>Haniya</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Georgetown University Hospital, Washington, DC, USA. haniyaraza@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Pao</LastName><ForeName>Maryland</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rosenstein</LastName><ForeName>Donald L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 MH999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychosomatics</MedlineTA><NlmUniqueID>0376506</NlmUniqueID><ISSNLinking>0033-3182</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18794513</ArticleId><ArticleId IdType="pii">49/5/438</ArticleId><ArticleId IdType="doi">10.1176/appi.psy.49.5.438</ArticleId><ArticleId IdType="pmc">PMC2680550</ArticleId><ArticleId IdType="mid">NIHMS104641</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drugs. 2005;65(11):1493-520</Citation><ArticleIdList><ArticleId IdType="pubmed">16033289</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1995 Oct;99(4):397-401</Citation><ArticleIdList><ArticleId IdType="pubmed">7573096</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1993 Winter;5(1):37-42</Citation><ArticleIdList><ArticleId IdType="pubmed">8094019</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2002 Mar 7;346(10):752-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11882732</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998 Jan;59(1):20-3</Citation><ArticleIdList><ArticleId IdType="pubmed">9491061</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1994 Dec;151(12):1841-2</Citation><ArticleIdList><ArticleId IdType="pubmed">7977899</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2001 May;40(5):565-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11371668</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hematol. 1988 Apr;27(4):272-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3128108</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiology. 1999;92(1):65-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10640799</ArticleId></ArticleIdList></Reference><Reference><Citation>Intern Med. 1994 Jun;33(6):373-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7919628</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 1999 Jul;42(7):1309-11</Citation><ArticleIdList><ArticleId IdType="pubmed">10403256</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1997 Mar;62(3):300-1</Citation><ArticleIdList><ArticleId IdType="pubmed">9069503</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2003 Feb;42(2):200-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12595612</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1987 Aug;44(8):876-83</Citation><ArticleIdList><ArticleId IdType="pubmed">3115237</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med J. 2003 Feb;79(928):81-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12612321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2002;11(1):4-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11898917</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2002 Apr;46(4):1019-27</Citation><ArticleIdList><ArticleId IdType="pubmed">11953980</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 1998;7 Suppl 2:S67-74</Citation><ArticleIdList><ArticleId IdType="pubmed">9814677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2003;12(7):514-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12892390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2003;12(12):903-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14714909</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1993 Mar;87(3):160-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8465663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2003;12(12):883-90</Citation><ArticleIdList><ArticleId IdType="pubmed">14714906</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2003 May;30(5):985-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12734893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1997 Aug 1;100(3):613-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9239409</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1990 Apr 15;27(8):863-70</Citation><ArticleIdList><ArticleId IdType="pubmed">1970485</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Rheumatol Rep. 2002 Oct;4(5):392-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12217243</ArticleId></ArticleIdList></Reference><Reference><Citation>Autoimmunity. 2004 Jun;37(4):309-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15518048</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Neuroophthalmol. 1988 Dec;8(4):255-61</Citation><ArticleIdList><ArticleId IdType="pubmed">2977141</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9448659</PMID><DateCompleted><Year>1998</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>12</Issue><PubDate><Year>1997</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania from dexfenfluramine.</ArticleTitle><Pagination><MedlinePgn>548-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019440">Anti-Obesity Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2DS058H2CF</RegistryNumber><NameOfSubstance UI="D005277">Fenfluramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019440" MajorTopicYN="N">Anti-Obesity Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005277" MajorTopicYN="N">Fenfluramine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015430" MajorTopicYN="N">Weight Gain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9448659</ArticleId><ArticleId IdType="doi">10.4088/jcp.v58n1206b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3837889</PMID><DateCompleted><Year>1986</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2658</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>10</Issue><PubDate><Year>1985</Year></PubDate></JournalIssue><Title>Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica</Title><ISOAbbreviation>Seishin Shinkeigaku Zasshi</ISOAbbreviation></Journal><ArticleTitle>[Problems associated with diagnosis and treatment of endogenous manias].</ArticleTitle><Pagination><MedlinePgn>725-41</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Seishin Shinkeigaku Zasshi</MedlineTA><NlmUniqueID>9801787</NlmUniqueID><ISSNLinking>0033-2658</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003988">Dibenzothiepins</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>U29O83JAZW</RegistryNumber><NameOfSubstance UI="C022172">zotepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003988" MajorTopicYN="N">Dibenzothiepins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3837889</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28365466</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1778-3585</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><PubDate><Year>2017</Year><Month>06</Month></PubDate></JournalIssue><Title>European psychiatry : the journal of the Association of European Psychiatrists</Title><ISOAbbreviation>Eur Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Early clinical predictors and correlates of long-term morbidity in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>35-43</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-9338(17)32751-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eurpsy.2017.02.480</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Identifying factors predictive of long-term morbidity should improve clinical planning limiting disability and mortality associated with bipolar disorder (BD).</AbstractText><AbstractText Label="METHODS">We analyzed factors associated with total, depressive and mania-related long-term morbidity and their ratio D/M, as %-time ill between a first-lifetime major affective episode and last follow-up of 207 BD subjects. Bivariate comparisons were followed by multivariable linear regression modeling.</AbstractText><AbstractText Label="RESULTS">Total % of months ill during follow-up was greater in 96 BD-II (40.2%) than 111 BD-I subjects (28.4%; P=0.001). Time in depression averaged 26.1% in BD-II and 14.3% in BD-I, whereas mania-related morbidity was similar in both, averaging 13.9%. Their ratio D/M was 3.7-fold greater in BD-II than BD-I (5.74 vs. 1.96; P&lt;0.0001). Predictive factors independently associated with total %-time ill were: [a] BD-II diagnosis, [b] longer prodrome from antecedents to first affective episode, and [c] any psychiatric comorbidity. Associated with %-time depressed were: [a] BD-II diagnosis, [b] any antecedent psychiatric syndrome, [c] psychiatric comorbidity, and [d] agitated/psychotic depressive first affective episode. Associated with %-time in mania-like illness were: [a] fewer years ill and [b] (hypo)manic first affective episode. The long-term D/M morbidity ratio was associated with: [a] anxious temperament, [b] depressive first episode, and [c] BD-II diagnosis.</AbstractText><AbstractText Label="CONCLUSIONS">Long-term depressive greatly exceeded mania-like morbidity in BD patients. BD-II subjects spent 42% more time ill overall, with a 3.7-times greater D/M morbidity ratio, than BD-I. More time depressed was predicted by agitated/psychotic initial depressive episodes, psychiatric comorbidity, and BD-II diagnosis. Longer prodrome and any antecedent psychiatric syndrome were respectively associated with total and depressive morbidity.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serra</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Child Psychiatry Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; International Consortium for Mood &amp; Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, USA; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA; International Consortium for Mood &amp; Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, USA; Lucio Bini Mood Disorder Center, Rome, Italy. Electronic address: giuliaserra@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koukopoulos</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>International Consortium for Mood &amp; Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, USA; Lucio Bini Mood Disorder Center, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Chiara</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NESMOS Department (Neuroscience, Mental Health, and Sensory Organs), Sapienza University, School of Medicine and Psychology, Sant'Andrea Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koukopoulos</LastName><ForeName>A E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>NESMOS Department (Neuroscience, Mental Health, and Sensory Organs), Sapienza University, School of Medicine and Psychology, Sant'Andrea Hospital, Rome, Italy; Lucio Bini Mood Disorder Center, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sani</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>NESMOS Department (Neuroscience, Mental Health, and Sensory Organs), Sapienza University, School of Medicine and Psychology, Sant'Andrea Hospital, Rome, Italy; Lucio Bini Mood Disorder Center, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tondo</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Child Psychiatry Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy; International Consortium for Mood &amp; Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, USA; Lucio Bini Mood Disorder Center, Cagliari, Sardinia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girardi</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NESMOS Department (Neuroscience, Mental Health, and Sensory Organs), Sapienza University, School of Medicine and Psychology, Sant'Andrea Hospital, Rome, Italy; Lucio Bini Mood Disorder Center, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reginaldi</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>International Consortium for Mood &amp; Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, USA; Lucio Bini Mood Disorder Center, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA; International Consortium for Mood &amp; Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Psychiatry</MedlineTA><NlmUniqueID>9111820</NlmUniqueID><ISSNLinking>0924-9338</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">D/M ratio</Keyword><Keyword MajorTopicYN="Y">Long-term morbidity</Keyword><Keyword MajorTopicYN="Y">Outcome</Keyword><Keyword MajorTopicYN="Y">Prediction</Keyword><Keyword MajorTopicYN="Y">Prodrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>01</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>02</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28365466</ArticleId><ArticleId IdType="pii">S0924-9338(17)32751-7</ArticleId><ArticleId IdType="doi">10.1016/j.eurpsy.2017.02.480</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31758547</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>02</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Differentiating borderline personality disorder (BPD) from bipolar disorder: diagnostic efficiency of DSM BPD criteria.</ArticleTitle><Pagination><MedlinePgn>142-148</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.13133</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We sought to determine the differential diagnostic efficiency of all DSM-IV borderline personality disorder (BPD) criteria by studying a sample of those with BPD and a contrast group with a bipolar disorder (BP).</AbstractText><AbstractText Label="METHOD">Participants were clinically assessed and assigned diagnoses based on DSM criteria - with prevalence rates and diagnostic efficiency values calculated.</AbstractText><AbstractText Label="RESULTS">Fifty-three participants were assigned a BPD diagnosis, 83 a BP diagnosis, with comorbid participants excluded. The mean number of DSM BPD criteria assigned was 6.6 (SD = 1.0) in the BPD group and 1.9 (SD = 1.3) in the BP group. The most prevalent criterion in the BPD group was 'affective instability' (AI) (92.5%), with 'inappropriate anger' least endorsed (49%). The highest specificity criterion was 'abandonment fears', which displayed the greatest positive predictive value (PPV) = 0.9, and with AI offering the lowest specificity. 'Unstable relationships' had the highest overall negative predictive value (NPV) = 0.91. The highest percentage accuracy of classification was provided by 'identity disturbance' and 'abandonment fears' criteria, both 85%.</AbstractText><AbstractText Label="CONCLUSION">The transdiagnostic nature of 'affective instability' means it is less useful for diagnostic decisions, whereas 'abandonment fears' and 'identity disturbance' offer superior diagnostic efficiency in distinguishing BPD from BP.</AbstractText><CopyrightInformation>© 2019 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bayes</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-2976-822X</Identifier><AffiliationInfo><Affiliation>School of Psychiatry, UNSW, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Dog Institute, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>G B</ForeName><Initials>GB</Initials><Identifier Source="ORCID">0000-0003-3424-5519</Identifier><AffiliationInfo><Affiliation>School of Psychiatry, UNSW, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Dog Institute, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1037196</GrantID><Agency>National Health and Medical Research Council</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000342" MajorTopicYN="N">Affective Symptoms</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">borderline personality disorder</Keyword><Keyword MajorTopicYN="Y">diagnosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31758547</ArticleId><ArticleId IdType="doi">10.1111/acps.13133</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Bassett D. Borderline personality disorder and bipolar affective disorder. Spectra or spectre? A review. Aust N Z J Psychiatry 2012;46:327-339.</Citation></Reference><Reference><Citation>Bayes AJ, McClure G, Fletcher K et al. Differentiating the bipolar disorders from borderline personality disorder. Acta Psychiatr Scand 2016;133:187-195.</Citation></Reference><Reference><Citation>Joyce PR, Light KJ, Rowe SL. Self-mutilation and suicide attempts: relationships to bipolar disorder, borderline personality disorder, temperament and character. Aust N Z J Psychiatry 2010;44:250-257.</Citation></Reference><Reference><Citation>Di Giacomo E, Aspesi F, Fotiadou M et al. Unblending borderline personality and bipolar disorders. J Psychiatr Res 2017;91:90-97.</Citation></Reference><Reference><Citation>World Health Organization (WHO). ICD-11 Clinical Descriptions and Diagnostic Guidelines for Mental and Behavioural Disorders. Geneva: WHO; 2018.</Citation></Reference><Reference><Citation>Association American Psychiatric (Ed). Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.</Citation></Reference><Reference><Citation>Clarkin JF, Widiger TA, Frances A et al. Prototypic typology and the borderline personality disorder. J Abnorm Psychol 1983;92:263-275.</Citation></Reference><Reference><Citation>Farmer RF, Chapman AL. Evaluation of DSM-IV personality disorder criteria as assessed by the structured clinical interview for DSM-IV personality disorders. Compr Psychiatry 2002;43:285-300.</Citation></Reference><Reference><Citation>Grilo CM, McGlashan TH, Morey LC et al. Internal consistency, intercriterion overlap, and diagnostic efficiency of criteria sets for DSM-IV personality disorders. Acta Psychiatr Scand 2001;104:264-272.</Citation></Reference><Reference><Citation>Grilo CM, Becker DF, Anez LM et al. Diagnostic efficiency of DSM-IV criteria for borderline personality disorder: an evaluation in Hispanic men and women with substance use disorders. J Consult Clin Psychol 2004;72:126-131.</Citation></Reference><Reference><Citation>Blais MA, Hilsenroth MJ, Fowler JC. Diagnostic efficiency and hierarchical functioning of the DSM-IV borderline personality disorder criteria. J Nerv Ment Dis 1999;187:167-173.</Citation></Reference><Reference><Citation>Bayes A, Parker G. Cognitive and behavioural differentiation of bipolar disorder and borderline personality disorder. J Nerv Ment Dis 2019;207:620-625.</Citation></Reference><Reference><Citation>Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33.</Citation></Reference><Reference><Citation>Zanarini MC. The Diagnostic Interview for DSM-IV Personality Disorders. Belmont MA: McLean Hospital and Harvard Medical School; 1996.</Citation></Reference><Reference><Citation>Bayes A, Parker G, McClure G. Emotional dysregulation in those with bipolar disorder, borderline personality disorder and their comorbid expression. J Affect Disord 2016;204:103-111.</Citation></Reference><Reference><Citation>Aggen SH, Neale MC, Røysamb E et al. A psychometric evaluation of the DSM-IV borderline personality disorder criteria: age and sex moderation of criterion functioning. Psychol Med 2009;39:1967-1978.</Citation></Reference><Reference><Citation>Stepp SD, Pilkonis PA. Age-related differences in individual DSM criteria for borderline personality disorder. J Pers Disord 2008;22:427-432.</Citation></Reference><Reference><Citation>Richetin J, Preti E, Costantini G, De Panfilis C. The centrality of affective instability and identity in borderline personality disorder: evidence from network analysis. PLoS ONE 2017;12:e0186695.</Citation></Reference><Reference><Citation>Yen S, Frazier E, Hower H et al. Borderline personality disorder in transition age youth with bipolar disorder. Acta Psychiatr Scand 2015;132:270-280.</Citation></Reference><Reference><Citation>Fletcher K, Parker G, Bayes A, Paterson A, McClure G. Emotion regulation strategies in bipolar II disorder and borderline personality disorder: Differences and relationships with perceived parental style. J Affect Disord 2014;157:52-59.</Citation></Reference><Reference><Citation>Gunderson JG. Revising the borderline diagnosis for DSM-V: An alternative proposal. J Pers Disord 2010;24:694-708.</Citation></Reference><Reference><Citation>Nilsson AK, Jørgensen CR, Straarup KN, Licht RW. Severity of affective temperament and maladaptive self-schemas differentiate borderline patients, bipolar patients, and controls. Compr Psychiatry 2010;51:486-491.</Citation></Reference><Reference><Citation>Zandersen M, Parnas J. Exploring schizophrenia spectrum psychopathology in borderline personality disorder. Eur Arch Psy Clin N 2019;1-10.</Citation></Reference><Reference><Citation>Johansen M, Karterud S, Pedersen G, Gude T, Falkum E. An investigation of the prototype validity of the borderline DSM-IV construct. Acta Psychiatr Scand 2004;109:289-298.</Citation></Reference><Reference><Citation>Zimmerman M, Balling C, Dalrymple K, Chelminski I. screening for borderline personality disorder in psychiatric outpatients with major depressive disorder and bipolar disorder. J Clin Psychiatry 2019;80.</Citation></Reference><Reference><Citation>Bach B, Sellbom M. Continuity between DSM-5 categorical criteria and traits criteria for borderline personality disorder. Can J Psychiatry 2016;61:489-494.</Citation></Reference><Reference><Citation>Bach B, Sellbom M, Bo S, Simonsen E. Utility of DSM-5 section III personality traits in differentiating borderline personality disorder from comparison groups. Eur Psychiatry 2016;37:22-27.</Citation></Reference><Reference><Citation>Fowler JC, Madan A, Allen JG, Oldham JM, Frueh BC. Differentiating bipolar disorder from borderline personality disorder: Diagnostic accuracy of the difficulty in emotion regulation scale and personality inventory for DSM-5. J Affect Disord 2019;245:856-860.</Citation></Reference><Reference><Citation>Crawford MJ, Sanatinia R, Barrett B et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry 2018;175:756-764.</Citation></Reference><Reference><Citation>Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs 2008;22:671-692.</Citation></Reference><Reference><Citation>Gunderson JG. Borderline personality disorder. N Engl J Med 2011;364:2037-2042.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3970279</PMID><DateCompleted><Year>1985</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>142</Volume><Issue>3</Issue><PubDate><Year>1985</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Behavioral treatment in two cases of obsessive-compulsive disorder with concomitant bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>358-60</MedlinePgn></Pagination><Abstract><AbstractText>The authors describe two cases of obsessive-compulsive disorder with concomitant bipolar affective disorder. Behavior therapy consisting of in vivo exposure plus response prevention controlled the obsessive-compulsive symptoms only after the affective illness was well controlled pharmacologically.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baer</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Minichiello</LastName><ForeName>W E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Jenike</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical><Chemical><RegistryNumber>TG537D343B</RegistryNumber><NameOfSubstance UI="D003891">Desipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="Y">Behavior Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003891" MajorTopicYN="N">Desipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3970279</ArticleId><ArticleId IdType="doi">10.1176/ajp.142.3.358</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16879137</PMID><DateCompleted><Year>2006</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2007</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Early detection of bipolar disorder: a pilot familial high-risk study of parents with bipolar disorder and their adolescent children.</ArticleTitle><Pagination><MedlinePgn>362-72</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Disturbances in cognition, affect, sleep and activity have been identified in bipolar disorder (BD) but little is known about the possible role of these factors in the development of the condition. We studied these variables in a familial high-risk sample.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-five children (13-19 years) of bipolar parents were compared with 22 similar aged children of age- and sex-matched healthy controls. Participants were assessed using Schedule for Affective Disorders and Schizophrenia-Lifetime version (SADS-L) and completed self-report measures of dysfunctional attitudes, behavioural inhibition/activation, social rhythms, coping styles and subjective experience of sleep. Children completed a 7-day recording of actigraphy (sleep and activity) and a 7-day diary measuring self-esteem, positive and negative affect and reactions to positive and negative events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-six per cent of children of bipolar parents (CBP) reported mood symptoms compared to 9% of children of control parents (CC). The CBP group had coping styles and instability of self-esteem consistent with abnormal strategies for regulating affect. Both groups also differed on sleep measures. The majority of differences observed were between CBP with a current or past mood diagnosis and CC. BD parents reported dysfunctional coping styles and (to a lesser extent) disrupted activity patterns.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A familial high-risk strategy for studying the role of psychological factors in BD is feasible and informative. This pilot study indicates that abnormal coping styles, instability of self-esteem and dysregulation of sleep may be early markers of bipolar illness. However, current findings need to be explored further in longitudinal studies to clarify which potential markers are truly predictive of BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Steven Huntley</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>School of Psychological Sciences, University of Manchester, Manchester, UK. steven.jones@manchester.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Evershed</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Knowles</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bentall</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010287" MajorTopicYN="Y">Parent-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="N">Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>10</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16879137</ArticleId><ArticleId IdType="pii">BDI329</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2006.00329.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28901625</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>12</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Systemic challenges in bipolar disorder management: A patient-centered approach.</ArticleTitle><Pagination><MedlinePgn>676-688</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12547</ELocationID><Abstract><AbstractText Label="OBJECTIVES">As part of a series of Patient-Centered Outcomes Research Institute-funded large-scale retrospective observational studies on bipolar disorder (BD) treatments and outcomes, we sought the input of patients with BD and their family members to develop research questions. We aimed to identify systemic root causes of patient-reported challenges with BD management in order to guide subsequent studies and initiatives.</AbstractText><AbstractText Label="METHODS">Three focus groups were conducted where patients and their family members (total n = 34) formulated questions around the central theme, "What do you wish you had known in advance or over the course of treatment for BD?" In an affinity mapping exercise, participants clustered their questions and ranked the resulting categories by importance. The research team and members of our patient partner advisory council further rated the questions by expected impact on patients. Using a Theory of Constraints systems thinking approach, several causal models of BD management challenges and their potential solution were developed with patients using the focus group data.</AbstractText><AbstractText Label="RESULTS">A total of 369 research questions were mapped to 33 categories revealing 10 broad themes. The top priorities for patient stakeholders involved pharmacotherapy and treatment alternatives. Analysis of causal relationships underlying 47 patient concerns revealed two core conflicts: for patients, whether or not to take pharmacotherapy, and for mental health services, the dilemma of care quality vs quantity.</AbstractText><AbstractText Label="CONCLUSIONS">To alleviate the core conflicts identified, BD management requires a coordinated multidisciplinary approach including: improved access to mental health services, objective diagnostics, sufficient provider visit time, evidence-based individualized treatment, and psychosocial support.</AbstractText><CopyrightInformation>© 2017 The Authors. Bipolar Disorders Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nestsiarovich</LastName><ForeName>Anastasiya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5558-2381</Identifier><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurwitz</LastName><ForeName>Nathaniel G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>New Mexico Behavioral Health Institute, Las Vegas, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Stuart J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>University of New Mexico Health Sciences Library and Informatics Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Translational Informatics, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crisanti</LastName><ForeName>Annette S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerner</LastName><ForeName>Berit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuntz</LastName><ForeName>Matt J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>National Alliance on Mental Illness Montana, Helena, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Alicia N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>National Alliance on Mental Illness Montana, Helena, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volesky</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Alliance on Mental Illness Montana, Helena, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeter</LastName><ForeName>Quentin L</ForeName><Initials>QL</Initials><AffiliationInfo><Affiliation>National Alliance on Mental Illness Montana, Helena, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeShaw</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>National Alliance on Mental Illness Montana, Helena, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>S Stanley</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>CGStat, LLC, Raleigh, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obenchain</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Risk Benefit Statistics, LLC, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krall</LastName><ForeName>Ronald L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>Kimmie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Alliance on Mental Illness New Mexico, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fawcett</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8049-4351</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkins</LastName><ForeName>Douglas J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0003-1994-2893</Identifier><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Translational Informatics, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003256" MajorTopicYN="N">Community Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020380" MajorTopicYN="N">Needs Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057240" MajorTopicYN="N">Patient Preference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Theory of Constraints</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">operational excellence</Keyword><Keyword MajorTopicYN="Y">patient priorities</Keyword><Keyword MajorTopicYN="Y">patient-centered</Keyword><Keyword MajorTopicYN="Y">systems thinking</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28901625</ArticleId><ArticleId IdType="doi">10.1111/bdi.12547</ArticleId><ArticleId IdType="pmc">PMC5763323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2015 Jun;17(4):349-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25594775</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Jul;57(7):937-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16816277</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Inform Decis Mak. 2017 Jul 10;17(1):102</Citation><ArticleIdList><ArticleId IdType="pubmed">28693482</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Eff Res. 2015 Mar;4(2):133-45</Citation><ArticleIdList><ArticleId IdType="pubmed">25825842</ArticleId></ArticleIdList></Reference><Reference><Citation>Croat Med J. 2007 Oct;48(5):595-604</Citation><ArticleIdList><ArticleId IdType="pubmed">17948946</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2017 Dec;5(1):10</Citation><ArticleIdList><ArticleId IdType="pubmed">28188565</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 May;63(5):500-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16651507</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2016 Mar;208(3):213-22</Citation><ArticleIdList><ArticleId IdType="pubmed">26932483</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Psychiatry. 2017 Apr-Jun;39(2):88-89</Citation><ArticleIdList><ArticleId IdType="pubmed">28591270</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Expect. 2011 Dec;14(4):439-48</Citation><ArticleIdList><ArticleId IdType="pubmed">21176014</ArticleId></ArticleIdList></Reference><Reference><Citation>Adm Policy Ment Health. 2005 May-Jul;32(5-6):497-503</Citation><ArticleIdList><ArticleId IdType="pubmed">16082793</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2016 May-Jun;24(3):214-28</Citation><ArticleIdList><ArticleId IdType="pubmed">27075815</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Sep;110(1-2):16-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18456339</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Bioanal Chem. 2015 Jan;407(3):661-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25433685</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Ment Health Nurs. 2016 Feb;23(1):3-11</Citation><ArticleIdList><ArticleId IdType="pubmed">26459928</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2016 Mar 30;11(3):e0151174</Citation><ArticleIdList><ArticleId IdType="pubmed">27028297</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 2006 Feb;15(1):25-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16411028</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Expect. 2014 Jun;17(3):365-75</Citation><ArticleIdList><ArticleId IdType="pubmed">22221624</ArticleId></ArticleIdList></Reference><Reference><Citation>Res Involv Engagem. 2015 Jun 25;1:2</Citation><ArticleIdList><ArticleId IdType="pubmed">29062491</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Feb;69(2):183-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18211128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Jun;162:134-41</Citation><ArticleIdList><ArticleId IdType="pubmed">24767018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2015 Jun;2(6):564-70</Citation><ArticleIdList><ArticleId IdType="pubmed">26360452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 Dec;19(8):676-688</Citation><ArticleIdList><ArticleId IdType="pubmed">28901625</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Community Psychol. 2012 Jun;49(3-4):526-37</Citation><ArticleIdList><ArticleId IdType="pubmed">22302435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2015 Nov;2(11):1036-42</Citation><ArticleIdList><ArticleId IdType="pubmed">26404415</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2013 May 29;13:153</Citation><ArticleIdList><ArticleId IdType="pubmed">23714262</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2014 Feb;75(2):133-40</Citation><ArticleIdList><ArticleId IdType="pubmed">24345382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jul 4;374(9683):86-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19525005</ArticleId></ArticleIdList></Reference><Reference><Citation>Focus (Am Psychiatr Publ). 2014 Summer;12(3):251-266</Citation><ArticleIdList><ArticleId IdType="pubmed">26279641</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Health Res. 2017 Mar;27(4):591-608</Citation><ArticleIdList><ArticleId IdType="pubmed">27670770</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2017 Jun 1;68(6):618-620</Citation><ArticleIdList><ArticleId IdType="pubmed">28245703</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2017 Feb 1;20(2):196-205</Citation><ArticleIdList><ArticleId IdType="pubmed">27677983</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2017 Jun;135(6):515-526</Citation><ArticleIdList><ArticleId IdType="pubmed">28260229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 2014 Dec;29(12):1692-701</Citation><ArticleIdList><ArticleId IdType="pubmed">24893581</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion CNS Disord. 2014 Aug 28;16(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">25664214</ArticleId></ArticleIdList></Reference><Reference><Citation>Acad Med. 2016 Oct;91(10):1439-1461</Citation><ArticleIdList><ArticleId IdType="pubmed">27489018</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 15;174:45-50</Citation><ArticleIdList><ArticleId IdType="pubmed">25484176</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2016 Oct;77(10):e1301-e1308</Citation><ArticleIdList><ArticleId IdType="pubmed">27631140</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2014 May 30;12:90</Citation><ArticleIdList><ArticleId IdType="pubmed">24885933</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16677713</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2017 Jan;247:305-309</Citation><ArticleIdList><ArticleId IdType="pubmed">27974284</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Expect. 2010 Jun;13(2):160-73</Citation><ArticleIdList><ArticleId IdType="pubmed">20536537</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Aff (Millwood). 2013 Feb;32(2):393-400</Citation><ArticleIdList><ArticleId IdType="pubmed">23381533</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2017 Feb 1;20(2):121-179</Citation><ArticleIdList><ArticleId IdType="pubmed">27816941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">486614</PMID><DateCompleted><Year>1979</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>1979</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A longitudinal CNV study in a group of five bipolar cyclothymic patients.</ArticleTitle><Pagination><MedlinePgn>581-6</MedlinePgn></Pagination><Abstract><AbstractText>The authors carried out a longitudinal study in five subjects with bipolar cyclothymic psychosis, recording contingent negative variations in the same patients in the different phases of illness and under normal clinical conditions. An average voltage decrease was found in the depressive phases and a more conspicuous decrease in the manic phases. Furthermore, an evident postimperative negative variation was present in four subjects during the manic phase. The authors set forth tentative psychological and neurophysiological interpretation of their results.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>P A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Amabile</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Caporali</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pierelli</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Spadaro</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zanasi</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Morocutti</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003265" MajorTopicYN="Y">Contingent Negative Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="Y">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">486614</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31081991</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>11</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Is smartphone-based mood instability associated with stress, quality of life, and functioning in bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>611-620</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12796</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Mood instability in patients with bipolar disorder has been associated with impaired functioning and risk of relapse. The present study aimed to investigate whether increased mood instability is associated with increased perceived stress and impaired quality of life and functioning in patients with bipolar disorder.</AbstractText><AbstractText Label="METHODS">A total of 84 patients with bipolar disorder used a smartphone-based self-monitoring system on a daily basis for 9 months. Data on perceived stress, quality of life, and clinically rated functioning were collected at five fixed time points for each patient during follow-up. A group of 37 healthy individuals served as a control comparison of perceived stress, quality of life, and psychosocial functioning.</AbstractText><AbstractText Label="RESULTS">The majority of patients presented in full or partial remission. As hypothesized, mood instability was significantly associated with increased perceived stress (B: 10.52, 95% CI: 5.25; 15.77, P &lt; 0.0001) and decreased quality of life (B: -12.17, 95% CI. -19.54; -4.79, P &lt; 0.0001) and functioning (B: -12.04, 95% CI: -19.08; -4.99, P &lt; 0.0001) in patients with bipolar disorder. There were no differences in mood instability according to prescribed psychopharmacological treatment. Compared with healthy individuals, patients reported substantially increased perceived stress and experienced decreased quality of life and decreased functioning based on researcher-blinded evaluation.</AbstractText><AbstractText Label="CONCLUSION">Mood instability in bipolar disorder is associated with increased perceived stress and decreased quality of life and functioning even during full or partial remission. There is a need to monitor and identify subsyndromal inter-episodic symptoms. Future studies investigating the effect of treatment on mood instability are highly warranted.</AbstractText><CopyrightInformation>© 2019 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faurholt-Jepsen</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0462-6444</Identifier><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Mads</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Monsenso Aps, Valby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busk</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Ellen Margrethe</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bardram</LastName><ForeName>Jakob Eyvind</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>Maj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>Lars Vedel</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0001-9377-9436</Identifier><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2019 Nov;21(7):660-661</RefSource><PMID Version="1">31301683</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072860" MajorTopicYN="N">Ecological Momentary Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068997" MajorTopicYN="N">Smartphone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">mood instability</Keyword><Keyword MajorTopicYN="Y">smartphone</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31081991</ArticleId><ArticleId IdType="doi">10.1111/bdi.12796</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Pini S, de Queiroz V, Pagnin D, et al. Prevalence and burden of bipolar disorders in European countries. Eur Neuropsychopharmacol. 2005;15:425-434.</Citation></Reference><Reference><Citation>MacQueen GM, Marriott M, Begin H, Robb J, Joffe RT, Young LT. Subsyndromal symptoms assessed in longitudinal, prospective follow-up of a cohort of patients with bipolar disorder. Bipolar Disord. 2003;5:349-355.</Citation></Reference><Reference><Citation>Harrison PJ, Cipriani, A, Harmer, CJ, et al. Innovative approaches to bipolar disorder and its treatment. Ann. N.Y. Acad. Sci. 2016;1366:76-89.</Citation></Reference><Reference><Citation>Judd LL, Schettler, PJ, Akiskal, HS, et al. Long-term symptomatic status of bipolar I vs bipolar II disorders. Int. J. Neuropsychopharmacol. 2003;6:127-137.</Citation></Reference><Reference><Citation>Bopp JM, Miklowitz DJ, Goodwin GM, Stevens W, Rendell JM, Geddes JR. The longitudinal course of bipolar disorder as revealed through weekly text messaging: a feasibility study. Bipolar Disord. 2010;12:327-334.</Citation></Reference><Reference><Citation>Joffe RT, MacQueen GM, Marriott M, Trevor Young L. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord. 2004;6:62-66.</Citation></Reference><Reference><Citation>Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9:531-535.</Citation></Reference><Reference><Citation>Strejilevich SA, Martino DJ, Murru A, et al. Mood instability and functional recovery in bipolar disorders. Acta Psychiatr Scand. 2013;128:194-202.</Citation></Reference><Reference><Citation>Patel R, Lloyd T, Jackson R, et al. Mood instability is a common feature of mental health disorders and is associated with poor clinical outcomes. BMJ Open. 2015;5:e007504.</Citation></Reference><Reference><Citation>Gershon A, Eidelman P. Affective intensity and instability: predictors of depression and functional impairment in bipolar disorder. J Behav Ther Exp Psychiatry. 2015;46:14-18.</Citation></Reference><Reference><Citation>O'Donnell LA, Ellis AJ, Van de Loo MM, et al. Mood instability as a predictor of clinical and functional outcomes in adolescents with bipolar I and bipolar II disorder. J Affect Disord. 2018;236:199-206.</Citation></Reference><Reference><Citation>Bonsall MB, Wallace-Hadrill S, Geddes JR, Goodwin GM, Holmes EA. Nonlinear time-series approaches in characterizing mood stability and mood instability in bipolar disorder. Proc Biol Sci. 2012;279:916-924.</Citation></Reference><Reference><Citation>Saunders K, Cipriani A, Rendell J, et al. Oxford Lithium Trial (OxLith) of the early affective, cognitive, neural and biochemical effects of lithium carbonate in bipolar disorder: study protocol for a randomised controlled trial. Trials. 2016;17:116.</Citation></Reference><Reference><Citation>Broome MR, Saunders K, Harrison PJ, Marwaha S. Mood instability: significance, definition and measurement. Br J Psyc. 2015;207:283-285.</Citation></Reference><Reference><Citation>FierceWireless. Report: Global smartphone penetration to jump 25% in 2014, led by Asia-Pacific. FierceWireless (2011). http://www.fiercewireless.com/story/report-global-smartphone-penetration-jump-25-2014-led-asia-pacific/2014-06-11. (Accessed: 23rd June 2016).</Citation></Reference><Reference><Citation>Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1-32.</Citation></Reference><Reference><Citation>Ebner-Priemer UW, Trull TJ. Ecological momentary assessment of mood disorders and mood dysregulation. Psychol Assess. 2009;21:463-475.</Citation></Reference><Reference><Citation>Faurholt-Jepsen M, Vinberg M, Frost M, Christensen EM, Bardram J, Kessing LV. Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones-the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial. BMC Psychiatry. 2014;14:309.</Citation></Reference><Reference><Citation>Kessing, LV, Hansen, HV, Hvenegaard, A, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013;202:212-219.</Citation></Reference><Reference><Citation>Wing JK, Babor, T, Brugha, TS, et al. Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry. 1990;47:589-593.</Citation></Reference><Reference><Citation>Faurholt-Jepsen M, Frost M, Christensen EM, Bardram JE, Vinberg M, Kessing LV. The effect of smartphone-based monitoring on illness activity in bipolar disorder- The MONARCA II randomized controlled single-blinded trial. Psychol Med. 2019.https://doi.org/10.1017/S0033291719000710</Citation></Reference><Reference><Citation>Kessing LV, Munkholm K, Faurholt-Jepsen M, et al. The bipolar illness onset study: research protocol for the BIO cohort study. BMJ Open. 2017;7:e015462.</Citation></Reference><Reference><Citation>Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.</Citation></Reference><Reference><Citation>Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.</Citation></Reference><Reference><Citation>Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385-396.</Citation></Reference><Reference><Citation>WHO. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28:551-558.</Citation></Reference><Reference><Citation>Rosa AR, Sánchez-Moreno J, Martínez-Aran A, et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.</Citation></Reference><Reference><Citation>Faurholt-Jepsen M, Ritz C, Frost M, et al. Mood instability in bipolar disorder type I versus type II-continuous daily electronic self-monitoring of illness activity using smartphones. J Affect Disord. 2015;186:342-349.</Citation></Reference><Reference><Citation>Bonnín CM, Martínez-Arán A, Reinares M, et al. Thresholds for severity, remission and recovery using the functioning assessment short test (FAST) in bipolar disorder. J Affect Disord. 2018;240:57-62.</Citation></Reference><Reference><Citation>Rote J, Dingelstadt A-M-L, Aigner A, et al. Impulsivity predicts illness severity in long-term course of bipolar disorder: a prospective approach. Aust N Z J Psychiatry. 2018;52:876-886.</Citation></Reference><Reference><Citation>Rosa AR, González-Ortega I, González-Pinto A, et al. One-year psychosocial functioning in patients in the early vs late stage of bipolar disorder. Acta Psychiatr Scand. 2012;125:335-341.</Citation></Reference><Reference><Citation>Rosa AR, Reinares M, Michalak EE, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health. 2010;13:984-988.</Citation></Reference><Reference><Citation>McKnight RF, Bilderbeck AC, Miklowitz DJ, Hinds C, Goodwin GM, Geddes JR. Longitudinal mood monitoring in bipolar disorder: course of illness as revealed through a short messaging service. J Affect Disord. 2017;223:139-145.</Citation></Reference><Reference><Citation>Conner TS, Barrett LF. Trends in ambulatory self-report: the role of momentary experience in psychosomatic medicine. Psychosom Med. 2012;74:327-337.</Citation></Reference><Reference><Citation>Faurholt-Jepsen M, Munkholm K, Frost M, Bardram JE, Kessing LV. Electronic self-monitoring of mood using IT platforms in adult patients with bipolar disorder: a systematic review of the validity and evidence. BMC Psychiatry. 2016;16:7.</Citation></Reference><Reference><Citation>Bardram J, Frost M, Szanto K, Margu G. The MONARCA self-assessment system: a persuasive personal monitoring system for bipolar patients. in Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium (IHI ’12). ACM, New York, NY, USA, 21-30. 2012, 21-30 (2012)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32275224</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><PubDate><Year>2020</Year><Month>06</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A commentary on "Risk of bipolar disorder in patients with polycystic ovary syndrome".</ArticleTitle><Pagination><MedlinePgn>83-84</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(20)30711-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2020.03.043</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Luís Afonso</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Hospital Prof. Doutor Fernando Fonseca, E.P.E., IC 19 Venteira, 2720-276 Amadora, Portugal. Electronic address: luis.fernandes@hff.min-saude.pt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borja Santos</LastName><ForeName>Nuno</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Hospital Prof. Doutor Fernando Fonseca, E.P.E., IC 19 Venteira, 2720-276 Amadora, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Affect Disord. 2020 Feb 15;263:458-462</RefSource><PMID Version="1">31969278</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Affect Disord. 2020 Jul 1;272:15-16</RefSource><PMID Version="1">32379607</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011085" MajorTopicYN="Y">Polycystic Ovary Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Affective disorders</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Polycystic ovary syndrome</Keyword><Keyword MajorTopicYN="Y">Population studies</Keyword></KeywordList><CoiStatement>Declaration of Competing interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32275224</ArticleId><ArticleId IdType="pii">S0165-0327(20)30711-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2020.03.043</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7234481</PMID><DateCompleted><Year>1981</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>3</Issue><PubDate><Year>1981</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Manic-depressive states and daily temperature. Some circadian studies.</ArticleTitle><Pagination><MedlinePgn>277-89</MedlinePgn></Pagination><Abstract><AbstractText>Proceeding from the hypothesis of disturbed circadian rhythms in endogenous depression, we observed the oral temperature of four patients in a long-term study. The results showed the following: 1) Depression is linked to higher mean daily temperatures compared with normal states. In manic states, the mean daily temperature is even higher than in depressive states. Sleep deprivation as effective treatment causes a decrease in mean daily temperature. 2) The daily temperature maximum changes its position in depressive states. This is interpreted as indicating a disturbed circadian system. 3) A period shorter or longer than 24 h cannot be observed in depressive states.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pflug</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Johnsson</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ekse</LastName><ForeName>A T</ForeName><Initials>AT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001831" MajorTopicYN="Y">Body Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7234481</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1981.tb00675.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10459403</PMID><DateCompleted><Year>1999</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>4</Issue><PubDate><Year>1999</Year><Month>Aug</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Declarative and procedural memory in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>525-31</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Memory function is an important but under researched area for neuropsychological investigation in persons with bipolar disorder. Previous studies have reported cognitive deficits on tasks of declarative memory in bipolar patients in the euthymic state.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study extended these findings by investigating declarative as well as procedural learning and memory in bipolar patients (with and without alcohol abuse) who were examined in the euthymic state. The California Verbal Learning Test, Star Mirror Tracing Task, Pursuit Rotor Task, American National Adult Reading Test, and the Vocabulary Subtest of the WAIS-R, were administered to bipolar patients and control subjects by researchers who were blind to the subject's group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar patients performed worse than control subjects on a measure of declarative memory (California Verbal Learning Test) but did not differ from the performance of control subjects on either of the two procedural learning tasks (Pursuit Rotor Task and Star Mirror Task).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results suggest disturbed function of temporal lobe, but not basal ganglia, structures in persons with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Gorp</LastName><ForeName>W G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Cornell University Medical College, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Theberge</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Mintz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="Y">Verbal Learning</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>8</Month><Day>25</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>8</Month><Day>25</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10459403</ArticleId><ArticleId IdType="pii">S0006-3223(98)00336-9</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(98)00336-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15208769</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>[Magnetic resonance spectroscopy (MRS) applications in bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>138-47</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Magnetic resonance spectroscopy (MRS) is a noninvasive in vivo imaging technique that can directly assess the living biochemistry in localized brain regions without involving ionizing radiation. This review provides a brief description of spectroscopy, followed by a literature review of the key spectroscopy findings in bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We conducted a Medline literature review for the period 1966-2003, and included all the controlled studies using MRS in bipolar disorder, as well as other relevant papers with important findings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Studies showed an increase in choline (Cho) levels in basal ganglia and cingulate, and a decrease in dorsolateral prefrontal cortical (DLPFC) and hippocampal N-acetyl aspartate (NAA) levels. Frontal lobe phosphomonoester (PME) levels were decreased in the euthymic state and were higher in the manic and depressive states. Myoinositol (mI) was reduced by lithium treatment and this decrease was positively correlated with treatment response.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings from MRS studies of bipolar disorder demonstrate alterations in the neurochemistry of key brain regions participating in the fronto-limbic-subcortical circuits implicated in the pathophysiology of the disorder. These findings suggest abnormalities of the membrane phospholipid metabolism, cellular energy metabolism and myelin formation /maintenance in the DLPFC, cingulate, hippocampus and basal ganglia in bipolar disorder. Further studies are needed to distinguish between the changes that are due to the pathophysiology of bipolar disorder and those due to the effects of medications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Monkul</LastName><ForeName>E Serap</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Araş. Gör., Psikiyatri Bölümü, Izmir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yildiz</LastName><ForeName>Ayşegül</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>C  Soares</LastName><ForeName>Jair</ForeName><Initials>J</Initials></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Bipolar Bozuklukta Manyetik Rezonans Spektroskopi (MRS) Uygulamalari.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009448" MajorTopicYN="N">Neurochemistry</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>59</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>6</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15208769</ArticleId><ArticleId IdType="pii">468</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16179814</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>5</Issue><PubDate><MedlineDate>2005 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Psychopathologic correlates of suicidal ideation in major depressive outpatients: is it all due to unrecognized (bipolar) depressive mixed states?</ArticleTitle><Pagination><MedlinePgn>273-80</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent transatlantic concern about suicidality in patients receiving antidepressants prompted us to examine the psychopathologic correlates of suicidal ideation occurring in clinically depressed patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study sample, which consisted of 644 consecutive major depressive outpatients, of which 58.0% had bipolar II disorder (BP-II), was systematically interviewed with the SCID, in order to delineate the diagnostic and psychopathologic correlates of suicidal ideation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Such ideation, which was present in 49.5% [and favoring BP-II vs. major depressive disorder (MDD)] at an odds ratio (OR) of 1.3 (95% confidence interval = 0.98-1.8), was clinically significantly associated with depressive mixed state (racing/crowded thoughts and psychomotor agitation/activation during index depression), mood lability, decreased self-esteem, anorexia, as well as melancholic and psychotic features. Multiple logistic regression of suicidal ideation versus depressive symptoms and intradepressive excitatory symptoms revealed that decreased self-esteem (OR = 3.3), racing/crowded thoughts (OR = 1.5), and psychomotor agitation/activation (OR = 1.4) were independent and clinically significant correlates of suicidal ideation, irrespective of depression severity.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">From a psychopathologic standpoint, suicidality might be conferred by a combination of both the excited (mixed) depressive and agitated (melancholic) clusters. Trait mood lability appears to favor the genesis of these affective clusters. Within the framework of Kraepelinian psychiatry, both clusters represent depressive mixed states. Given that such states are more prevalent in BP-II, our data provide a possible explanation for the greater suicidality in BP-II patients reported in the literature. In light of the higher odds of suicidal ideation in BP-II versus MDD patients, we hypothesize that the higher prevalence of mental and psychomotor activation in BP-II might be one factor among others that favors the greater likelihood of the transition from suicidal ideation to suicidal action in BP-II. Our analyses delineate a mixed depressive substrate at risk for suicidality. To what extent, if any, antidepressant monotherapy might contribute to the genesis of such states and/or suicidality cannot be answered with the methodology of the present study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>International Mood Center, University of California at San Diego, Calif. 92161, USA. hakiskal@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>01</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16179814</ArticleId><ArticleId IdType="pii">88445</ArticleId><ArticleId IdType="doi">10.1159/000088445</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26415581</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Response inhibition and interference control in patients with bipolar I disorder and first-degree relatives.</ArticleTitle><Pagination><MedlinePgn>781-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12335</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The current study aimed to assess both response inhibition (RI) and interference control (IC) in euthymic patients with bipolar disorder (BD-Ps) as well as asymptomatic first-degree relatives (BD-Rs) and healthy controls (HCs) in order to evaluate trait-as opposed to illness-associated features of these components.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">BD-Ps (n = 35) who had been in the euthymic state for at least six months, BD-Rs (n = 30), and HCs (n = 33) completed a Stop-Signal Task (SST) and Stroop Task to assess RI and IC, respectively. Groups were compared on the stop-signal reaction time (SSRT), stop-signal delay (SSD), mean reaction time on go trials (go-RT), Stroop interference score (S-interference), and number of errors on the color-word-naming trial (S-error). Associations between the patient's clinical features and RI and IC, between the patient's treatment and RI and IC, and between RI and IC in each group were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BD-Ps and BD-Rs had significantly shorter go-RT and SSD, and longer SSRT compared to HCs, with these scores being similar between the BD-Ps and BD-Rs. Also, both BD-Ps and BD-Rs made significantly more S-errors than HCs, whereas, the S-interference score was not significantly different between groups. There were no significant correlations between Stroop Task and SST scores within each group, nor between clinical features or treatment variables and RI and IC in BD-Ps.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, impairment in RI and IC (only on S-error score) was present in both patients and relatives. The persistence of these deficits in the absence of mood symptoms suggests that these features may represent candidate endophenotypes for bipolar disorder.</AbstractText><CopyrightInformation>© 2015 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hıdıroğlu</LastName><ForeName>Ceren</ForeName><Initials>C</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5754-6042</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, Faculty of Arts, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Ivan J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Er</LastName><ForeName>Ayşe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Işık</LastName><ForeName>Gizem</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yalın</LastName><ForeName>Nefize</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>Lakshmi N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceylan</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Özerdem</LastName><ForeName>Ayşegül</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="N">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="Y">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057190" MajorTopicYN="N">Stroop Test</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">endophenotype</Keyword><Keyword MajorTopicYN="N">first-degree relatives</Keyword><Keyword MajorTopicYN="N">interference control</Keyword><Keyword MajorTopicYN="N">response inhibition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>08</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26415581</ArticleId><ArticleId IdType="doi">10.1111/bdi.12335</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18635719</PMID><DateCompleted><Year>2008</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2008</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0269-8811</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of psychopharmacology (Oxford, England)</Title><ISOAbbreviation>J Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Overcoming the current approach in bipolar disorder research: towards DSM-V and beyond.</ArticleTitle><Pagination><MedlinePgn>406-7; discussion 408</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0269881108089592</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain. evieta@clinic.ub.es</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychopharmacol</MedlineTA><NlmUniqueID>8907828</NlmUniqueID><ISSNLinking>0269-8811</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Psychopharmacol. 2008 Jun;22(4):397-400</RefSource><PMID Version="1">18635715</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18635719</ArticleId><ArticleId IdType="pii">22/4/406</ArticleId><ArticleId IdType="doi">10.1177/0269881108089592</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21668080</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1939-1846</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of abnormal psychology</Title><ISOAbbreviation>J Abnorm Psychol</ISOAbbreviation></Journal><ArticleTitle>Progression along the bipolar spectrum: a longitudinal study of predictors of conversion from bipolar spectrum conditions to bipolar I and II disorders.</ArticleTitle><Pagination><MedlinePgn>16-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1037/a0023973</ELocationID><Abstract><AbstractText>Little longitudinal research has examined progression to more severe bipolar disorders in individuals with "soft" bipolar spectrum conditions. We examine rates and predictors of progression to bipolar I and II diagnoses in a nonpatient sample of college-age participants (n = 201) with high General Behavior Inventory scores and childhood or adolescent onset of "soft" bipolar spectrum disorders followed longitudinally for 4.5 years from the Longitudinal Investigation of Bipolar Spectrum (LIBS) project. Of 57 individuals with initial cyclothymia or bipolar disorder not otherwise specified (BiNOS) diagnoses, 42.1% progressed to a bipolar II diagnosis and 10.5% progressed to a bipolar I diagnosis. Of 144 individuals with initial bipolar II diagnoses, 17.4% progressed to a bipolar I diagnosis. Consistent with hypotheses derived from the clinical literature and the Behavioral Approach System (BAS) model of bipolar disorder, and controlling for relevant variables (length of follow-up, initial depressive and hypomanic symptoms, treatment-seeking, and family history), high BAS sensitivity (especially BAS Fun Seeking) predicted a greater likelihood of progression to bipolar II disorder, whereas early age of onset and high impulsivity predicted a greater likelihood of progression to bipolar I (high BAS sensitivity and Fun-Seeking also predicted progression to bipolar I when family history was not controlled). The interaction of high BAS and high Behavioral Inhibition System (BIS) sensitivities also predicted greater likelihood of progression to bipolar I. We discuss implications of the findings for the bipolar spectrum concept, the BAS model of bipolar disorder, and early intervention efforts.</AbstractText><CopyrightInformation>PsycINFO Database Record (c) 2012 APA, all rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alloy</LastName><ForeName>Lauren B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Psychology, Temple University, Philadelphia, PA 19122, USA. lalloy@temple.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urošević</LastName><ForeName>Snežana</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Abramson</LastName><ForeName>Lyn Y</ForeName><Initials>LY</Initials></Author><Author ValidYN="Y"><LastName>Jager-Hyman</LastName><ForeName>Shari</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nusslock</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Whitehouse</LastName><ForeName>Wayne G</ForeName><Initials>WG</Initials></Author><Author ValidYN="Y"><LastName>Hogan</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH052617</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R10 MH052662</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH052662-06A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52617</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH77908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH077908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH52662</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH052662</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH052617-07</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R10 MH052617</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH077908-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH077908-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Abnorm Psychol</MedlineTA><NlmUniqueID>0034461</NlmUniqueID><ISSNLinking>0021-843X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21668080</ArticleId><ArticleId IdType="pii">2011-11840-001</ArticleId><ArticleId IdType="doi">10.1037/a0023973</ArticleId><ArticleId IdType="pmc">PMC3192298</ArticleId><ArticleId IdType="mid">NIHMS303445</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1981 Oct;90(5):381-437</Citation><ArticleIdList><ArticleId IdType="pubmed">7298991</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jul;166(7):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">19448190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2009 Sep;97(3):549-65</Citation><ArticleIdList><ArticleId IdType="pubmed">19686007</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2007 Feb;116(1):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17324021</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 May;36(5):619-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16438739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Apr;79(1-3):193-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15023494</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 May;109(2):222-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10895560</ArticleId></ArticleIdList></Reference><Reference><Citation>Minerva Pediatr. 2008 Feb;60(1):41-50</Citation><ArticleIdList><ArticleId IdType="pubmed">18277364</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):49-57</Citation><ArticleIdList><ArticleId IdType="pubmed">12507737</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol (New York). 2009 Jun 1;16(2):206-226</Citation><ArticleIdList><ArticleId IdType="pubmed">20161008</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2004 Jun;38(6):433-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15209835</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):310-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18271911</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2009 Aug;118(3):459-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19685944</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Sep;162(9):1680-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16135628</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Mar;30(2):467-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10824667</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1997 Feb;106(1):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9103728</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 May;160(5):999-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">12727708</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2008 Oct;28(7):1188-205</Citation><ArticleIdList><ArticleId IdType="pubmed">18565633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2008 Feb;117(1):164-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18266494</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1984 Nov;172(11):681-91</Citation><ArticleIdList><ArticleId IdType="pubmed">6491653</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Oct;34(10):1229-35</Citation><ArticleIdList><ArticleId IdType="pubmed">911222</ArticleId></ArticleIdList></Reference><Reference><Citation>Addict Behav. 2004 Sep;29(7):1389-405</Citation><ArticleIdList><ArticleId IdType="pubmed">15345272</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):637-49</Citation><ArticleIdList><ArticleId IdType="pubmed">19689506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Mar;85(1-2):181-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15780688</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2008 May;117(2):268-277</Citation><ArticleIdList><ArticleId IdType="pubmed">18489203</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 1989;40:457-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2648983</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 May;58(5):510-2</Citation><ArticleIdList><ArticleId IdType="pubmed">11343533</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1977 Nov;134(11):1227-33</Citation><ArticleIdList><ArticleId IdType="pubmed">910973</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Apr 1;63(7):693-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17919457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 2001 Sep 1;23(3):133-143</Citation><ArticleIdList><ArticleId IdType="pubmed">21765592</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 2):281-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11249806</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):204-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15117399</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Mar;152(3):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7864264</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 May;9(3):206-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17430294</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 Nov;109(4):721-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11195996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 1999 Dec 1;21(4):275-292</Citation><ArticleIdList><ArticleId IdType="pubmed">21765591</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Mar;2(1):3-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11254017</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Nov;103(1-3):181-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17324469</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2002 Nov;111(4):589-97</Citation><ArticleIdList><ArticleId IdType="pubmed">12428772</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):724-31</Citation><ArticleIdList><ArticleId IdType="pubmed">7608045</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jul;35(7):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">678037</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1989 May;98(2):117-26</Citation><ArticleIdList><ArticleId IdType="pubmed">2708652</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2003;(418):47-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12956814</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Sep 15;52(6):457-77</Citation><ArticleIdList><ArticleId IdType="pubmed">12361664</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Dir Psychol Sci. 2010 Jun 1;19(3):189-194</Citation><ArticleIdList><ArticleId IdType="pubmed">20606725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20591494</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><Issue>1-3</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Obsessive-compulsive disorder and cyclothymic temperament: an exploration of clinical features.</ArticleTitle><Pagination><MedlinePgn>295-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2010.06.007</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder comorbidity in obsessive-compulsive disorder (OCD) has relevant implications on the symptomatological expression, complications and pharmacologic treatment of the disorder. Relatively few data exist on OCD comorbid with soft-bipolar forms. The aims of the study are to evaluate affective temperaments in patients with OCD and to analyze differences in socio-demographic and clinical characteristics according to the presence or absence of cyclothymic temperament.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The sample consisted of 167 patients with a principal diagnosis of OCD (DSM-IV-TR). Affective temperaments have been evaluated through the Italian semistructured interview version of the Temperament Evaluation of Memphis, Pisa, Paris and San Diego (TEMPS-I).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 90 patients (53.9%) were diagnosed with a dominant affective temperament. Cyclothymic affective temperament (CT) was the most represented in the sample of OCD patients (19.2%). Patients with CT showed significant lower mean age at onset, higher scores at the HAM-A, more repeating compulsions, higher rates of eating disorder comorbidity, OCD spectrum disorder comorbidity and higher rates of Axis II comorbidity (particularly Cluster A).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Recruitment of OCD patients from a tertiary center. Absence of an investigation about treatment implications associated with cyclothymic temperament.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with OCD and CT could be more severe and complicated compared to patients without CT. Moreover, individuals with OCD spectrum disorders may be vulnerable to bipolarity. Systematic assessment of affective temperament is necessary to detect OCD with such a soft-bipolar comorbidity.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Ambrosio</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Mood and Anxiety Disorders Unit, Department of Neuroscience, University of Turin, Via Cherasco 11, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert</LastName><ForeName>Umberto</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Bogetto</LastName><ForeName>Filippo</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Maina</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20591494</ArticleId><ArticleId IdType="pii">S0165-0327(10)00420-9</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2010.06.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1991943</PMID><DateCompleted><Year>1991</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-8614</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>2</Issue><PubDate><Year>1991</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Comorbid psychiatric disorders in elderly medical patients: a 1-year prospective study.</ArticleTitle><Pagination><MedlinePgn>124-31</MedlinePgn></Pagination><Abstract><AbstractText>Cross-sectional studies have revealed a high prevalence of comorbid psychological problems among geriatric medical patients, a low rate of detection by primary care professionals, and greater psychosocial dysfunction and poorer physical health associated with comorbidity. Less is known about the course and impact of psychiatric comorbidity. Psychiatric status, physical health status, psychosocial functioning, and health care utilization for a sample of geriatric patients (n = 102) were assessed on admission to a medical hospital and again one year later. Results revealed a very stable and high prevalence of comorbid psychological problems, especially depression, a low rate of treatment by mental health professionals, greater physical impairment consistently associated with psychiatric comorbidity, but few health care utilization differences. A closer look at depression revealed that it typically began in late life and did not readily resolve.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rapp</LastName><ForeName>S R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Medicine, Bowman-Gray School of Medicine, Winston-Salem, North Carolina 27103.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003258" MajorTopicYN="N">Consumer Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006299" MajorTopicYN="N">Health Services for the Aged</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011610" MajorTopicYN="N">Psychosocial Deprivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1991943</ArticleId><ArticleId IdType="doi">10.1111/j.1532-5415.1991.tb01613.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15460356</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2941</ISSN><JournalIssue CitedMedium="Print"><Volume>95</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychological reports</Title><ISOAbbreviation>Psychol Rep</ISOAbbreviation></Journal><ArticleTitle>Sustained attention and visual processing speed in children and adolescents with bipolar disorder and other psychiatric disorders.</ArticleTitle><Pagination><MedlinePgn>39-47</MedlinePgn></Pagination><Abstract><AbstractText>To investigate the cognitive functioning of children and adolescents with bipolar illness, 112 child and adolescent psychiatric inpatients and day-hospital patients at a state psychiatric hospital were administered the Wechsler Intelligence Scale for Children-III (WISC-III) as part of an admission psychological assessment. There were 22 patients with Bipolar Disorder and 90 with other psychiatric disorders; all were between 8 and 17 years of age. The patients with Bipolar Disorder had a mean age of 14 yr., a mean Verbal IQ of 78, a mean Performance IQ of 76, and a mean Full Scale IQ of 75. When their WISC-III scores were compared with those who had Schizophrenia Spectrum disorders (Schizophrenia and Schizoaffective Disorder), Psychosis Not Otherwise Specified, Attention Deficit Hyperactivity Disorder, and Conduct Disorder and Oppositional Defiant Disorder, there were no significant between-group mean differences for Verbal IQ, but patients with Bipolar Disorder had a significantly lower mean Performance IQ than those with ADHD and those with Conduct Disorder and Oppositional Defiant Disorder. Contrary to the expectation that the patients with Bipolar Disorder might have better sustained attention (higher Digit Span scores) than those with Schizophrenia Spectrum disorders and worse visual processing speed (lower Coding scores) than the other diagnostic groups, the bipolar patients' Digit Span and Coding scores did not differ significantly from those of the other groups. The patients with Psychosis, Not Otherwise Specified had significantly lower mean Performance IQ, Full Scale IQ, and Coding than the ADHD and the Conduct Disorder and Oppositional Disorder groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Queens Children's Psychiatric Center, Bellerose, NY 11426, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrese</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>McGlashan</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rappaport</LastName><ForeName>Brad</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kraseski</LastName><ForeName>Keith</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Conway</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Mule</LastName><ForeName>Carmelina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychol Rep</MedlineTA><NlmUniqueID>0376475</NlmUniqueID><ISSNLinking>0033-2941</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="Y">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003631" MajorTopicYN="N">Day Care, Medical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010364" MajorTopicYN="Y">Pattern Recognition, Visual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="Y">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>10</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15460356</ArticleId><ArticleId IdType="doi">10.2466/pr0.95.1.39-47</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24895741</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Secondary mania in a patient with solitary red nucleus lesion.</ArticleTitle><Pagination><MedlinePgn>243</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Young Min</ForeName><Initials>YM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020520" MajorTopicYN="N">Brain Infarction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012012" MajorTopicYN="N">Red Nucleus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24895741</ArticleId><ArticleId IdType="doi">10.1111/pcn.12113</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21271823</PMID><DateCompleted><Year>2011</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1360-0567</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of mental health (Abingdon, England)</Title><ISOAbbreviation>J Ment Health</ISOAbbreviation></Journal><ArticleTitle>Developing an online psychoeducation package for bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>21-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/09638237.2010.525565</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Medications are known to be effective for bipolar disorder but treatment non-adherence and psychosocial effects can impact adversely on long-term outcome. Psychoeducation may help address some of these issues.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">This article describes the development of a novel online psychoeducation programme ( www.BeatingBipolar.org ) for patients with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The programme was developed in three stages--a literature review, development of a draft outline of the programme and focus groups with mental health professionals and service users.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data highlighted the importance of presenting a supportive style of programme, realistic stories and positive role models within the programme and providing a variety of information delivery styles. Desired outcomes of the programme were an increased sense of control over bipolar disorder, reduced stigma and improved understanding for family and carers.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The iterative development process using focus groups with service users and mental health professionals provided important insights into users' needs and preferences as well as identifying valued outcomes. Interactive online psychoeducation materials benefit from a systematic design process which is informed by a range of viewpoints.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine and Neurology, Cardiff University, Heath Park, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Griffiths</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hood</LastName><ForeName>Kerry</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Craddock</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Ment Health</MedlineTA><NlmUniqueID>9212352</NlmUniqueID><ISSNLinking>0963-8237</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017144" MajorTopicYN="N">Focus Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007206" MajorTopicYN="N">Individuality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009862" MajorTopicYN="N">Online Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="Y">Patient Education as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016730" MajorTopicYN="N">Program Development</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013240" MajorTopicYN="N">Stereotyping</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21271823</ArticleId><ArticleId IdType="doi">10.3109/09638237.2010.525565</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22775344</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-0600</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Cognition &amp; emotion</Title><ISOAbbreviation>Cogn Emot</ISOAbbreviation></Journal><ArticleTitle>Emotion regulation characteristics and cognitive vulnerabilities interact to predict depressive symptoms in individuals at risk for bipolar disorder: a prospective behavioural high-risk study.</ArticleTitle><Pagination><MedlinePgn>63-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/02699931.2012.689758</ELocationID><Abstract><AbstractText>Recent work has identified behavioural approach system (BAS) sensitivity as a risk factor for the first onset and recurrence of mood episodes in bipolar disorder, but little work has evaluated risk factors for depression in individuals at risk for, but without a history of, bipolar disorder. The present study evaluated cognitive styles and the emotion-regulatory characteristics of emotional clarity and ruminative brooding as prospective predictors of depressive symptoms in individuals with high versus moderate BAS sensitivity. Three separate regressions indicated that the associations between dysfunctional attitudes, self-criticism, and neediness with prospective increases in depressive symptoms were moderated by emotional clarity and brooding. Whereas brooding interacted with these cognitive styles to exacerbate their impact on depressive symptoms, emotional clarity buffered against their negative impact. These interactions were specific to high-BAS individuals for dysfunctional attitudes, but were found across the full sample for self-criticism and neediness. These results indicate that emotion-regulatory characteristics and cognitive styles may work in conjunction to confer risk for and resilience against depression, and that some of these relationships may be specific to individuals at risk for bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stange</LastName><ForeName>Jonathan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Psychology, Temple University, 1701 N. 13th Street, Philadelphia, PA 19122, USA. jstange@temple.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccia</LastName><ForeName>Angelo S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Shapero</LastName><ForeName>Benjamin G</ForeName><Initials>BG</Initials></Author><Author ValidYN="Y"><LastName>Molz</LastName><ForeName>Ashleigh R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Flynn</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Matt</LastName><ForeName>Lindsey M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Abramson</LastName><ForeName>Lyn Y</ForeName><Initials>LY</Initials></Author><Author ValidYN="Y"><LastName>Alloy</LastName><ForeName>Lauren B</ForeName><Initials>LB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH077908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 77908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cogn Emot</MedlineTA><NlmUniqueID>8710375</NlmUniqueID><ISSNLinking>0269-9931</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001290" MajorTopicYN="N">Attitude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015143" MajorTopicYN="N" Type="Geographic">Philadelphia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012647" MajorTopicYN="N">Self-Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22775344</ArticleId><ArticleId IdType="doi">10.1080/02699931.2012.689758</ArticleId><ArticleId IdType="pmc">PMC3470770</ArticleId><ArticleId IdType="mid">NIHMS378114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Clin Psychol. 1998 Nov;37(4):409-14</Citation><ArticleIdList><ArticleId IdType="pubmed">9856294</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2005 Jun;35(6):855-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15997605</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychol. 2010 Summer;123(2):181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20518434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1993 Feb;102(1):20-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8436695</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Assess. 1995 Apr;64(2):319-39</Citation><ArticleIdList><ArticleId IdType="pubmed">7722857</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 1989;40:457-92</Citation><ArticleIdList><ArticleId IdType="pubmed">2648983</ArticleId></ArticleIdList></Reference><Reference><Citation>Emotion. 2007 Aug;7(3):555-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17683212</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Emot. 2011 Dec;25(8):1349-57</Citation><ArticleIdList><ArticleId IdType="pubmed">21432645</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Apr;68(2-3):167-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12063145</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Jun;47(6):511-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2350203</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Dir Psychol Sci. 2009 Jan 1;18(1):32-36</Citation><ArticleIdList><ArticleId IdType="pubmed">20539833</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Aug;8(4):382-99</Citation><ArticleIdList><ArticleId IdType="pubmed">16879139</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1997 May;106(2):221-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9131842</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1984 Feb;93(1):19-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6699270</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2011 Jul;67(7):673-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21425259</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol (New York). 2009 Jun 1;16(2):206-226</Citation><ArticleIdList><ArticleId IdType="pubmed">20161008</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 2008 Mar;134(2):163-206</Citation><ArticleIdList><ArticleId IdType="pubmed">18298268</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognit Ther Res. 2013 Feb;37(1):139-149</Citation><ArticleIdList><ArticleId IdType="pubmed">23459574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):310-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18271911</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2009 Aug;118(3):459-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19685944</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1991 Nov;100(4):569-82</Citation><ArticleIdList><ArticleId IdType="pubmed">1757671</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Sep;27(5):1079-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9300513</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1986 Aug;95(3):214-22</Citation><ArticleIdList><ArticleId IdType="pubmed">3745642</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Mar;30(2):467-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10824667</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1986 Nov;21(13):1340-3</Citation><ArticleIdList><ArticleId IdType="pubmed">3756280</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2012 Feb;121(1):16-27</Citation><ArticleIdList><ArticleId IdType="pubmed">21668080</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2008 Oct;28(7):1188-205</Citation><ArticleIdList><ArticleId IdType="pubmed">18565633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1997 Feb;106(1):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9103728</ArticleId></ArticleIdList></Reference><Reference><Citation>Emotion. 2001 Mar;1(1):25-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12894809</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Psychol. 2002 Sep;41(Pt 3):309-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12396257</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Feb;194(2):146-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19182176</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 1990 Mar;58(3):519-27</Citation><ArticleIdList><ArticleId IdType="pubmed">2324941</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Sep;163(9):1561-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16946181</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2009 Sep;65(9):891-905</Citation><ArticleIdList><ArticleId IdType="pubmed">19455611</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):436-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11018216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2008 Nov;95(5):1202-16</Citation><ArticleIdList><ArticleId IdType="pubmed">18954202</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Jun;100(1-3):249-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17134763</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Assess. 1990 Fall;55(1-2):65-72</Citation><ArticleIdList><ArticleId IdType="pubmed">2231260</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognit Ther Res. 2008 Oct 1;32(5):702-713</Citation><ArticleIdList><ArticleId IdType="pubmed">20360996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2012 May;121(2):339-351</Citation><ArticleIdList><ArticleId IdType="pubmed">22004113</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2011 Nov;120(4):956-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21553935</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Psychol. 2005 Mar;44(Pt 1):99-112</Citation><ArticleIdList><ArticleId IdType="pubmed">15826347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1999 Feb;108(1):3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">10066988</ArticleId></ArticleIdList></Reference><Reference><Citation>J Appl Dev Psychol. 2010 Jul;31(4):291-297</Citation><ArticleIdList><ArticleId IdType="pubmed">22021945</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 Aug;109(3):403-18</Citation><ArticleIdList><ArticleId IdType="pubmed">11016110</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Feb;63(2):120-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11874212</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1996 Jul 24-31;276(4):293-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8656541</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Addict Behav. 2004 Sep;18(3):275-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Ther. 2008 Sep;46(9):1096-100</Citation><ArticleIdList><ArticleId IdType="pubmed">18684436</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2005 Feb;25(2):241-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15642648</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1995 Nov;118(3):358-78</Citation><ArticleIdList><ArticleId IdType="pubmed">7501741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Child Psychol. 2004 Aug;32(4):435-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15305548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 1998 Apr;74(4):1024-40</Citation><ArticleIdList><ArticleId IdType="pubmed">9569657</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychophysiology. 1988 Jul;25(4):373-91</Citation><ArticleIdList><ArticleId IdType="pubmed">3051073</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Nov 15;42(10):948-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9359982</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2006 Feb;115(1):145-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16492105</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jun;35(6):773-82</Citation><ArticleIdList><ArticleId IdType="pubmed">655775</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cogn Ther. 2009 Dec 1;2(4):354</Citation><ArticleIdList><ArticleId IdType="pubmed">20161631</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1976 Aug;85(4):383-9</Citation><ArticleIdList><ArticleId IdType="pubmed">956505</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Dir Psychol Sci. 2010 Jun 1;19(3):189-194</Citation><ArticleIdList><ArticleId IdType="pubmed">20606725</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19543566</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2009</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>84</Issue><PubDate><MedlineDate>2009 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[Revision of systematic treatment enhancement program for bipolar disorder (STEP-BD)].</ArticleTitle><Pagination><MedlinePgn>144-55</MedlinePgn></Pagination><Abstract><AbstractText>The STEP-BD is a public initiative, created to generate data, obtained in pragmatic or real life research environments, from the bipolar disorder. The primary objectives are: to investigate the effectiveness of therapeutic interventions in bipolar disorder, the impact on the disease course of these interventions in the 'real life' and to raise the knowledge about the disease. This program included in six years, n = 4361 patients. This program is not a study in phases but an infrastructure for more than 40 published studies and 30 conference presentations. These studies aim to capture the heterogeneity of the disease in their different clinical presentations, treatments, comorbidities, functionality and quality of life. Patients entering the program have a common assessment. The program consists of two main pathways: the standard treatment and randomized treatment of acute bipolar depression, bipolar depression and refractory relapse prevention. In addition several studies completed the program in an attempt to give coherence to the different clinical presentations of this disease, different treatments and interventions for similar clinical phenomena.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herbst</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Consultorios Externos. Hospital José T. Borda, Buenos Aires, Argentina. herbst@arnet.com.ar</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldchluk</LastName><ForeName>Aníbal</ForeName><Initials>A</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Revisión del Programa para la Mejoría Sistemática del Tratamiento del Trastorno Bipolar (STEP-BD).</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19543566</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25046739</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5.</ArticleTitle><Pagination><MedlinePgn>136-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2014.06.039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(14)00407-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">These analyses compared efficacy of olanzapine in patients with bipolar mania with or without mixed features, as defined in the DSM-5.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Pooled data from 3 placebo-controlled olanzapine studies in patients having bipolar I disorder with manic/mixed episode were analyzed (N=228 olanzapine; N=219 placebo). Patients were categorized for mixed features by number of concurrent depressive symptoms at baseline (0, 1, and 2 [category A; without mixed features], and ≥3 [category B; with mixed features]), as determined by HAM-D17 item score ≥1. Depressive symptoms corresponded to 6 HAM-D17 items in the DSM-5 definition of manic episode with mixed features. Primary efficacy was evaluated by changes in the baseline-to-3-week YMRS total score.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients were categorized into A (N=322; 72.0%) or B (N=125; 28.0%). Mean baseline YMRS total scores were 28.1 in category A and 27.8 in category B. Least-squares mean change of YMRS total scores in categories A and B (olanzapine versus placebo) were -11.78 versus -6.86 and -13.21 versus -4.72, respectively. Patients in the olanzapine- compared with placebo-group experienced a greater decrease in YMRS total score for both categories (p&lt;0.001). An interaction between mixed features and treatment was seen in YMRS change at a 0.3 significance level (p=0.175).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The results are from post-hoc analyses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Olanzapine was efficacious in the treatment of bipolar I mania, in patients both with and without mixed features, defined by DSM-5; however, greater efficacy was observed in patients with mixed features having more severe depressive symptoms.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of New Mexico, Health Sciences Center, Department of Psychiatry, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanba</LastName><ForeName>Shigenobu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kyushu University, Department of Neuropsychiatry, Fukuoka, Japan; East Asian Bipolar Forum, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujikoshi</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Eli Lilly Japan K.K., Lilly Research Laboratories, Statistical Science, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katagiri</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Eli Lilly Japan K.K., Lilly Research Laboratories, Medical Science, Sannomiya Plaza Building, 7-1-5, Isogamidori, Chuo-ku, Kobe 651-0086, Japan. Electronic address: katagiri_hideaki@lilly.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">DSM-5</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">Mixed features</Keyword><Keyword MajorTopicYN="N">Olanzapine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25046739</ArticleId><ArticleId IdType="pii">S0165-0327(14)00407-8</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2014.06.039</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15005752</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD.</ArticleTitle><Pagination><MedlinePgn>139-43</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the frequency and correlates of lamotrigine therapy among the first 500 patients enrolled into the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Systematic recording of psychiatric history and medication data at intake into the STEP-BD project.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the participants with bipolar disorder type I or II (n = 483), 77 (15.4%) were currently taking lamotrigine (mean dose: 258.12 mg/day) and 52 (10.4%) reported prior lamotrigine use. The groups were comparable with regard to duration of illness and mood state at study entry. Compared with participants who had never taken lamotrigine, those currently treated with lamotrigine were significantly more likely to have a prior history of rapid cycling (62.5% vs. 43.1%; p &lt; 0.01) and an antidepressant-induced switch to (hypo)mania (49.3% vs. 33.3%; p &lt; 0.01). In contrast, only 16.9% of lamotrigine-treated participants were taking an antidepressant at study intake, as compared with 29.1% of participants with no history of lamotrigine therapy (p &lt; 0.03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While noting the limitations of a cross-sectional assessment, these data suggest that lamotrigine therapy was commonly used in these academic centers for patients with bipolar disorder several years before it was recommended in the American Psychiatric Association practice guidelines, particularly in patients with a history of rapid cycling or antidepressant-induced mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marangell</LastName><ForeName>Lauren B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Mood Disorders Program, Department of Psychiatry, Baylor College of Medicine, Houston, TX 77030, USA. laurenm@bcm.tmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>James M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>Terence A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Miyahara</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Gary S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><CollectiveName>STEP-BD Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N01 MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15005752</ArticleId><ArticleId IdType="pii">098</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00098.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27367308</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>204</Volume><PubDate><Year>2016</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Positive beliefs about mental illness: Associations with sex, age, diagnosis, and clinical outcomes.</ArticleTitle><Pagination><MedlinePgn>197-204</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.06.038</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(16)30177-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Beliefs about mental illness affect how individuals cope with their symptoms. Positive beliefs about mental illness (PBMI) refer to perceptions of positive attributes individuals may identify in their illness, such as beneficial consequences, enhanced creativity or cognition, or growth through adversity.</AbstractText><AbstractText Label="METHODS">The present study developed and tested a brief measure of PBMI in 332 adults presenting for partial hospitalization with a variety of acute psychiatric conditions.</AbstractText><AbstractText Label="RESULTS">Results indicated that older individuals and women had lower levels of PBMI than others, while individuals with bipolar disorder had higher levels of PBMI than others. PBMI significantly increased over the course of brief standard treatment. Baseline levels of PBMI, as well as changes in PBMI over the course of treatment, were associated with clinical outcomes including, but not limited to, depression and well-being. A diagnosis of bipolar disorder moderated the relationship between PBMI and only one clinical outcome, emotional lability. Increases in PBMI during treatment were associated with reduced emotional lability only in participants without bipolar disorder.</AbstractText><AbstractText Label="LIMITATIONS">Our findings are limited by the naturalistic study design. In addition, the lack of ethnoracial diversity in our sample limits the generalization of results.</AbstractText><AbstractText Label="CONCLUSIONS">Our results suggest that PBMI are a distinct set of beliefs that meaningfully relate to demographic characteristics, diagnostic characteristics, and clinical outcomes. Future research should examine the mechanisms through which PBMI and outcomes are related, as well as determine whether interventions designed to address PBMI (and perhaps tailored for different diagnostic groups) have clinical utility.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Forgeard</LastName><ForeName>Marie J C</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Belmont, MA 02478, United States; Department of Psychiatry, Harvard Medical School, Boston, MA 02115, United States. Electronic address: mforgeard@mclean.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearl</LastName><ForeName>Rebecca L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Belmont, MA 02478, United States; Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Joey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Belmont, MA 02478, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rifkin</LastName><ForeName>Lara S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Belmont, MA 02478, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beard</LastName><ForeName>Courtney</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Belmont, MA 02478, United States; Department of Psychiatry, Harvard Medical School, Boston, MA 02115, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Björgvinsson</LastName><ForeName>Thröstur</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, McLean Hospital, Belmont, MA 02478, United States; Department of Psychiatry, Harvard Medical School, Boston, MA 02115, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003469" MajorTopicYN="Y">Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="Y">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057545" MajorTopicYN="Y">Social Stigma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Positive beliefs</Keyword><Keyword MajorTopicYN="Y">Psychopathology</Keyword><Keyword MajorTopicYN="Y">Treatment outcomes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>02</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27367308</ArticleId><ArticleId IdType="pii">S0165-0327(16)30177-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.06.038</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20636646</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2010</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Letter to the editor regarding "A critical appraisal of lithium's efficacy and effectiveness: the last 60 years".</ArticleTitle><Pagination><MedlinePgn>455-6; author reply 457-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2010.00819.x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Bipolar Disord. 2009 Jun;11 Suppl 2:10-9</RefSource><PMID Version="1">19538682</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049674" MajorTopicYN="N">History, 21st Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20636646</ArticleId><ArticleId IdType="pii">BDI819</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2010.00819.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8500074</PMID><DateCompleted><Year>1993</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>1993</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mood disorders: developmental and precipitating events.</ArticleTitle><Pagination><MedlinePgn>217-24</MedlinePgn></Pagination><Abstract><AbstractText>A consecutive sample of 298 mainly non psychotic outpatients was classified according to DSM-III criteria. The differences in the reports from childhood and the precipitating events among the various subgroups of mood disorders (bipolar disorder, major depression, cyclothymic disorder, dysthymic disorder) and a residual group of patients with other mental disorders were examined. The patients in the non bipolar group reported more traumatic childhood experiences than the patients in the bipolar group. Precipitating events among patients in the group with major depression consisted more often of acute external stressors. Developmental factors and precipitating events in adulthood seem to be relevant in differentiating between the depressive disorders. The study supports the validity of the unipolar-bipolar distinction. The cyclothymic group seem to be a special variant of the major mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alnaes</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torgersen</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="Y">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010287" MajorTopicYN="N">Parent-Child Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010553" MajorTopicYN="Y">Personality Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8500074</ArticleId><ArticleId IdType="doi">10.1177/070674379303800311</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21620484</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>189</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Theory of mind and facial emotion recognition in euthymic bipolar I and bipolar II disorders.</ArticleTitle><Pagination><MedlinePgn>379-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2011.04.033</ELocationID><Abstract><AbstractText>The main aim of this study was to compare patients with euthymic bipolar I (BDI) and bipolar II (BDII) disorders and healthy controls in measures of social cognition. Additional aims were to explore the association between social cognition performance with neurocognitive impairments and psychosocial functioning. Eighty one euthymic patients with BDI or BDII and 34 healthy controls were included. All subjects completed tests to assess verbal memory, attention, and executive functions. Additionally theory of mind (ToM) and facial emotion recognition measures were included. Psychosocial functioning was assessed with the GAF. Both groups of patients had lower performance than healthy controls in ToM, and a lower recognition of fear facial expression. When neurocognitive impairments and exposure to medications were controlled, performance in ToM and recognition of fear facial expression did not allow predicting if a subject was patient or healthy control. Social cognition measures not enhance variance beyond explained by neurocognitive impairments and they were not independent predictors of psychosocial functioning. Impairments in facial emotion recognition and ToM are mediated, at least partly, by attention-executive functions deficits and exposure to psychotropic medications. Likewise, social cognition measures did not contribute to variance beyond neurocognitive impairments.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Diego Javier</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Department of Psychiatry, Neuroscience Institute, Favaloro University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio Adrián</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Fassi</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Marengo</LastName><ForeName>Eliana</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Igoa</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Psychiatry Res. 2012 Oct 30;199(3):228-9</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="Y">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056345" MajorTopicYN="Y">Theory of Mind</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>03</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21620484</ArticleId><ArticleId IdType="pii">S0165-1781(11)00364-7</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2011.04.033</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">26721636</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-1246</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>08</Month></PubDate></JournalIssue><Title>Journal of attention disorders</Title><ISOAbbreviation>J Atten Disord</ISOAbbreviation></Journal><ArticleTitle>Receiver Operating Characteristic Curve Analysis of Screening Tools for Bipolar Disorder Comorbid With ADHD in Schoolchildren.</ArticleTitle><Pagination><MedlinePgn>1403-1412</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1087054715620897</ELocationID><Abstract><AbstractText><b>Objective:</b> We compared Child Behavior Checklist (CBCL)-AAA (Attention Problems, Aggressive Behavior, and Anxious/Depressed) and Parent-Young Mania Rating Scale (P-YMRS) profiles in Brazilian children with ADHD, pediatric-onset bipolar disorder (PBD), and PBD + ADHD. <b>Method:</b> Following analyses of variance or Kruskal-Wallis tests with multiple-comparison Least Significant Difference (LSD) or Dunn's Tests, thresholds were determined by Mann-Whitney <i>U</i> Tests and receiver operating characteristic (ROC) plots. <b>Results:</b> Relative to ADHD, PBD and PBD + ADHD groups scored higher on the Anxious/Depressed, Thought Problems, Rule-Breaking, and Aggressive Behavior subscales and Conduct/Delinquency Diagnostic Scale of the CBCL; all three had similar attention problems. The PBD and PBD + ADHD groups scored higher than the ADHD and healthy control (HC) groups on all CBCL problem scales. The AAA-profile ROC had good diagnostic prediction of PBD + ADHD. PBD and PBD-ADHD were associated with (similarly) elevated P-YMRS scores. <b>Conclusion:</b> The CBCL-PBD and P-YMRS can be used to screen for manic behavior and assist in differential diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cordeiro</LastName><ForeName>Mara L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pelé Pequeno Príncipe Research Institute, Curitiba, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdades Pequeno Príncipe, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Antonio C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Pelé Pequeno Príncipe Research Institute, Curitiba, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Hospital Pequeno Príncipe, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whybrow</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felden</LastName><ForeName>Erico P G</ForeName><Initials>EPG</Initials><AffiliationInfo><Affiliation>Santa Catarina State University, Florianópolis, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunha</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pelé Pequeno Príncipe Research Institute, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Veiga</LastName><ForeName>Vilmar</ForeName><Initials>V</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Pelé Pequeno Príncipe Research Institute, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benko</LastName><ForeName>Cássia R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Pelé Pequeno Príncipe Research Institute, Curitiba, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCracken</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Atten Disord</MedlineTA><NlmUniqueID>9615686</NlmUniqueID><ISSNLinking>1087-0547</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057189" MajorTopicYN="N">Checklist</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ADHD</Keyword><Keyword MajorTopicYN="Y">bipolar</Keyword><Keyword MajorTopicYN="Y">diagnostic validity</Keyword><Keyword MajorTopicYN="Y">receiver operating characteristic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26721636</ArticleId><ArticleId IdType="pii">1087054715620897</ArticleId><ArticleId IdType="doi">10.1177/1087054715620897</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24200153</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>152-154</Volume><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A prospective study of the trajectories of clinical insight, affective symptoms, and cognitive ability in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>250-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.09.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00706-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Clinical insight in bipolar disorder is associated with treatment adherence and psychosocial outcome. The short-term dynamics of clinical insight in relationship to symptoms and cognitive abilities are unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a prospective observational study, a total of 106 outpatients with bipolar disorder I or II were assessed at baseline, 6 weeks, 12 weeks, and 26 weeks. Participants were administered a comprehensive neuropsychological battery, clinical ratings of manic and depressive symptom severity, and self-reported clinical insight. Lagged correlations and linear mixed-effects models were used to determine the temporal associations between symptoms and insight, as well as the moderating influence of global cognitive abilities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At baseline, insight was modestly correlated with severity of manic symptoms, but not with depressive symptoms or cognitive abilities. Insight and depressive symptoms fluctuated to approximately the same extent over time. Both lagged correlations and mixed effects models with lagged effects indicated that the severity of manic symptoms predicted worse insight at later assessments, whereas the converse was not significant. There were no direct or moderating influences of global cognitive abilities.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Our sample size was modest, and included relatively psychiatrically stable outpatients, followed for a six month period. Our results may not generalize to acutely symptomatic patients followed over a longer period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical insight varies substantially over time within patients with bipolar disorder. Impaired insight in bipolar disorder is more likely to follow than to precede manic symptoms.</AbstractText><CopyrightInformation>© 2013 Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Depp</LastName><ForeName>Colin A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, USA; VA San Diego Healthcare System, USA. Electronic address: cdepp@ucsd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmell</LastName><ForeName>Alexandrea L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Savla</LastName><ForeName>Gauri N</ForeName><Initials>GN</Initials></Author><Author ValidYN="Y"><LastName>Mausbach</LastName><ForeName>Brent T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Barton W</ForeName><Initials>BW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH019934</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019934</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH080002</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH100417</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH091260</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30MH080002</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH064722</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH064722</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH100417</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH091260</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014888" MajorTopicYN="N">Wechsler Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Insight</Keyword><Keyword MajorTopicYN="N">Neuropsychology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24200153</ArticleId><ArticleId IdType="pii">S0165-0327(13)00706-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.09.020</ArticleId><ArticleId IdType="pmc">PMC4011138</ArticleId><ArticleId IdType="mid">NIHMS538418</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2003 Oct;77(1):21-30</Citation><ArticleIdList><ArticleId IdType="pubmed">14550932</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropsychol. 1999 Aug;13(3):348-58</Citation><ArticleIdList><ArticleId IdType="pubmed">10726605</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Oct;4(5):315-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12479664</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2008 Jul-Aug;49(4):335-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18555052</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1979 Apr;134:382-9</Citation><ArticleIdList><ArticleId IdType="pubmed">444788</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Clin Neuropsychol. 2001 Jan;16(1):75-91</Citation><ArticleIdList><ArticleId IdType="pubmed">14590193</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2004 Feb;34(2):285-92</Citation><ArticleIdList><ArticleId IdType="pubmed">14982134</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2009 Mar-Apr;50(2):100-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19216885</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2009 Aug 12;9:50</Citation><ArticleIdList><ArticleId IdType="pubmed">19674448</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2000 May-Jun;41(3):167-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10834624</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Jul;90(1):46-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7976449</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2010 Oct 05;6:627-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20957122</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2009 Jul;24(4):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19521247</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Jul;42(7):1409-16</Citation><ArticleIdList><ArticleId IdType="pubmed">22152983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Jun;13(4):343-54</Citation><ArticleIdList><ArticleId IdType="pubmed">21843274</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12695318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2004 Nov;192(11):771-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15505521</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Q. 2012 Sep;83(3):293-310</Citation><ArticleIdList><ArticleId IdType="pubmed">22101737</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Sep;110(1-2):75-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18272231</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Jan;89(1):62-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7908156</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2012;45(4):235-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22627702</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 Sep;122(1-3):94-103</Citation><ArticleIdList><ArticleId IdType="pubmed">20382507</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1988 Nov;26(2):223-38</Citation><ArticleIdList><ArticleId IdType="pubmed">3237915</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):737-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17988364</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2008 Feb;117(2):139-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18028248</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 May;9(3):238-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17430298</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Mar;91(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16442637</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2003 Mar 1;60(1):71-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12505140</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Jan;158(1):122-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11136644</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11 Suppl 2:110-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19538690</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(10):e47655</Citation><ArticleIdList><ArticleId IdType="pubmed">23144705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8561195</PMID><DateCompleted><Year>1996</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>153</Volume><Issue>2</Issue><PubDate><Year>1996</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Women with bipolar illness: clinical and research issues.</ArticleTitle><Pagination><MedlinePgn>163-73</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purpose of this article is to review the literature concerning gender differences in the course of bipolar illness and discuss issues relevant to the treatment of women with the illness.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The literature concerning the following topics is reviewed: gender differences in the course of bipolar illness; effects of the female reproductive cycle on the course of bipolar illness; special considerations in the treatment of bipolar women (focusing on the hypothalamic-pituitary-gonadal and hypothalamic-pituitary-thyroid axes); and hypotheses to explain the greater prevalence of rapid cycling among bipolar women than among bipolar men.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data clearly indicate that rapid cycling is more common among bipolar women. Data also suggest that bipolar women may have more depressive episodes (and fewer manic episodes) and may be more likely to suffer from mixed (as opposed to pure) mania than bipolar men. While it is clear that bipolar women are at high risk for postpartum episodes, the effects of other reproductive system events (i.e., puberty, menstrual cycle, pregnancy, menopause, use of oral contraceptives or hormone replacement therapy) on the course or treatment of bipolar illness have received little systematic study. It is unclear whether women are at higher risk than men for developing lithium-induced hypothyroidism. Higher rates of hypothyroidism, greater use of antidepressants, and gonadal steroid effects are possible explanations for the greater prevalence of rapid cycling among bipolar women.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Gender differences in bipolar illness and the effects of the female reproductive system on the course and treatment of the illness deserve more study. The importance of a longitudinal approach to these questions is emphasized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leibenluft</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Psychobiology Branch, NIMH, Bethesda, MD 20892-1390, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 1997 Mar;154(3):441</RefSource><PMID Version="1">9054807</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015914" MajorTopicYN="N">Estrogen Replacement Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008593" MajorTopicYN="N">Menopause</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008597" MajorTopicYN="N">Menstrual Cycle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011627" MajorTopicYN="N">Puberty</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="N">Puerperal Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>132</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8561195</ArticleId><ArticleId IdType="doi">10.1176/ajp.153.2.163</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21183010</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2402</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>188-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopsych.2010.09.039</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">MicroRNAs (miRNAs) are potent regulators of gene expression with proposed roles in brain development and function. We hypothesized that miRNA expression profiles are altered in individuals with severe psychiatric disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">With real-time quantitative polymerase chain reaction, we compared the expression of 435 miRNAs and 18 small nucleolar RNAs in postmortem brain tissue samples from individuals with schizophrenia, individuals with bipolar disorder, and psychiatrically healthy control subjects (n = 35 each group). Detailed demographic data, sample selection and storage conditions, and drug and substance exposure histories were available for all subjects. Bayesian model averaging was used to simultaneously assess the impact of these covariates as well as the psychiatric phenotype on miRNA expression profiles.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the variables considered, sample storage time, brain pH, alcohol at time of death, and postmortem interval were found to affect the greatest proportion of miRNAs. Of miRNAs analyzed, 19% exhibited positive evidence of altered expression due to a diagnosis of schizophrenia or bipolar disorder. Both conditions were associated with reduced miRNA expression levels, with a much more pronounced effect observed for bipolar disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study suggests that modest underexpression of several miRNAs might be involved in the complex pathogenesis of major psychosis.</AbstractText><CopyrightInformation>Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Genetics, Rutgers University, Piscataway, New Jersey 08854-8095, USA. moreau@biology.rutgers.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruse</LastName><ForeName>Shannon E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>David-Rus</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Buyske</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brzustowicz</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH080429-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019957-10</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AA015346</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH080429</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH80429</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K25 AA015346-01</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019957</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Biol Psychiatry. 2016 Sep 1;80(5):e33-5</RefSource><PMID Version="1">26774964</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Biol Psychiatry. 2016 Sep 1;80(5):e37-8</RefSource><PMID Version="1">26774966</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011180" MajorTopicYN="N">Postmortem Changes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>01</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21183010</ArticleId><ArticleId IdType="pii">S0006-3223(10)01008-5</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2010.09.039</ArticleId><ArticleId IdType="pmc">PMC3038345</ArticleId><ArticleId IdType="mid">NIHMS257480</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Genome Biol. 2004;5(3):R13</Citation><ArticleIdList><ArticleId IdType="pubmed">15003116</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2008 Jun;40(6):751-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18469815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 Aug 7;459(2):100-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19406203</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2007;8(2):R27</Citation><ArticleIdList><ArticleId IdType="pubmed">17326821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Dec;15(12):1176-89</Citation><ArticleIdList><ArticleId IdType="pubmed">19721432</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2006 Jan;32(1):9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16319375</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2004;5(9):R68</Citation><ArticleIdList><ArticleId IdType="pubmed">15345052</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jan 19;439(7074):283-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16421561</ArticleId></ArticleIdList></Reference><Reference><Citation>RNA. 2003 Oct;9(10):1274-81</Citation><ArticleIdList><ArticleId IdType="pubmed">13130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2005 Nov 27;33(20):e179</Citation><ArticleIdList><ArticleId IdType="pubmed">16314309</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1995 Nov 24;200(3):151-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9064599</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2005 Jun;1(1):e13</Citation><ArticleIdList><ArticleId IdType="pubmed">16103902</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Sep 25;425(6956):415-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14508493</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry (Mosc). 2007 May;72(5):578-82</Citation><ArticleIdList><ArticleId IdType="pubmed">17573714</ArticleId></ArticleIdList></Reference><Reference><Citation>Addict Biol. 2005 Mar;10(1):5-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15849014</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Dev. 2003 Dec 15;17(24):3011-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14681208</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2005 Jul 15;65(14):6029-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16024602</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Mar 17;434(7031):338-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15735639</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Genet. 2006 Mar;22(3):165-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16446010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2008 Apr 15;17(8):1156-68</Citation><ArticleIdList><ArticleId IdType="pubmed">18184693</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Prax. 2004 Nov;31 Suppl 2:S189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15586309</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2007 Jun 7;54(5):813-29</Citation><ArticleIdList><ArticleId IdType="pubmed">17553428</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2004 Oct 13;23(20):4051-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15372072</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2005 Jan 14;120(1):15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15652477</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2001 Nov 15;20(21):3215-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11746314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2006 Sep 22;126(6):1203-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16990141</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2005 Mar;21(6):1469-77</Citation><ArticleIdList><ArticleId IdType="pubmed">15845075</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16476146</PMID><DateCompleted><Year>2006</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>3</Issue><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Pharmacological treatment in the early phase of bipolar disorders: what stage are we at?</ArticleTitle><Pagination><MedlinePgn>199-207</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review available guidelines, explore treatment strategies currently applied, identify critical issues and propose direction for new developments.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Literature review based on Medline search and hand search of relevant literature.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pharmacological treatment of the early phase of bipolar disorders lacks specific guidelines. Mood stabilizers are often prescribed after many years of illness, antipsychotic medications are frequently prescribed and often for extensive periods of time, and adherence to medication is relatively poor. In addition, mania is frequently misdiagnosed, and there is limited knowledge on which to base identification of bipolar depression and identification of the initial prodrome to bipolar disorders.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is an urgent need for more research in the early phases of bipolar disorders to develop means to identify patients earlier and to develop approaches that would address the specific needs of this population in a more adequate manner.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conus</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Département Universitaire de Psychiatrie CHUV, Université de Lausanne, Treatment and Early Intervention Program for Psychosis (TIPP), Clinique de Cery, Prilly, Switzerland. philippe.conus@chuv.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>McGorry</LastName><ForeName>Patrick D</ForeName><Initials>PD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16476146</ArticleId><ArticleId IdType="pii">ANP1775</ArticleId><ArticleId IdType="doi">10.1080/j.1440-1614.2006.01775.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>